analyze and provide insight:  






ER visit Administered Medications started 6/25/2025 ended 6/25/2025 acetaminophen, 1000 mg, PO, Augmentin (dx other), 875 mg, PO, cetirizine, 10 mg, PO, Tessalon Perles, 200 mg, PO

METHYLPREDNISOLONE 4 MG DSPK, 1 packet(s), PO, as directed on package labeling, X 6 day(s), # 21 tab(s),davenport for Bronchitis Started 7/3/2025 Medrol for cough. Trial Pepcid 40mg qHS for 2-3 weeks

METHYLPREDNISOLONE 4 MG DSPK TAKE BY MOUTH AS DIRECTED ON PACKAGE FOR 6 DAYS RICHARD CAIN Strain of distal biceps femoris tendon started 6/6/2025
 
LEVOTHYROXINE 88 MCG TAB TAKE ONE TABLET BY MOUTH ONE TIME DAILY started 11/7/2024

Clomid 50 mg twice week Date Started On: 7/9/2020 three times week Date Started On: 10/13/2020 Date stopped On:5/5/2025

BISOPROLOL 5 MG TAB TAKE ONE-HALF TABLET BY MOUTH ONE TIME DAILY started 4/19/2025 Ordered By:Clark , Kailey R APRN Paroxysmal atrial fibrillation some of the episodes could be atypical atrial flutter start bisoprolol for rate control.- CHADS2VASC score 3

apixaban 5 mg oral tablet, 5 mg, 1 tab(s), PO, 2xDaily Date Started On:Apr 29, 2025 Ordered By:Clark , Kailey R APRN for stroke risk reduction


DOXYCYCLINE HYC 100 MG CAP TAKE ONE CAPSULE BY MOUTH TWICE A DAY Prescribed LEXY HAZLE Date Started On:2/6/2025

SERTRALINE 150 MG TAB TAKE ONE TABLET BY MOUTH ONE TIME DAILY, Prescribed 6/10/2024
SERTRALINE 200 MG TAB TAKE one TABLET BY MOUTH ONE TIME DAILY started on: 12/23/2024



AMOXI-CLAV 875-125 MG TAB TAKE ONE TABLET BY MOUTH TWICE A DAY FOR 7 DAYS Prescribed SEAN BEATTIE started on 6/25/2025

CETIRIZINE 10 MG TAB TAKE ONE TABLET BY MOUTH ONE TIME DAILY Prescribed SEAN BEATTIE started on 6/25/2025

METHOCARBAMOL 500 MG TAB TAKE ONE TABLET BY MOUTH THREE TIMES A DAY FOR 30 DAYS Prescribed SEAN BEATTIE started on 6/6/2025  DOB: 06/20/1958
 Patient Report
 Weixelbaum, Lee S
 Patient ID:
 Specimen ID: 319-216-2065-0
 Age: 63
 Sex: Male
 Account Number: 09241500
 Ordering Physician: A HENRY
 Ordered Items: Comp. Metabolic Panel (14); Thyroxine (T4) Free, Direct; Testosterone; TSH; Vitamin D, 25-Hydroxy; Ambig Abbrev
 CMP14 Default; Venipuncture
 Date Collected: 11/15/2021
 Comp. Metabolic Panel (14)
 Test
 Glucose 01
 BUN 01
 Creatinine 01
 eGFR If NonAfricn Am
 eGFR If Africn Am
 BUN/Creatinine Ratio
 Sodium 01
 Potassium 01
 Chloride 01
 Carbon Dioxide, Total 01
 Calcium 01
 Protein, Total 01
 Albumin 01
 Globulin, Total
 A/G Ratio
 Bilirubin, Total 01
 Alkaline Phosphatase 01
 AST (SGOT) 01
 ALT (SGPT) 01
 Date Received: 11/15/2021
 Current Result and Flag
 95
 15
 1.43
 52
 60
 High
 Low
 Date Reported: 11/16/2021
 Previous Result and Date
 89
 14
 1.44
 51
 59
 07/28/2021
 07/28/2021
 07/28/2021
 07/28/2021
 07/28/2021
 **In accordance with recommendations from the NKF-ASN Task force,**
  Labcorp is in the process of updating its eGFR calculation to the
  2021 CKD-EPI creatinine equation that estimates kidney function
  without a race variable.
 10
 142
 4.5
 106
 22
 9.1
 6.6
 4.2
 2.4
 1.8
 0.7
 67
 * Previous Reference Interval: (Alkaline Phosphatase: 48-121 IU/L IU/L)
 Thyroxine (T4) Free, Direct
 Test
 T4,Free(Direct) 01
 Testosterone
 Test
 10
 139
 Fasting: Yes
 Units
 mg/dL
 mg/dL
 mg/dL
 mL/min/1.73
 mL/min/1.73
 07/28/2021
 07/28/2021
 4.8
 104
 22
 9.0
 6.9
 4.3
 2.6
 1.7
 0.9
 62*
 07/28/2021
 07/28/2021
 07/28/2021
 07/28/2021
 07/28/2021
 07/28/2021
 07/28/2021
 07/28/2021
 07/28/2021
 07/28/2021
 mmol/L
 mmol/L
 mmol/L
 mmol/L
 mg/dL
 g/dL
 g/dL
 g/dL
 mg/dL
 IU/L
                             **Please note reference interval change**
 21
 18
 Current Result and Flag
 1.15
 Current Result and Flag
 Testosterone 01
 367
 18
 16
 07/28/2021
 07/28/2021
 Previous Result and Date
 1.11
 10/07/2021
 Previous Result and Date
 324
 05/06/2021
 Adult male reference interval is based on a population of
 healthy nonobese males (BMI <30) between 19 and 39 years old.
 Travison, et.al. JCEM 2017,102;1161-1173. PMID: 28324103.
 IU/L
 IU/L
 Units
 ng/dL
 Units
 ng/dL
 Reference Interval
 65-99
 8-27
 0.76-1.27
 >59
 >59
 10-24
 134-144
 3.5-5.2
 96-106
 20-29
 8.6-10.2
 6.0-8.5
 3.8-4.8
 1.5-4.5
 1.2-2.2
 0.0-1.2
 44-121
 0-40
 0-44
 Reference Interval
 0.82-1.77
 Reference Interval
 264-916
 ©2021 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  11/16/21 0822 ET   Final Report  Page 1 of 3
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
DOB: 06/20/1958
 Patient Report
 Weixelbaum, Lee S
 Patient ID:
 Specimen ID: 319-216-2065-0
 Age: 63
 Sex: Male
 Account Number: 09241500
 Ordering Physician: A HENRY
 TSH
 Test
 TSH 01
 Current Result and Flag
 6.420
 High
 Previous Result and Date
 Units
 Reference Interval
 5.44
 Vitamin D, 25-Hydroxy
 Test
 Current Result and Flag
 10/07/2021
 Previous Result and Date
 Vitamin D, 25-Hydroxy 01
 39.7
 uIU/mL
 Units
 0.450-4.500
 Reference Interval
 29.8
 06/28/2021
 Vitamin D deficiency has been defined by the Institute of
 Medicine and an Endocrine Society practice guideline as a
 level of serum 25-OH vitamin D less than 20 ng/mL (1,2).
 The Endocrine Society went on to further define vitamin D
 insufficiency as a level between 21 and 29 ng/mL (2).
 1. IOM (Institute of Medicine). 2010. Dietary reference
   intakes for calcium and D. Washington DC: The
   National Academies Press.
 2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al.
   Evaluation, treatment, and prevention of vitamin D
   deficiency: an Endocrine Society clinical practice
   guideline. JCEM. 2011 Jul; 96(7):1911-30.
 ng/mL
 30.0-100.0
 Ambig Abbrev CMP14 Default
 Test
 Ambig Abbrev CMP14 Default 01
 Current Result and Flag
 Previous Result and Date
 Units
 Reference Interval
 A hand-written panel/profile was received from your office. In
 accordance with the LabCorp Ambiguous Test Code Policy dated July
 2003, we have completed your order by using the closest currently
 or formerly recognized AMA panel.  We have assigned Comprehensive
 Metabolic Panel (14), Test Code #322000 to this request.  If this
 is not the testing you wished to receive on this specimen, please
 contact the LabCorp Client Inquiry/Technical Services Department
 to clarify the test order.  We appreciate your business.
 Disclaimer
 The Previous Result is listed for the most recent test performed by Labcorp in the past 3 years where there is sufficient patient demographic data to
 match the result to the patient.
 Icon Legend
 Out of reference range      
Performing Labs
 Critical or Alert
 01: TA - LabCorp Tampa 5610 W LaSalle Street, Tampa, FL, 33607-1770 Dir: Sean Farrier, MD
 For Inquiries, the physician can contact Branch: 800-877-5227 Lab: 800-877-5227
 ©2021 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  11/16/21 0822 ET   Final Report  Page 2 of 3
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
DOB: 06/20/1958
 Patient Report
 Weixelbaum, Lee S
 Patient ID:
 Specimen ID: 319-216-2065-0
 Age: 63
 Sex: Male
 Account Number: 09241500
 Ordering Physician: A HENRY
 Patient Details
 Weixelbaum, Lee S
 2811 WINDING TRAIL DR, VALRICO, FL, 33596
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Date of Birth: 06/20/1958
 Age: 63
 Sex: Male
 Patient ID:
 Alternate Patient ID:
 Physician Details
 A HENRY
 Andrew Henry MD
 9260 BAY PLAZA BLVD, STE 502, Brandon, FL,
 33619
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Account Number: 09241500
 Physician ID:
 NPI: 1194892141
 Specimen Details
 Specimen ID: 319-216-2065-0
 Control ID: 30185050493
 Alternate Control Number:
 Date Collected: 11/15/2021 0753  Local
 Date Received: 11/15/2021 0000  ET
 Date Entered: 11/15/2021 1629  ET
 Date Reported: 11/16/2021 0813  ET
 Rte: 00
 ©2021 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  11/16/21 0822 ET   Final Report  Page 3 of 3
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
DOB: 06/20/1958
 Patient Report
 Weixelbaum, Lee S
 Patient ID: 106001600156
 Specimen ID: 319-216-1981-0
 Age: 63
 Sex: Male
 Account Number: 09621402
 Ordering Physician: S STEVENSON
 Ordered Items: Comp. Metabolic Panel (14); Litholink CKD Program; Thyroxine (T4) Free, Direct; TSH; Venipuncture
 Date Collected: 11/15/2021
 Comp. Metabolic Panel (14)
 Test
 Glucose 01
 BUN 01
 Creatinine 01
 eGFR If NonAfricn Am
 eGFR If Africn Am
 BUN/Creatinine Ratio
 Sodium 01
 Potassium 01
 Chloride 01
 Carbon Dioxide, Total 01
 Calcium 01
 Protein, Total 01
 Albumin 01
 Globulin, Total
 A/G Ratio
 Bilirubin, Total 01
 Alkaline Phosphatase 01
 AST (SGOT) 01
 ALT (SGPT) 01
 Date Received: 11/15/2021
 Current Result and Flag
 98
 14
 1.47
 50
 58
 High
 Low
 Low
 Date Reported: 11/16/2021
 Previous Result and Date
 89
 14
 1.44
 51
 59
 07/28/2021
 07/28/2021
 07/28/2021
 07/28/2021
 **In accordance with recommendations from the NKF-ASN Task force,**
  Labcorp is in the process of updating its eGFR calculation to the
  2021 CKD-EPI creatinine equation that estimates kidney function
  without a race variable.
 10
 144
 4.5
 107
 24
 9.1
 6.6
 4.3
 High
 Fasting: No
 Units
 mg/dL
 mg/dL
 mg/dL
 mL/min/1.73
 07/28/2021
 10
 139
 4.8
 104
 22
 9.0
 6.9
 4.3
 2.3
 1.9
 0.7
 66
 2.6
 1.7
 0.9
 62*
 07/28/2021
 07/28/2021
 07/28/2021
 07/28/2021
 07/28/2021
 07/28/2021
 07/28/2021
 07/28/2021
 07/28/2021
 07/28/2021
 07/28/2021
 07/28/2021
 mL/min/1.73
 mmol/L
 mmol/L
 mmol/L
 mmol/L
 mg/dL
 g/dL
 g/dL
 g/dL
 mg/dL
 IU/L
                             **Please note reference interval change**
 20
 19
 * Previous Reference Interval: (Alkaline Phosphatase: 48-121 IU/L IU/L)
 Litholink CKD Program
 Test
 Interpretation 02
 Current Result and Flag
 Note
 18
 16
 07/28/2021
 07/28/2021
 Previous Result and Date
 Note
 07/28/2021------------------------------
CHRONIC KIDNEY DISEASE:
 EGFR, BLOOD PRESSURE, AND PROTEINURIA ASSESSMENT
 The overall regression of eGFR with time is not
 statistically significant. Current eGFR is 50 mL/min/1.73mE2
 corresponding to CKD stage 3a. Multiply eGFR by 1.159 if
 patient is African American. Potassium is within goal and
 has not changed significantly, was 4.8 and now is 4.5
 mmol/L.
 EGFR, BLOOD PRESSURE, AND PROTEINURIA TREATMENT SUGGESTIONS
Guidelines recommend a target blood pressure of 120/80 mmHg
 or less in CKD patients to reduce cardiovascular risk and
 IU/L
 IU/L
 Units
 Reference Interval
 65-99
 8-27
 0.76-1.27
 >59
 >59
 10-24
 134-144
 3.5-5.2
 96-106
 20-29
 8.6-10.2
 6.0-8.5
 3.8-4.8
 1.5-4.5
 1.2-2.2
 0.0-1.2
 44-121
 0-40
 0-44
 Reference Interval
 ©2021 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  11/16/21 0614 ET   Final Report  Page 1 of 3
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
DOB: 06/20/1958
 Patient Report
 Weixelbaum, Lee S
 Patient ID: 106001600156
 Specimen ID: 319-216-1981-0
 Age: 63
 Sex: Male
 Account Number: 09621402
 Ordering Physician: S STEVENSON
 Litholink CKD Program (Cont.)
 CKD progression. Assessment of albuminuria (urine
 albumin:creatinine ratio or urine protein:creatinine ratio
 preferred) is recommended at least annually in CKD patients
 for staging and disease prognosis.
 EGFR, BLOOD PRESSURE, AND PROTEINURIA FOLLOW-UP
fasting Renal Panel within 12 months; Spot Urine Panel is
 recommended by KDOQI guidelines, at least yearly;
 BONE and MINERAL ASSESSMENT
 Calcium is within goal and has not changed significantly,
 was 9.0 and now is 9.1 mg/dL. Carbon Dioxide is within goal
 and has risen, was 22 and now is 24 mmol/L.
 BONE and MINERAL TREATMENT SUGGESTIONS
Interpretations require simultaneous measurements of serum
 calcium and phosphorus.
 BONE and MINERAL FOLLOW-UP
fasting PTH with Renal Panel and 25-Hydroxy Vitamin D are
 due;
 LIPIDS ASSESSMENT
 Most recent order does not include a fasting Lipid Panel.
 LIPIDS FOLLOW-UP
fasting Lipid Panel is due;
 ANEMIA ASSESSMENT
 Most recent order does not include a CBC Panel or iron
 studies.
 ANEMIA FOLLOW-UP
CBC within 7 months;------------------------------
DISCLAIMER
 These assessments and treatment suggestions are provided as
 a convenience in support of the physician-patient
 relationship and are not intended to replace the physician's
 clinical judgment. They are derived from national guidelines
 in addition to other evidence and expert opinion. The
 clinician should consider this information within the
 context of clinical opinion and the individual patient.
 SEE GUIDANCE FOR CHRONIC KIDNEY DISEASE PROGRAM: Kidney
 Disease Improving Global Outcomes (KDIGO) clinical practice
 guidelines are at http://kdigo.org/home/guidelines/.
 National Kidney Foundation Kidney Disease Outcomes Quality
 Initiative (KDOQI (TM)), with its limitations and
 disclaimers, are at www.kidney.org/professionals/KDOQI. This
 program is intended for patients who have been diagnosed
 with stages 3, 4, or pre-dialysis 5 CKD. It is not intended
 for children, pregnant patients, or transplant patients.
 PDF 02
 Not applicable
 Not applicable
 07/28/2021
 ©2021 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  11/16/21 0614 ET   Final Report  Page 2 of 3
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
DOB: 06/20/1958
 Patient Report
 Weixelbaum, Lee S
 Patient ID: 106001600156
 Specimen ID: 319-216-1981-0
 Age: 63
 Sex: Male
 Account Number: 09621402
 Ordering Physician: S STEVENSON
 Thyroxine (T4) Free, Direct
 Test
 T4,Free(Direct) 01
 Current Result and Flag
 1.37
 Previous Result and Date
 Units
 Reference Interval
 1.11
 TSH
 Current Result and Flag
 10/07/2021
 Previous Result and Date
 6.200
 High
 ng/dL
 Units
 0.82-1.77
 Reference Interval
 5.44
 10/07/2021
 Test
 TSH 01
 Disclaimer
 The Previous Result is listed for the most recent test performed by Labcorp in the past 3 years where there is sufficient patient demographic data to
 match the result to the patient.
 uIU/mL
 Icon Legend
 Out of reference range      
Performing Labs
 Critical or Alert
 01: TA - LabCorp Tampa 5610 W LaSalle Street, Tampa, FL, 33607-1770 Dir: Sean Farrier, MD
 02: LITIL - Litholink Corporation 150 Spring Lake Dr Ste A, Itasca, IL, 60143-2091 Dir: John Asplin, MD
 For Inquiries, the physician can contact Branch: 800-877-5227 Lab: 800-877-5227
 0.450-4.500
 Patient Details
 Weixelbaum, Lee S
 2811 WINDING TRAIL DR, VALRICO, FL, 33596
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Date of Birth: 06/20/1958
 Age: 63
 Sex: Male
 Patient ID: 106001600156
 Alternate Patient ID: 301181250
 Physician Details
 S STEVENSON
 BayCare Medical Group
 2470 Bloomingdale Ave Ste 123, Valrico, FL,
 33596
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Account Number: 09621402
 Physician ID: 1952866097
 NPI: 1952866097
 Specimen Details
 Specimen ID: 319-216-1981-0
 Control ID: 10600160015
 Alternate Control Number:
 106001600156L16705
 Date Collected: 11/15/2021 0750  Local
 Date Received: 11/15/2021 0000  ET
 Date Entered: 11/15/2021 1629  ET
 Date Reported: 11/16/2021 0608  ET
 Rte: 27
 ©2021 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  11/16/21 0614 ET   Final Report  Page 3 of 3
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
DOB: 06/20/1958
 Patient Report
 Weixelbaum, Lee S
 Patient ID:
 Specimen ID: 280-216-2441-0
 Age: 63
 Sex: Male
 Account Number: 09521990
 Ordering Physician: R PATEL
 Ordered Items: TSH+Free T4; Venipuncture; Non LCA Req
 Date Collected: 10/07/2021
 Date Received: 10/07/2021
 Date Reported: 10/08/2021
 TSH+Free T4
 Test
 TSH 01
 T4,Free(Direct) 01
 Current Result and Flag
 5.440
 High
 Fasting: Yes
 Previous Result and Date
 10.7
 05/06/2021
 Units
 Reference Interval
 1.11
 Disclaimer
 0.9
 01/12/2021
 uIU/mL
 ng/dL
 0.450-4.500
 0.82-1.77
 The Previous Result is listed for the most recent test performed by Labcorp in the past 3 years where there is sufficient patient demographic data to
 match the result to the patient.
 Icon Legend
 Out of reference range      
Performing Labs
 Critical or Alert
 01: TA - LabCorp Tampa 5610 W LaSalle Street, Tampa, FL, 33607-1770 Dir: Sean Farrier, MD
 For Inquiries, the physician can contact Branch: 800-877-5227 Lab: 800-877-5227
 Patient Details
 Weixelbaum, Lee S
 2811 WINDING TRAIL DR, VALRICO, FL, 33596
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Date of Birth: 06/20/1958
 Age: 63
 Sex: Male
 Patient ID:
 Alternate Patient ID:
 Physician Details
 R PATEL
 Endocrinology at Bloomingdale
 2470 Bloomingdale Ave Ste 123, Valrico, FL,
 33596
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Account Number: 09521990
 Physician ID:
 NPI: 1457776577
 Specimen Details
 Specimen ID: 280-216-2441-0
 Control ID: 30185048498
 Alternate Control Number:
 Date Collected: 10/07/2021 0818  Local
 Date Received: 10/07/2021 0000  ET
 Date Entered: 10/07/2021 1146  ET
 Date Reported: 10/08/2021 0307  ET
 Rte: 00
 ©2021 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  10/08/21 0313 ET   Final Report  Page 1 of 1
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
DOB: 06/20/1958
 Patient Report
 Weixelbaum, Lee S
 Patient ID: 106001072320
 Specimen ID: 280-216-2313-0
 Age: 63
 Sex: Male
 Account Number: 09621402
 Ordering Physician: S STEVENSON
 Ordered Items: Prostate-Specific Ag; Venipuncture
 Date Collected: 10/07/2021
 Date Received: 10/07/2021
 Date Reported: 10/08/2021
 Prostate-Specific Ag
 Test
 Prostate Specific Ag 01
 Current Result and Flag
 0.8
 Fasting: Yes
 Previous Result and Date
 Units
 Reference Interval
 0.9
 06/28/2021
 ng/mL
 Roche ECLIA methodology.
 According to the American Urological Association, Serum PSA should
 decrease and remain at undetectable levels after radical
 prostatectomy. The AUA defines biochemical recurrence as an initial
 PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory
 PSA value 0.2 ng/mL or greater.
 Values obtained with different assay methods or kits cannot be used
 interchangeably. Results cannot be interpreted as absolute evidence
 of the presence or absence of malignant disease.
 0.0-4.0
 Disclaimer
 The Previous Result is listed for the most recent test performed by Labcorp in the past 3 years where there is sufficient patient demographic data to
 match the result to the patient.
 Icon Legend
 Out of reference range      
Performing Labs
 Critical or Alert
 01: TA - LabCorp Tampa 5610 W LaSalle Street, Tampa, FL, 33607-1770 Dir: Sean Farrier, MD
 For Inquiries, the physician can contact Branch: 800-877-5227 Lab: 800-877-5227
 Patient Details
 Weixelbaum, Lee S
 2811 WINDING TRAIL DR, VALRICO, FL, 33596
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Date of Birth: 06/20/1958
 Age: 63
 Sex: Male
 Patient ID: 106001072320
 Alternate Patient ID: 301181250
 Physician Details
 S STEVENSON
 BayCare Medical Group
 2470 Bloomingdale Ave Ste 123, Valrico, FL,
 33596
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Account Number: 09621402
 Physician ID: 1952866097
 NPI: 1952866097
 Specimen Details
 Specimen ID: 280-216-2313-0
 Control ID: 10600107232
 Alternate Control Number:
 106001072320L01765
 Date Collected: 10/07/2021 0817  Local
 Date Received: 10/07/2021 0000  ET
 Date Entered: 10/07/2021 1146  ET
 Date Reported: 10/08/2021 0609  ET
 Rte: 27
 ©2021 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  10/08/21 0620 ET   Final Report  Page 1 of 1
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee S DOB: 06/20/1958 Patient Report
 Patient ID: 106000846829 Age: 63 Account Number: 09621402
 Specimen ID: 209-216-3468-0 Sex: Male Ordering Physician: S STEVENSON
 
Ordered Items: Comp. Metabolic Panel (14); Litholink CKD Program; Venipuncture
 
Date Collected: 07/28/2021 Date Received: 07/28/2021 Date Reported: 07/29/2021 Fasting: No
 Comp. Metabolic Panel (14)
  Test Current Result and Flag Previous Result and Date Units Reference Interval
 Glucose 01 89 91 06/28/2021 mg/dL 65-99
 BUN 01 14 17 06/28/2021 mg/dL 8-27
 Creatinine 01 1.44 High 1.51 06/28/2021 mg/dL 0.76-1.27
 eGFR If NonAfricn Am 51 Low 48 06/28/2021 mL/min/1.73 >59
 eGFR If Africn Am 59 Low 56 06/28/2021 mL/min/1.73 >59
            
 
**Labcorp currently reports eGFR in compliance with the current**
  recommendations of the National Kidney Foundation. Labcorp will
  update reporting as new guidelines are published from the NKF-ASN
  Task force.
 BUN/Creatinine Ratio 10 11 06/28/2021 10-24
 Sodium 01 139 139 06/28/2021 mmol/L 134-144
 Potassium 01 4.8 4.4 06/28/2021 mmol/L 3.5-5.2
 Chloride 01 104 103 06/28/2021 mmol/L 96-106
 Carbon Dioxide, Total 01 22 23 06/28/2021 mmol/L 20-29
 Calcium 01 9.0 9.5 06/28/2021 mg/dL 8.6-10.2
 Protein, Total 01 6.9 6.8 06/28/2021 g/dL 6.0-8.5
 Albumin 01 4.3 4.4 06/28/2021 g/dL 3.8-4.8
 Globulin, Total 2.6 2.4 06/28/2021 g/dL 1.5-4.5
 A/G Ratio 1.7 1.8 06/28/2021 1.2-2.2
 Bilirubin, Total 01 0.9 1.2 06/28/2021 mg/dL 0.0-1.2
 Alkaline Phosphatase 01 62 68 06/28/2021 IU/L 48-121
 AST (SGOT) 01 18 26 06/28/2021 IU/L 0-40
 ALT (SGPT) 01 16 21 06/28/2021 IU/L 0-44
 Litholink CKD Program
  Test Current Result and Flag Previous Result and Date Units Reference Interval
 Interpretation 02 Note Note 06/28/2021
            
 ------------------------------
CHRONIC KIDNEY DISEASE:
 EGFR, BLOOD PRESSURE, AND PROTEINURIA ASSESSMENT
 Date Issued  07/29/21 0617 ET   Final Report  Page 1 of 3
 ©1995-2021 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
               This document contains private and confidential health information protected by state and federal law.
               If you have received this document in error please call 800-877-5227.
DOB: 06/20/1958
 Patient Report
 Weixelbaum, Lee S
 Patient ID: 106000846829
 Specimen ID: 209-216-3468-0
 Litholink CKD Program (Cont.)
 Age: 63
 Sex: Male
 Account Number: 09621402
 Ordering Physician: S STEVENSON
 The overall regression of eGFR with time is not
 statistically significant. Current eGFR is 51 mL/min/1.73mE2
 corresponding to CKD stage 3a. Multiply eGFR by 1.159 if
 patient is African American. Potassium is within goal and
 has not changed significantly, was 4.4 and now is 4.8
 mmol/L. Hemoglobin A1C is 5.0 % (measured on 6/28/2021);
 diabetic status is unknown. Refer to ADA guidelines for
 clinical practice recommendations.
 EGFR, BLOOD PRESSURE, AND PROTEINURIA TREATMENT SUGGESTIONS
eGFR is no longer below the expected value and has not
 changed significantly, was 48 and now is 51 mL/min/1.73mE2.
 Guidelines recommend a target blood pressure of 120/80 mmHg
 or less in CKD patients to reduce cardiovascular risk and
 CKD progression. Assessment of albuminuria (urine
 albumin:creatinine ratio or urine protein:creatinine ratio
 preferred) is recommended at least annually in CKD patients
 for staging and disease prognosis.
 EGFR, BLOOD PRESSURE, AND PROTEINURIA FOLLOW-UP
fasting Renal Panel within 12 months; Spot Urine Panel is
 recommended by KDOQI guidelines, at least yearly;
 BONE and MINERAL ASSESSMENT
 Calcium is within goal and has decreased, was 9.5 and now is
 9.0 mg/dL. Carbon Dioxide is within goal and has not changed
 significantly, was 23 and now is 22 mmol/L.
 BONE and MINERAL TREATMENT SUGGESTIONS
Interpretations require simultaneous measurements of serum
 calcium and phosphorus.
 BONE and MINERAL FOLLOW-UP
fasting PTH with Renal Panel and 25-Hydroxy Vitamin D are
 due;
 LIPIDS ASSESSMENT
 Most recent order does not include a fasting Lipid Panel.
 LIPIDS FOLLOW-UP
fasting Lipid Panel within 2 months;
 ANEMIA ASSESSMENT
 Most recent order does not include a CBC Panel or iron
 studies.
 ANEMIA FOLLOW-UP
CBC within 11 months;------------------------------
DISCLAIMER
 These assessments and treatment suggestions are provided as
 a convenience in support of the physician-patient
 ©1995-2021 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Issued  07/29/21 0617 ET   Final Report  Page 2 of 3
               This document contains private and confidential health information protected by state and federal law.
               If you have received this document in error please call 800-877-5227.
DOB: 06/20/1958
 Patient Report
 Weixelbaum, Lee S
 Patient ID: 106000846829
 Specimen ID: 209-216-3468-0
 Age: 63
 Sex: Male
 Account Number: 09621402
 Ordering Physician: S STEVENSON
 Litholink CKD Program (Cont.)
 relationship and are not intended to replace the physician's
 clinical judgment. They are derived from national guidelines
 in addition to other evidence and expert opinion. The
 clinician should consider this information within the
 context of clinical opinion and the individual patient.
 SEE GUIDANCE FOR CHRONIC KIDNEY DISEASE PROGRAM: Kidney
 Disease Improving Global Outcomes (KDIGO) clinical practice
 guidelines are at http://kdigo.org/home/guidelines/.
 National Kidney Foundation Kidney Disease Outcomes Quality
 Initiative (KDOQI (TM)), with its limitations and
 disclaimers, are at www.kidney.org/professionals/KDOQI. This
 program is intended for patients who have been diagnosed
 with stages 3, 4, or pre-dialysis 5 CKD. It is not intended
 for children, pregnant patients, or transplant patients.
 PDF 02
 Disclaimer
 Not applicable
 Not applicable
 06/28/2021
 The Previous Result is listed for the most recent test performed by Labcorp in the past 3 years where there is sufficient patient demographic data to match the
 result to the patient.
 Icon Legend
 Out of reference range      
Performing Labs
 Critical or Alert
 01: TA - LabCorp Tampa 5610 W LaSalle Street, Tampa, FL, 33607-1770 Dir: Sean Farrier, MD
 02: LITIL - Litholink Corporation 150 Spring Lake Dr Ste A, Itasca, IL, 60143-2091 Dir: John Asplin, MD
 For Inquiries, the physician can contact Branch: 800-877-5227 Lab: 800-877-5227
 Patient Details
 Weixelbaum, Lee S
 2811 WINDING TRAIL DR, VALRICO, FL, 33596
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Date of Birth: 06/20/1958
 Age: 63
 Sex: Male
 Patient ID: 106000846829
 Alternate Patient ID: 301181250
 Physician Details
 S STEVENSON
 BayCare Medical Group
 2470 Bloomingdale Ave Ste 123, Valrico, FL,
 33596
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Account Number: 09621402
 Physician ID: 1952866097
 NPI: 1952866097
 Specimen Details
 Specimen ID: 209-216-3468-0
 Control ID: 10600084682
 Alternate Control Number:
 106000846829L25219
 Date Collected: 07/28/2021 0846  Local
 Date Received: 07/28/2021 0000  ET
 Date Entered: 07/28/2021 1121  ET
 Date Reported: 07/29/2021 0608  ET
 Rte: 27
 ©1995-2021 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Issued  07/29/21 0617 ET   Final Report  Page 3 of 3
               This document contains private and confidential health information protected by state and federal law.
               If you have received this document in error please call 800-877-5227.
DOB: 06/20/1958
 Patient Report
 Weixelbaum, Lee S
 Patient ID: 106000725569
 Specimen ID: 179-216-2978-0
 Age: 63
 Sex: Male
 Account Number: 09621402
 Ordering Physician: S STEVENSON
 Ordered Items: Vitamin D, 25-Hydroxy
 Date Collected: 06/28/2021
 Date Received: 06/28/2021
 Vitamin D, 25-Hydroxy
  Test
 Vitamin D, 25-Hydroxy 01
 Current Result and Flag
 29.8
 Date Reported: 06/29/2021
 Previous Result and Date
 Low
 28.1
 05/06/2021
 Fasting: Yes
 Units
 ng/mL
 Reference Interval
 30.0-100.0
 Vitamin D deficiency has been defined by the Institute of
 Medicine and an Endocrine Society practice guideline as a
 level of serum 25-OH vitamin D less than 20 ng/mL (1,2).
 The Endocrine Society went on to further define vitamin D
 insufficiency as a level between 21 and 29 ng/mL (2).
 1. IOM (Institute of Medicine). 2010. Dietary reference
   intakes for calcium and D. Washington DC: The
   National Academies Press.
 2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al.
   Evaluation, treatment, and prevention of vitamin D
   deficiency: an Endocrine Society clinical practice
   guideline. JCEM. 2011 Jul; 96(7):1911-30.
 Disclaimer
 The Previous Result is listed for the most recent test performed by Labcorp in the past 3 years where there is sufficient patient demographic data to match the
 result to the patient.
 Icon Legend
 Out of reference range      
Performing Labs
 Critical or Alert
 01: TA - LabCorp Tampa 5610 W LaSalle Street, Tampa, FL, 33607-1770 Dir: Sean Farrier, MD
 For Inquiries, the physician can contact Branch: 800-877-5227 Lab: 800-877-5227
 Patient Details
 Weixelbaum, Lee S
 2811 WINDING TRAIL DR, VALRICO, FL, 33596
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Date of Birth: 06/20/1958
 Age: 63
 Sex: Male
 Patient ID: 106000725569
 Alternate Patient ID: 301181250
 Physician Details
 S STEVENSON
 BayCare Medical Group
 2470 Bloomingdale Ave Ste 123, Valrico, FL,
 33596
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Account Number: 09621402
 Physician ID: 1952866097
 NPI: 1952866097
 Specimen Details
 Specimen ID: 179-216-2978-0
 Control ID: 10600072556
 Alternate Control Number:
 106000725569L59585
 Date Collected: 06/28/2021 0827  Local
 Date Received: 06/28/2021 0000  ET
 Date Entered: 06/28/2021 1140  ET
 Date Reported: 06/29/2021 0607  ET
 Rte: 27
 ©1995-2021 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Issued  06/29/21 0614 ET   Final Report  Page 1 of 1
               This document contains private and confidential health information protected by state and federal law.
               If you have received this document in error please call 800-877-5227.
DOB: 06/20/1958
 Patient Report
 Weixelbaum, Lee S
 Patient ID: 106000725569
 Specimen ID: 179-216-2978-0
 Age: 63
 Sex: Male
 Account Number: 09621402
 Ordering Physician: S STEVENSON
 Ordered Items: Vitamin D, 25-Hydroxy
 Date Collected: 06/28/2021
 Date Received: 06/28/2021
 Vitamin D, 25-Hydroxy
  Test
 Vitamin D, 25-Hydroxy 01
 Current Result and Flag
 29.8
 Date Reported: 06/29/2021
 Previous Result and Date
 Low
 28.1
 05/06/2021
 Fasting: Yes
 Units
 ng/mL
 Reference Interval
 30.0-100.0
 Vitamin D deficiency has been defined by the Institute of
 Medicine and an Endocrine Society practice guideline as a
 level of serum 25-OH vitamin D less than 20 ng/mL (1,2).
 The Endocrine Society went on to further define vitamin D
 insufficiency as a level between 21 and 29 ng/mL (2).
 1. IOM (Institute of Medicine). 2010. Dietary reference
   intakes for calcium and D. Washington DC: The
   National Academies Press.
 2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al.
   Evaluation, treatment, and prevention of vitamin D
   deficiency: an Endocrine Society clinical practice
   guideline. JCEM. 2011 Jul; 96(7):1911-30.
 Disclaimer
 The Previous Result is listed for the most recent test performed by Labcorp in the past 3 years where there is sufficient patient demographic data to match the
 result to the patient.
 Icon Legend
 Out of reference range      
Performing Labs
 Critical or Alert
 01: TA - LabCorp Tampa 5610 W LaSalle Street, Tampa, FL, 33607-1770 Dir: Sean Farrier, MD
 For Inquiries, the physician can contact Branch: 800-877-5227 Lab: 800-877-5227
 Patient Details
 Weixelbaum, Lee S
 2811 WINDING TRAIL DR, VALRICO, FL, 33596
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Date of Birth: 06/20/1958
 Age: 63
 Sex: Male
 Patient ID: 106000725569
 Alternate Patient ID: 301181250
 Physician Details
 S STEVENSON
 BayCare Medical Group
 2470 Bloomingdale Ave Ste 123, Valrico, FL,
 33596
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Account Number: 09621402
 Physician ID: 1952866097
 NPI: 1952866097
 Specimen Details
 Specimen ID: 179-216-2978-0
 Control ID: 10600072556
 Alternate Control Number:
 106000725569L59585
 Date Collected: 06/28/2021 0827  Local
 Date Received: 06/28/2021 0000  ET
 Date Entered: 06/28/2021 1140  ET
 Date Reported: 06/29/2021 0607  ET
 Rte: 27
 ©1995-2021 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Issued  06/29/21 0614 ET   Final Report  Page 1 of 1
               This document contains private and confidential health information protected by state and federal law.
               If you have received this document in error please call 800-877-5227.
Weixelbaum, Lee S DOB: 06/20/1958 Patient Report
 Patient ID: 106000725569 Age: 63 Account Number: 09621402
 Specimen ID: 179-216-2859-0 Sex: Male Ordering Physician: S STEVENSON
 
Ordered Items: CBC With Differential/Platelet; Comp. Metabolic Panel (14); Lipid Panel; Litholink CKD Program; HCV Antibody
 RFX to Quant PCR; PSA Total (Reflex To Free); Hemoglobin A1c; Thyroid Cascade Profile; Venipuncture
 
Date Collected: 06/28/2021 Date Received: 06/28/2021 Date Reported: 07/02/2021 Fasting: Yes
 CBC With Differential/Platelet
  Test Current Result and Flag Previous Result and Date Units Reference Interval
 WBC 01 6.3 7.0 09/21/2020 x10E3/uL 3.4-10.8
 RBC 01 4.88 4.64 09/21/2020 x10E6/uL 4.14-5.80
 Hemoglobin 01 15.1 14.3 09/21/2020 g/dL 13.0-17.7
 Hematocrit 01 44.0 42.1 09/21/2020 % 37.5-51.0
 MCV 01 90 91 09/21/2020 fL 79-97
 MCH 01 30.9 30.8 09/21/2020 pg 26.6-33.0
 MCHC 01 34.3 34.0 09/21/2020 g/dL 31.5-35.7
 RDW 01 14.1 14.1 09/21/2020 % 11.6-15.4
 Platelets 01 217 211 09/21/2020 x10E3/uL 150-450
 Neutrophils 01 60 66 09/21/2020 % Not Estab.
 Lymphs 01 26 19 09/21/2020 % Not Estab.
 Monocytes 01 8 10 09/21/2020 % Not Estab.
 Eos 01 5 4 09/21/2020 % Not Estab.
 Basos 01 1 1 09/21/2020 % Not Estab.
 Neutrophils (Absolute) 01 3.8 4.6 09/21/2020 x10E3/uL 1.4-7.0
 Lymphs (Absolute) 01 1.6 1.3 09/21/2020 x10E3/uL 0.7-3.1
 Monocytes(Absolute) 01 0.5 0.7 09/21/2020 x10E3/uL 0.1-0.9
 Eos (Absolute) 01 0.3 0.2 09/21/2020 x10E3/uL 0.0-0.4
 Baso (Absolute) 01 0.1 0.1 09/21/2020 x10E3/uL 0.0-0.2
 Immature Granulocytes 01 0 0 09/21/2020 % Not Estab.
 Immature Grans (Abs) 01 0.0 0.0 09/21/2020 x10E3/uL 0.0-0.1
 Comp. Metabolic Panel (14)
  Test Current Result and Flag Previous Result and Date Units Reference Interval
 Glucose 01 91 89 01/12/2021 mg/dL 65-99
 BUN 01 17 19 01/12/2021 mg/dL 8-27
 Creatinine 01 1.51 High 1.42 01/12/2021 mg/dL 0.76-1.27
 eGFR If NonAfricn Am 48 Low 53 01/12/2021 mL/min/1.73 >59
 eGFR If Africn Am 56 Low 61 01/12/2021 mL/min/1.73 >59
            
 
**Labcorp currently reports eGFR in compliance with the current**
 Date Issued  07/02/21 0624 ET   Final Report  Page 1 of 6
 ©1995-2021 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
               This document contains private and confidential health information protected by state and federal law.
               If you have received this document in error please call 800-877-5227.
DOB: 06/20/1958
 Patient Report
 Weixelbaum, Lee S
 Patient ID: 106000725569
 Specimen ID: 179-216-2859-0
 Age: 63
 Sex: Male
 Comp. Metabolic Panel (14) (Cont.)
 Account Number: 09621402
 Ordering Physician: S STEVENSON
  recommendations of the National Kidney Foundation. Labcorp will
  update reporting as new guidelines are published from the NKF-ASN
  Task force.
 BUN/Creatinine Ratio
 Sodium 01
 Potassium 01
 Chloride 01
 Carbon Dioxide, Total 01
 Calcium 01
 Protein, Total 01
 Albumin 01
 Globulin, Total
 A/G Ratio
 Bilirubin, Total 01
 Alkaline Phosphatase 01
 AST (SGOT) 01
 ALT (SGPT) 01
 11
 139
 4.4
 103
 23
 9.5
 6.8
 4.4
 2.4
 1.8
 1.2
 68
 26
 21
 * Previous Reference Interval: (Alkaline Phosphatase: 39-117 IU/L IU/L)
 Lipid Panel
  Test
 Cholesterol, Total 01
 Triglycerides 01
 HDL Cholesterol 01
 VLDL Cholesterol Cal
 LDL Chol Calc (NIH)
 Litholink CKD Program
  Test
 Interpretation 02
 Current Result and Flag
 208
 157
 37
 13
 142
 4.4
 107
 23
 9.0
 6.5
 4.1
 2.4
 1.7
 1.0
 01/12/2021
 01/12/2021
 01/12/2021
 01/12/2021
 01/12/2021
 01/12/2021
 01/12/2021
 mmol/L
 mmol/L
 mmol/L
 mmol/L
 mg/dL
 g/dL
 01/12/2021
 01/12/2021
 01/12/2021
 01/12/2021
 65*
 21
 19
 01/12/2021
 01/12/2021
 01/12/2021
 Previous Result and Date
 High
 High
 Low
 28
 143
 High
 Current Result and Flag
 Note
 182
 147
 37
 26
 119
 09/21/2020
 09/21/2020
 09/21/2020
 09/21/2020
 09/21/2020
 Previous Result and Date
 Note
 01/12/2021------------------------------
CHRONIC KIDNEY DISEASE:
 EGFR, BLOOD PRESSURE, AND PROTEINURIA ASSESSMENT
 Potassium is within goal and has not changed significantly,
 was 4.3 and now is 4.4 mmol/L. Hemoglobin A1C is 5.0 %;
 diabetic status is unknown. Refer to ADA guidelines for
 clinical practice recommendations.
 g/dL
 g/dL
 mg/dL
 IU/L
 IU/L
 IU/L
 Units
 mg/dL
 mg/dL
 mg/dL
 mg/dL
 mg/dL
 Units
 10-24
 134-144
 3.5-5.2
 96-106
 20-29
 8.6-10.2
 6.0-8.5
 3.8-4.8
 1.5-4.5
 1.2-2.2
 0.0-1.2
 48-121
 0-40
 0-44
 Reference Interval
 100-199
 0-149
 >39
 5-40
 0-99
 Reference Interval
 ©1995-2021 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Issued  07/02/21 0624 ET   Final Report  Page 2 of 6
               This document contains private and confidential health information protected by state and federal law.
               If you have received this document in error please call 800-877-5227.
DOB: 06/20/1958
 Patient Report
 Weixelbaum, Lee S
 Patient ID: 106000725569
 Specimen ID: 179-216-2859-0
 Litholink CKD Program (Cont.)
 Age: 63
 Sex: Male
 Account Number: 09621402
 Ordering Physician: S STEVENSON
 EGFR, BLOOD PRESSURE, AND PROTEINURIA TREATMENT SUGGESTIONS
Recent eGFR remains below the expected value (p less than
 0.05) and has not changed significantly, was 45 and now is
 48 mL/min/1.73mE2. Guidelines recommend a target blood
 pressure of 120/80 mmHg or less in CKD patients to reduce
 cardiovascular risk and CKD progression. Assessment of
 albuminuria (urine albumin:creatinine ratio or urine
 protein:creatinine ratio preferred) is recommended at least
 annually in CKD patients for staging and disease prognosis.
 EGFR, BLOOD PRESSURE, AND PROTEINURIA FOLLOW-UP
fasting Renal Panel within 1 week; Spot Urine Panel is
 recommended by KDOQI guidelines, at least yearly;
 BONE and MINERAL ASSESSMENT
 Calcium is within goal and has risen, was 9.1 and now is 9.5
 mg/dL. Carbon Dioxide is within goal and has risen, was 19
 and now is 23 mmol/L. Vitamin D insufficiency is present
 (16.2 ng/mL 1/12/2021) .
 BONE and MINERAL TREATMENT SUGGESTIONS
Interpretations require simultaneous measurements of serum
 calcium and phosphorus. Begin vitamin D (ergocalciferol
 50,000 IU/month orally for 6 months; alternatively,
 cholecalciferol 1000-2000 IU/d for 6 months).
 BONE and MINERAL FOLLOW-UP
25-Hydroxy Vitamin D and fasting PTH with Renal Panel within
 2 weeks;
 LIPIDS ASSESSMENT
 LDL-C is high and has risen, was 119 and now is 143 mg/dL.
 Triglyceride is borderline high and has not changed
 significantly, was 147 and now is 157 mg/dL. Non-HDL
 Cholesterol is high and has risen, was 145 and now is 171
 mg/dL. HDL-C is low and has not changed significantly, was
 37 and now is 37 mg/dL.
 LIPIDS TREATMENT SUGGESTIONS
Therapeutic lifestyle changes are always valuable to
 maintain optimal blood lipid status (diet, exercise, weight
 management). Begin statin. If statin already in use,
 consider increasing dose to achieve at least a 50% LDL
 reduction from baseline. Moderate or high intensity statin
 is preferred. If statin cannot be tolerated or increased,
 alternatives include use of an intestinal agent (ezetimibe
 or bile acid sequestrant), niacin, and/or fish oil.
 LIPIDS FOLLOW-UP
fasting Lipid Panel within 3 months;
 ©1995-2021 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Issued  07/02/21 0624 ET   Final Report  Page 3 of 6
               This document contains private and confidential health information protected by state and federal law.
               If you have received this document in error please call 800-877-5227.
Weixelbaum, Lee S DOB: 06/20/1958 Patient Report
 Patient ID: 106000725569 Age: 63 Account Number: 09621402
 Specimen ID: 179-216-2859-0 Sex: Male Ordering Physician: S STEVENSON
 Litholink CKD Program (Cont.)
 ANEMIA ASSESSMENT
 Hemoglobin is normal and has risen, was 14.3 and now is 15.1
 g/dL. Hemoglobin target assumes ESA is not in use.
 ANEMIA TREATMENT SUGGESTIONS
No specific change of treatment is indicated at this time.
 ANEMIA FOLLOW-UP
CBC within 12 months;------------------------------
DISCLAIMER
 These assessments and treatment suggestions are provided as
 a convenience in support of the physician-patient
 relationship and are not intended to replace the physician's
 clinical judgment. They are derived from national guidelines
 in addition to other evidence and expert opinion. The
 clinician should consider this information within the
 context of clinical opinion and the individual patient.
 SEE GUIDANCE FOR CHRONIC KIDNEY DISEASE PROGRAM: Kidney
 Disease Improving Global Outcomes (KDIGO) clinical practice
 guidelines are at http://kdigo.org/home/guidelines/.
 National Kidney Foundation Kidney Disease Outcomes Quality
 Initiative (KDOQI (TM)), with its limitations and
 disclaimers, are at www.kidney.org/professionals/KDOQI. This
 program is intended for patients who have been diagnosed
 with stages 3, 4, or pre-dialysis 5 CKD. It is not intended
 for children, pregnant patients, or transplant patients.
 PDF 02 Not applicable . 01/12/2021
 HCV Antibody RFX to Quant PCR
  Test Current Result and Flag Previous Result and Date Units Reference Interval
 HCV Ab 01 0.1 s/co ratio 0.0-0.9
 Interpretation: 01
            
 
Negative
 Not infected with HCV, unless recent infection is suspected or other
 evidence exists to indicate HCV infection.
 PSA Total (Reflex To Free)
  Test Current Result and Flag Previous Result and Date Units Reference Interval
 Prostate Specific Ag, Serum 01 0.9 0.9 01/12/2021 ng/mL 0.0-4.0
            
 
Roche ECLIA methodology.
 Date Issued  07/02/21 0624 ET   Final Report  Page 4 of 6
 ©1995-2021 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
               This document contains private and confidential health information protected by state and federal law.
               If you have received this document in error please call 800-877-5227.
Weixelbaum, Lee S DOB: 06/20/1958 Patient Report
 Patient ID: 106000725569 Age: 63 Account Number: 09621402
 Specimen ID: 179-216-2859-0 Sex: Male Ordering Physician: S STEVENSON
 PSA Total (Reflex To Free) (Cont.)
 According to the American Urological Association, Serum PSA should
 decrease and remain at undetectable levels after radical
 prostatectomy. The AUA defines biochemical recurrence as an initial
 PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory
 PSA value 0.2 ng/mL or greater.
 Values obtained with different assay methods or kits cannot be used
 interchangeably. Results cannot be interpreted as absolute evidence
 of the presence or absence of malignant disease.
 Reflex Criteria 01
            
 
The percent free PSA is performed on a reflex basis only when the
 total PSA is between 4.0 and 10.0 ng/mL.
 Hemoglobin A1c
  Test Current Result and Flag Previous Result and Date Units Reference Interval
 Hemoglobin A1c 01 5.0 % 4.8-5.6
 Please Note: 01
            
 
         Prediabetes: 5.7 - 6.4
         Diabetes: >6.4
         Glycemic control for adults with diabetes: <7.0
 Thyroid Cascade Profile
  Test Current Result and Flag Previous Result and Date Units Reference Interval
 TSH 01 7.670 High uIU/mL 0.450-4.500
 T4,Free (Direct) 01 0.91 ng/dL 0.82-1.77
 Thyroid Peroxidase (TPO) Ab 01 166 High IU/mL 0-34
 Interpretive Comment
            
 
An elevation of TSH with a normal FT4 in the presence of antithyroid
 peroxidase antibody is suggestive of Subclinical Hypothyroidism.
 
Disclaimer
 The Previous Result is listed for the most recent test performed by Labcorp in the past 3 years where there is sufficient patient demographic data to match the
 result to the patient.
 
Icon Legend
 Out of reference range       Critical or Alert
 
Performing Labs
 01: TA - LabCorp Tampa 5610 W LaSalle Street, Tampa, FL, 33607-1770 Dir: Sean Farrier, MD
 02: LITIL - Litholink Corporation 150 Spring Lake Dr Ste A, Itasca, IL, 60143-2091 Dir: John Asplin, MD
 For Inquiries, the physician can contact Branch: 800-877-5227 Lab: 800-877-5227
 
Date Issued  07/02/21 0624 ET   Final Report  Page 5 of 6
 ©1995-2021 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
               This document contains private and confidential health information protected by state and federal law.
               If you have received this document in error please call 800-877-5227.
DOB: 06/20/1958
 Patient Report
 Weixelbaum, Lee S
 Patient ID: 106000725569
 Specimen ID: 179-216-2859-0
 Age: 63
 Sex: Male
 Account Number: 09621402
 Ordering Physician: S STEVENSON
 Patient Details
 Weixelbaum, Lee S
 2811 WINDING TRAIL DR, VALRICO, FL, 33596
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Date of Birth: 06/20/1958
 Age: 63
 Sex: Male
 Patient ID: 106000725569
 Alternate Patient ID: 301181250
 Physician Details
 S STEVENSON
 BayCare Medical Group
 2470 Bloomingdale Ave Ste 123, Valrico, FL,
 33596
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Account Number: 09621402
 Physician ID: 1952866097
 NPI: 1952866097
 Specimen Details
 Specimen ID: 179-216-2859-0
 Control ID: 10600072556
 Alternate Control Number:
 106000725569L69537
 Date Collected: 06/28/2021 0825  Local
 Date Received: 06/28/2021 0000  ET
 Date Entered: 06/28/2021 1140  ET
 Date Reported: 07/02/2021 0608  ET
 Rte: 27
 ©1995-2021 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Issued  07/02/21 0624 ET   Final Report  Page 6 of 6
               This document contains private and confidential health information protected by state and federal law.
               If you have received this document in error please call 800-877-5227.
Weixelbaum, Lee S DOB: 06/20/1958 Patient Report
 Patient ID: Age: 62 Account Number: 09241500
 Specimen ID: 126-216-1685-0 Sex: Male Ordering Physician: A HENRY
 
Ordered Items: Testosterone,Free and Total; Free T4 by Dialysis/Mass Spec; TSH; Vitamin D, 25-Hydroxy; Triiodothyronine (T3);
 Venipuncture
 
Date Collected: 05/06/2021 Date Received: 05/06/2021 Date Reported: 05/15/2021 Fasting: No
 
General Comments & Additional Information
 A courtesy copy of this report has been sent to
 8136760237.
 
Testosterone,Free and Total
  Test Current Result and Flag Previous Result and Date Units Reference Interval
 Testosterone, Serum 01 324 ng/dL 264-916
            
 
Adult male reference interval is based on a population of
 healthy nonobese males (BMI <30) between 19 and 39 years old.
 Travison, et.al. JCEM 2017,102;1161-1173. PMID: 28324103.
                    **Effective May 10, 2021 Testosterone, Serum**
                      reference interval will be changing to:
                            Age                Male          Female
                         0 - 30 days          0 - 650        4 - 190
                         1 -  5 months        0 - 650        0 -  42
                              6 months        0 -  36        0 -  42
                         7m-  1 year          0 -  36        1 -  26
                         2 -  5 years         0 -  36        3 -  33
                         6 -  8 years         0 -  36        3 -  25
                         9 - 10 years         0 -  21        1 -  33
                             11 years         1 - 161        5 -  58
                             12 years         2 - 521        5 -  58
                        13 - 15 years        28 - 656       12 -  71
                        16 - 17 years       150 - 785       12 -  71
                        18 - 19 years       150 - 785       13 -  71
                        20 - 30 years       264 - 916       13 -  71
                        31 - 40 years       264 - 916        8 -  60
                        41 - 60 years       264 - 916        4 -  50
                        61 - 80 years       264 - 916        3 -  67
                            >80 years       264 - 916        2 -  45
 Free Testosterone(Direct) 02 10.9 13.3 10/05/2020 pg/mL 6.6-18.1
 Free T4 by Dialysis/Mass Spec
  Test Current Result and Flag Previous Result and Date Units Reference Interval
 Free T4 by Dialysis/Mass Spec 03 0.81 0.91 01/12/2021 ng/dL
            
 
This test was developed and its performance characteristics
 determined by LabCorp. It has not been cleared or approved
 by the Food and Drug Administration.
 Date Issued  05/15/21 0821 ET   Final Report  Page 1 of 3
 ©1995-2021 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
               This document contains private and confidential health information protected by state and federal law.
               If you have received this document in error please call 800-877-5227.
DOB: 06/20/1958
 Patient Report
 Weixelbaum, Lee S
 Patient ID:
 Specimen ID: 126-216-1685-0
 Age: 62
 Sex: Male
 Free T4 by Dialysis/Mass Spec (Cont.)
 Reference Range:
 Pubertal Children and Adults:
 0.8 - 1.7
 TSH
  Test
 TSH 01
 Vitamin D, 25-Hydroxy
  Test
 Vitamin D, 25-Hydroxy 01
  Test
 Current Result and Flag
 10.700
 Current Result and Flag
 28.1
 Account Number: 09241500
 Ordering Physician: A HENRY
 Previous Result and Date
 High
 Low
 6.74
 01/12/2021
 Previous Result and Date
 16.2
 01/12/2021
 Vitamin D deficiency has been defined by the Institute of
 Medicine and an Endocrine Society practice guideline as a
 level of serum 25-OH vitamin D less than 20 ng/mL (1,2).
 The Endocrine Society went on to further define vitamin D
 insufficiency as a level between 21 and 29 ng/mL (2).
 1. IOM (Institute of Medicine). 2010. Dietary reference
   intakes for calcium and D. Washington DC: The
   National Academies Press.
 2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al.
   Evaluation, treatment, and prevention of vitamin D
   deficiency: an Endocrine Society clinical practice
   guideline. JCEM. 2011 Jul; 96(7):1911-30.
 Triiodothyronine (T3)
 Triiodothyronine (T3) 01
  Disclaimer
 Current Result and Flag
 120
 Previous Result and Date
 109
 01/12/2021
 Units
 uIU/mL
 Units
 ng/mL
 Units
 ng/dL
 Reference Interval
 0.450-4.500
 Reference Interval
 30.0-100.0
 Reference Interval
 71-180
  The Previous Result is listed for tests performed by Labcorp in the past 3 years where there is sufficient patient demographic data to match the results to the
 patient.
  Icon Legend
 Out of reference range      
  Performing Labs
 Critical or Alert
  01: TA - LabCorp Tampa 5610 W LaSalle Street, Tampa, FL, 33607-1770 Dir: Sean Farrier, MD
  02: BN - LabCorp Burlington 1447 York Court, Burlington, NC, 27215-3361 Dir: Sanjai Nagendra, MD
  03: ES - Esoterix Inc 4301 Lost Hills Road, Calabasas Hills, CA, 91301-5358 Dir: Brian Poirier, MD
  For Inquiries, the physician can contact Branch: 800-877-5227 Lab: 800-877-5227
 ©1995-2021 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Issued  05/15/21 0821 ET   Final Report  Page 2 of 3
               This document contains private and confidential health information protected by state and federal law.
               If you have received this document in error please call 800-877-5227.
DOB: 06/20/1958
 Patient Report
 Weixelbaum, Lee S
 Patient ID:
 Specimen ID: 126-216-1685-0
 Age: 62
 Sex: Male
 Account Number: 09241500
 Ordering Physician: A HENRY
 Patient Details
 Weixelbaum, Lee S
 2811 WINDING TRAIL DR, VALRICO, FL, 33596
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Date of Birth: 06/20/1958
 Age: 62
 Sex: Male
 Patient ID:
 Alternate Patient ID:
 Physician Details
 A HENRY
 Andrew Henry MD
 9260 BAY PLAZA BLVD, STE 502, Brandon, FL,
 33619
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Account Number: 09241500
 Physician ID:
 NPI: 1194892141
 Specimen Details
 Specimen ID: 126-216-1685-0
 Control ID: 30185040322
 Alternate Control Number:
 Date Collected: 05/06/2021 0742  Local
 Date Received: 05/06/2021 0000  ET
 Date Entered: 05/06/2021 1150  ET
 Date Reported: 05/15/2021 0811  ET
 Rte: 00
 ©1995-2021 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Issued  05/15/21 0821 ET   Final Report  Page 3 of 3
               This document contains private and confidential health information protected by state and federal law.
               If you have received this document in error please call 800-877-5227.
 1 Patient Report   
Specimen ID:  012-216-1320-0 Acct #: 09683682 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER> Rte: 30
 Control ID: 15658713CE1
 Bloomingdale Medical Assoc.
 13403 BOYETTE RD
 RIVERVIEW FL 33569
 WEIXELBAUM, LEE S.
 2811 WINDING TRAIL DR
 VALRICO FL  33596
 (813) 445-1261
 Patient Details
 DOB: 06/20/1958
 Age(y/m/d): 062/06/23
 Gender:  M
 Patient ID: 4352438
 Specimen Details
 Date collected: 01/12/2021  0727 Local
 Date received: 01/12/2021
 Date entered: 01/12/2021
 Date reported: 01/13/2021  0607 ET
 Physician Details
 Ordering: J  CAMERON
 Referring:
 ID:     1720044027
 NPI:  1720044027
 Date Issued: 01/13/21 0611 ET FINAL REPORT Page 1 of 2
 This document contains private and confidential health information protected by state and federal law.
 If you have received this document in error, please call 800-877-5227
 © 1995-2021 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version:          
General Comments & Additional Information
 Alternate Control Number: 15658713CE13122 Alternate Patient ID: 4352438
 Total Volume: Not Provided Fasting: No
 Ordered Items
 TSH+Free T4; Comp. Metabolic Panel (14); Litholink CKD Program; Vitamin D, 25-Hydroxy; PTH, Intact
           TESTS              RESULT     FLAG      UNITS  REFERENCE INTERVAL  LAB
 TSH+Free T4
  TSH                                6.890   High uIU/mL  0.450-4.500 01
  T4,Free(Direct)                     0.90 ng/dL   0.82-1.77 01
 Comp. Metabolic Panel (14)
  Glucose                               88 mg/dL     65-99 01
  BUN                                   18 mg/dL      8-27 01
  Creatinine                          1.61   High mg/dL   0.76-1.27 01
  eGFR If NonAfricn Am                  45    Low mL/min/1.73        >59
  eGFR If Africn Am                     52    Low mL/min/1.73        >59
  BUN/Creatinine Ratio                  11     10-24
  Sodium                               141 mmol/L    134-144 01
  Potassium                            4.3 mmol/L    3.5-5.2 01
  Chloride                             105 mmol/L     96-106 01
  Carbon Dioxide, Total                 19    Low mmol/L     20-29 01
  Calcium                              9.1 mg/dL    8.6-10.2 01
  Protein, Total                       6.7 g/dL    6.0-8.5 01
  Albumin                              4.4 g/dL    3.8-4.8 01
  Globulin, Total                      2.3 g/dL    1.5-4.5
  A/G Ratio                            1.9    1.2-2.2
  Bilirubin, Total                     0.9 mg/dL    0.0-1.2 01
  Alkaline Phosphatase                  69 IU/L     39-117 01
  AST (SGOT)                            21 IU/L      0-40 01
  ALT (SGPT)                            17 IU/L      0-44 01
 Litholink CKD Program
  Interpretation                      Note 02
     Supplemental report is available.
  PDF                                    . 02
 Vitamin D, 25-Hydroxy                16.2    Low ng/mL   30.0-100.0 01
 1.00
1 Patient Report   
Patient: WEIXELBAUM, LEE S.
 DOB: 06/20/1958
 Patient ID: 4352438
 Specimen ID: 012-216-1320-0
 Control ID: 15658713CE1
 Date collected: 01/12/2021  0727 Local
           TESTS              RESULT     FLAG      UNITS  REFERENCE INTERVAL  LAB
 Vitamin D deficiency has been defined by the Institute of
 Medicine and an Endocrine Society practice guideline as a
 level of serum 25-OH vitamin D less than 20 ng/mL (1,2).
 The Endocrine Society went on to further define vitamin D
 insufficiency as a level between 21 and 29 ng/mL (2).
 1. IOM (Institute of Medicine). 2010. Dietary reference
   intakes for calcium and D. Washington DC: The
   National Academies Press.
 2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al.
   Evaluation, treatment, and prevention of vitamin D
   deficiency: an Endocrine Society clinical practice
   guideline. JCEM. 2011 Jul; 96(7):1911-30.
 PTH, Intact       
01 TA
                     41
 LabCorp Tampa
 5610 W LaSalle Street, Tampa, FL 33607-1770
 pg/mL
 Dir: Sean Farrier, MD
     15-65
 01
 02 LITIL Litholink Corporation
 150 Spring Lake Dr Ste A, Itasca, IL 60143-2091
 For inquiries, the physician may contact Branch: 800-877-5227 Lab: 800-877-5227
 Dir: John Asplin, MD
 Date Issued: 01/13/21 0611 ET
 FINAL REPORT
 This document contains private and confidential health information protected by state and federal law.
 If you have received this document in error, please call 800-877-5227
 Page 2 of 2
 © 1995-2021 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version:          
1.00
Accessions: 01221613200
 DISCLAIMER:These assessments and treatment suggestions are provided as a convenience in support of the physician-patient relationship and are not intended to
 replace the physician’s clinical judgment.  They are derived from national guidelines in addition to other evidence and expert opinion.  The clinician should consider
 this information within the context of clinical opinion and the individual patient.
 SEE GUIDANCE FOR CHRONIC KIDNEY DISEASE PROGRAM: Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines are at
 http://kdigo.org/home/guidelines/. National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI (TM)), with its limitations and disclaimers, are at
 www.kidney.org/professionals/KDOQI. This program is intended for patients who have been diagnosed with stages 3, 4, or pre-dialysis 5 CKD. It is not intended for
 children, pregnant patients, or transplant patients.
 Note:  Please refer to your LabCorp Report for all results as well as any test-specific and specimen-specific comments.
 Laboratory Director's Notes
 COLLECTION DATE RELATED NOTES ITEM
 Laboratory test values flagged with an asterisk (*) within this report refer to the following commentary from our physicians and quality assurance staff.
 01/12/2021 25-Hydroxy
 Vitamin D
 Vitamin D deficiency has been defined by the Institute of Medicine and an Endocrine Society practice
 guideline as a level of serum 25-OH vitamin D less than 20 ng/mL (1,2). The Endocrine Society went on to
 further define vitamin D insufficiency as a level between 21 and 29 ng/mL (2). 1. IOM (Institute of Medicine).
 2010. Dietary reference intakes for calcium and D. Washington DC: The National Academies Press. 2. Holick
 MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an
 Endocrine Society clinical practice guideline. JCEM. 2011 Jul; 96(7):1911-30.
 John Asplin, MD - Laboratory Director
 Current Laboratory Results
 Blood Draw Date: Date Received: 01/12/2021 Date Completed: 01/13/2021 01/12/2021 Fasting:NO
 Comp. Metabolic Panel (14)
 REF. INTERVAL RESULT ANALYTE LOW HIGH
 Glucose mg/dL 65-99 88
 BUN mg/dL 8-27 18
 Creatinine mg/dL 0.76-1.27 1.61H
 Sodium mmol/L 134-144 141
 Potassium mmol/L 3.5-5.2 4.3
 Chloride mmol/L 96-106 105
 Carbon Dioxide mmol/L 20-29 19L
 Calcium mg/dL 8.6-10.2 9.1
 Protein, Total, Serum g/dL 6.0-8.5 6.7
 Albumin g/dL 3.8-4.8 4.4
 Globulin, Total g/dL 1.5-4.5 2.3
 A/G Ratio 1.2-2.2 1.9
 Bilirubin, Total mg/dL 0.0-1.2 0.9
 Alkaline Phosphatase, S IU/L 39-117 69
 AST IU/L 0-40 21
 ALT IU/L 0-44 17
 BUN: Creatinine Ratio 10-24 11
 Anion Gap mmol/L 10 - 18 17
 estimated GFR
 mL/min/1.73mE2
 > 59 45
 Albumin testing performed on the Roche Modular using the ALB PLUS assay.
 Intact PTH
 REF. INTERVAL RESULT ANALYTE LOW HIGH
 Intact PTH pg/mL 15-65 41
 PTH testing performed using the PTH assay on Roche testing platforms.
 25-Hydroxy Vitamin D
 REF. INTERVAL RESULT ANALYTE LOW HIGH
 25-Hydroxy Vitamin D ng/mL 30.0-100.0 * 16.2L
 Vitamin D testing performed using the 25 OH Vitamin D Total Assay on the DiaSorin
 Liaison®.
 CAMERON, JOHN E
 LabCorp Account #: 09683682
 01/12/2021 3a M 06/20/1958 WEIXELBAUM, LEE
 Litholink Patient Results Report PATIENT DATE OF BIRTH GENDER CKD STAGEDATE OF SERVICE PHYSICIAN
 9.4.5.6992 Version:
 Page: 1 of 4
 Printed: 01/13/2021 Laboratory Director
 CLIA# 14D0897314
 150 Spring Lake Dr., Suite A
 Itasca, Illinois 60143 www.litholink.com
 866 361 7939 Facsimile
 John Asplin, MD Litholink, A LabCorp Company 800 338 4333 Telephone
CAMERON, JOHN E
 LabCorp Account #: 09683682
 01/12/2021 3a M 06/20/1958 WEIXELBAUM, LEE
 Litholink Patient Results Report PATIENT DATE OF BIRTH GENDER CKD STAGEDATE OF SERVICE PHYSICIAN
 L - Below Low Normal
 H - Above High Normal
 LL - Alert Low
 HH - Alert High
 < - Panic Low
 > - Panic High
 A - Abnormal (applies to non-numeric results)
 AA - Critical Abnormal (applies to non-numeric results)
 Legend for Abnormal Flags:
 GENDER SELF-REPORTED RACE MOST RECENT CKD STAGE
 M Missing 3a
 CURRENT eGFR
 45
 DIABETES
 ?
 Chronic Kidney Disease
 Analysis & Treatment Suggestions
 GFR Categories: (ml/min/1.73m  )
 G1
 Prognosis of CKD by GFR And Albuminuria Categories
 G2
 G3a
 G3b
 G4
 G5
 >=90
 60-89
 45-59
 30-44
 15-29
 <15
 NORMAL OR HIGH
 MILDLY DECREASED
 MILDLY TO MODERATELY DECREASED
 MODERATELY TO SEVERELY DECREASED
 SEVERELY DECREASED
 KIDNEY FAILURE
 A1 A2 A3
 Persistent Albuminura Categories
 A1
 A2
 A3
 = NORMAL TO MILDLY INCREASED; ACR <30 ug/mg; PCR <=200 mg/g
 = MODERATELY INCREASED; ACR 30-300 ug/mg; PCR 201-500 mg/g
 = SEVERELY INCREASED; ACR >300 ug/mg; PCR >500 mg/g
 = LOW RISK
 = HIGH RISK
 = MODERATELY INCREASED RISK
 = VERY HIGH RISK
 = PATIENT'S RESULT
 Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012
 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney
 Disease.                                      2013; 3: 1-150.
 2
 Kidney inter.; Suppl.
 The overall regression of eGFR with time is not statistically significant.
 Current eGFR is 45 mL/min/1.73mE2 corresponding to CKD stage 3a.
 Multiply eGFR by 1.159 if patient is African American.  Potassium is
 within goal and has not changed significantly, was 4.3 and now is 4.3
 mmol/L.
 Treatment Suggestions
 The current eGFR is significantly below the expected value  and has
 decreased, was 51 and now is 45 mL/min/1.73mE2.  Renal artery
 stenosis, obstruction, volume depletion, NSAIDs, ACEI or ARB, or other
 medications and contrast agents are common causes of a fall in
 eGFR.  Guidelines recommend a target blood pressure of 140/90
 mmHg or less in CKD patients to reduce cardiovascular risk and CKD
 progression.  Assessment of albuminuria (urine albumin:creatinine
 ratio or urine protein:creatinine ratio preferred) is recommended at
 least annually in CKD patients for staging and disease prognosis.
 eGFR, Blood Pressure, and Proteinuria
 Intact PTH is within goal, 41 pg/mL.  Calcium is within goal and has
 not changed significantly, was 9.1 and now is 9.1 mg/dL.  Carbon
 Dioxide is below goal and has decreased, was 21 and now is 19
 mmol/L.  Vitamin D insufficiency is present (16.2 ng/mL).
 Treatment Suggestions
 Plasma PTH cannot be interpreted without simultaneous
 measurements of serum calcium and phosphorus.  Begin vitamin D
 (ergocalciferol 50,000 IU/month orally for 6 months; alternatively,
 cholecalciferol 1000-2000 IU/d for 6 months).  If not on alkali, begin
 sodium bicarbonate, one 650 mg pill 2-3 times daily, otherwise
 increase dose.
 Bone & Mineral
 Most recent order does not include a fasting Lipid Panel.
 Lipids
 Most recent order does not include a CBC Panel or iron studies.
 Anemia
 Follow-Up Suggestions for CKD
 Recommended by KDOQI guidelines,
 at least yearly
 Spot Urine Panel
 Due
 Fasting Lipid Panel
 1 week
 Fasting Renal Panel
 6 months
 25-Hydroxy Vitamin D
 Fasting PTH with Renal Panel
 8 months
 CBC
 Graphs
 DISCLAIMER:These assessments and treatment suggestions are provided as a convenience and are neither comprehensive nor intended to replace the
 physician’s clinical judgment. They do not include information such as family history, personal history, or physical findings as would be obtained by the clinician
 during patient evaluation because LabCorp does not have access to the complete patient medical record.
 9.4.5.6992 Version:
 Page: 2 of 4
 Printed: 01/13/2021 Laboratory Director
 CLIA# 14D0897314
 150 Spring Lake Dr., Suite A
 Itasca, Illinois 60143 www.litholink.com
 866 361 7939 Facsimile
 John Asplin, MD Litholink, A LabCorp Company 800 338 4333 Telephone
CAMERON, JOHN E
 LabCorp Account #: 09683682
 01/12/2021 3a M 06/20/1958 WEIXELBAUM, LEE
 Litholink Patient Results Report PATIENT DATE OF BIRTH GENDER CKD STAGEDATE OF SERVICE PHYSICIAN
 months (since enrollment)
 eGFR
 months (since enrollment)
 PTH
 months (since enrollment)
 = serum calcium result was corrected for low serum albumin
 Calcium
 months (since enrollment)
 Hemoglobin
 Test Results & Treatments
 The 8 most recent lab results as well as the treatments are reported.
 K BUN SCr Date eGFR Weight (kg) HB A1c
 Protein/Cr
 ACEI/ARB Diuretic (mg/g) (ug/mg)
 Alb/Cr 1 Date Meds Reported DBP SBP
 eGFR
 4.3 18 01/12/21 1.61 45 ? ? ? ? ? ?
 4.3 18 09/21/20 1.46 51 ? ? ? ? ? ?
 4.5 20 08/02/19 1.42 53 ? ? ? ? ? ?
 4.5 17 07/31/18 1.38 55 ? ? ? ? ? ?
    The CKD-EPI eGFR equation has only been validated for patients aged 18-70.  Self-reported race was not provided; eGFR was calculated as if the patient was not African American.
 Multiply eGFR by 1.159 if African American.
 1
 LPD Date PTH P 25-D K Ca PB CaPB C0 AVD Vit D Alkali 2
 Bone & Mineral
 ? 01/12/21 41 9.1 16.2 4.3 19 ? ? ? ? ?
 ? 09/21/20 9.1 4.3 21 ? ? ? ? ?
 ? 08/02/19 9.4 4.5 20 ? ? ? ? ?
 ? 07/31/18 9.3 4.5 19 ? ? ? ? ?
 DISCLAIMER:These assessments and treatment suggestions are provided as a convenience and are neither comprehensive nor intended to replace the
 physician’s clinical judgment. They do not include information such as family history, personal history, or physical findings as would be obtained by the clinician
 during patient evaluation because LabCorp does not have access to the complete patient medical record.
 9.4.5.6992 Version:
 Page: 3 of 4
 Printed: 01/13/2021 Laboratory Director
 CLIA# 14D0897314
 150 Spring Lake Dr., Suite A
 Itasca, Illinois 60143 www.litholink.com
 866 361 7939 Facsimile
 John Asplin, MD Litholink, A LabCorp Company 800 338 4333 Telephone
PATIENT
 WEIXELBAUM, LEE
 Lipids
 Date
 LDL
 DATE OF BIRTH
 06/20/1958
 TG
 non-HDL
 Chol
 GENDER CKD STAGE DATE OF SERVICE
 M
 HDL
 3a
 01/12/2021
 PHYSICIAN
 Litholink Patient Results Report
 CAMERON, JOHN E
 LabCorp Account #: 09683682
 Statin
 Fibrate
 Niacin
 Fasting
 09/21/20
 119
 147
 145
 182
 37
 ?
 ?
 ?
 Yes
 08/02/19
 150
 152
 180
 220
 40
 ?
 ?
 ?
 Yes
 07/31/18
 87
 152
 117
 151
 34
 ?
 ?
 ?
 Yes
 Anemia
 Date
 Hb
 TSAT
 Ferritin
 Iron
 ESA
 09/21/20 14.3
 ?
 ?
 08/02/19 14.9
 ?
 ?
 07/31/18 14.1
 ?
 ?
 DISCLAIMER: These assessments and treatment suggestions are provided as a convenience and are neither comprehensive nor intended to replace the
 physician’s clinical judgment. They do not include information such as family history, personal history, or physical findings as would be obtained by the clinician
 during patient evaluation because LabCorp does not have access to the complete patient medical record.
 John Asplin, MD
 Laboratory Director
 CLIA# 14D0897314
 Litholink, A LabCorp Company
 150 Spring Lake Dr., Suite A
 Itasca, Illinois 60143
 800 338 4333 Telephone
 <PRESIDIO_ANONYMIZED_PHONE_NUMBER> Facsimile
 www.litholink.com
 Version:
 Printed:
 Page:
 9.4.5.6992
 01/13/2021
 4 of 4
PATIENT
 WEIXELBAUM, LEE
 Your Test Results
 Test
 DATE OF BIRTH
 06/20/1958
 GENDER CKD STAGE DATE OF SERVICE
 M
 3a
 Your Results
 01/12/2021
 PHYSICIAN
 Litholink Patient Results Report
 CAMERON, JOHN E
 LabCorp Account #: 09683682
 Comments
 Kidney Health
 eGFR estimates how well your kidneys
 are filtering blood.  The higher the
 number, the better your kidneys are
 working.
 45
 Ref Range: >59
 mL/min/1.73mE2
 YOU ARE IN STAGE 3a CHRONIC KIDNEY
 DISEASE (CKD). There are 5 stages of CKD. See
 below for more information.
 POTASSIUM helps keep your heart and
 muscles working properly. High or low
 levels can be dangerous.
 4.3
 Ref. Range: 3.5 to 5.2 mmol/L
 YOUR POTASSIUM IS NORMAL. To keep it in
 the normal range, make sure you avoid foods high
 in potassium. For more information, visit
 www.kidney.org/atoz/content/potassium.cfm.
 YOUR eGFR IS 45, YOU ARE IN STAGE 3a CKD. THINGS YOU NEED TO KNOW:
 · CKD means your kidneys show decreased function which may be caused by aging, diabetes, high blood
 pressure, or many other diseases. CKD can lead to heart disease.
 · Even if you feel fine, you may be at risk for problems such as high blood pressure, high cholesterol, anemia,
 and bone disease.  Your doctor should test you for these problems.
 · Avoid taking NSAIDs (e.g. ibuprofen, Advil®, Motrin®, Aleve®) as these may worsen your kidney function.
 · Your eGFR result may be slightly higher if you are African American.
 · To learn more, visit the National Kidney Foundation’s website: www.kidney.org/kidneydisease.
 DISCLAIMER: You should discuss this information with your physician. Litholink does not have a doctor-patient relationship with you, nor does it have access to a complete
 medical history or physical examination conducted by a physician that would be necessary for a complete diagnosis and comprehensive treatment plan. Neither you nor your
 physician should rely solely on this guidance. Bolded result descriptions in "Comments" consider either the reference range or target range for the test result. Reference range
 refers to the LabCorp reference interval. Target range refers to the guideline-suggested goal. REFERENCES:National Kidney Foundation Kidney Disease Outcomes Quality
 Initiative (KDOQI) at www.Kidney.org and Kidney Disease Improving Global Outcomes (KDIGO) at http://kdigo.org. Adapted from: http://nkdep.nih.gov/resources/nkdep-kidney
test-results-508.pdf.
 John Asplin, MD
 Laboratory Director
 CLIA# 14D0897314
 Litholink, A LabCorp Company
 150 Spring Lake Dr., Suite A
 Itasca, Illinois 60143
 800 338 4333 Telephone
 <PRESIDIO_ANONYMIZED_PHONE_NUMBER> Facsimile
 www.litholink.com
 Version:
 Printed:
 Page:
 9.4.5.6992
 01/13/2021
 1 of 1
 1 Patient Report   
Specimen ID:  012-216-1249-0 Acct #: 09241500 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER> Rte: 00
 Control ID: 30185034521
 Andrew Henry MD
 9260 BAY PLAZA BLVD, STE 502
 Brandon FL 33619
 WEIXELBAUM, LEE S.
 2811 WINDING TRAIL DR
 VALRICO FL  33596
 (813) 445-1261
 Patient Details
 DOB: 06/20/1958
 Age(y/m/d): 062/06/23
 Gender:  M
 Patient ID:
 Specimen Details
 Date collected: 01/12/2021  0727 Local
 Date received: 01/12/2021
 Date entered: 01/12/2021
 Date reported: 01/18/2021  0807 ET
 Physician Details
 Ordering: A  HENRY
 Referring:
 ID:
 NPI:  1194892141
 Date Issued: 01/20/21 1811 ET FINAL REPORT Page 1 of 2
 This document contains private and confidential health information protected by state and federal law.
 If you have received this document in error, please call 800-877-5227
 © 1995-2021 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version:          
General Comments & Additional Information
 Total Volume: Not Provided Fasting: No
 Ordered Items
 Comp. Metabolic Panel (14); Free T4 by Dialysis/Mass Spec; Testosterone, Serum; TSH; Prostate-Specific Ag, Serum; Triiodothyronine
 (T3); Ambig Abbrev CMP14 Default; Venipuncture; Handwritten Order
           TESTS              RESULT     FLAG      UNITS  REFERENCE INTERVAL  LAB
 Comp. Metabolic Panel (14)
  Glucose                               89 mg/dL     65-99 01
  BUN                                   19 mg/dL      8-27 01
  Creatinine                          1.42   High mg/dL   0.76-1.27 01
  eGFR If NonAfricn Am                  53    Low mL/min/1.73        >59
  eGFR If Africn Am                     61 mL/min/1.73        >59
  BUN/Creatinine Ratio                  13     10-24
  Sodium                               142 mmol/L    134-144 01
  Potassium                            4.4 mmol/L    3.5-5.2 01
  Chloride                             107   High mmol/L     96-106 01
  Carbon Dioxide, Total                 23 mmol/L     20-29 01
  Calcium                              9.0 mg/dL    8.6-10.2 01
  Protein, Total                       6.5 g/dL    6.0-8.5 01
  Albumin                              4.1 g/dL    3.8-4.8 01
  Globulin, Total                      2.4 g/dL    1.5-4.5
  A/G Ratio                            1.7    1.2-2.2
  Bilirubin, Total                     1.0 mg/dL    0.0-1.2 01
  Alkaline Phosphatase                  65 IU/L     39-117 01
  AST (SGOT)                            21 IU/L      0-40 01
  ALT (SGPT)                            19 IU/L      0-44 01
 Free T4 by Dialysis/Mass Spec
 0.91 ng/dL 02
     This test was developed and its performance characteristics
     determined by LabCorp. It has not been cleared or approved
     by the Food and Drug Administration.
     Reference Range:
     Pubertal Children and Adults:
     0.8 - 1.7
 Testosterone, Serum                   447 ng/dL    264-916 01
     Adult male reference interval is based on a population of
 1.00
1 Patient Report   
Patient: WEIXELBAUM, LEE S.
 DOB: 06/20/1958
 Patient ID:
 Specimen ID: 012-216-1249-0
 Control ID: 30185034521
 Date collected: 01/12/2021  0727 Local
           TESTS              RESULT     FLAG      UNITS  REFERENCE INTERVAL  LAB
     healthy nonobese males (BMI <30) between 19 and 39 years old.
     Travison, et.al. JCEM 2017,102;1161-1173. PMID: 28324103.
 TSH       
Prostate-Specific Ag, Serum
 Prostate Specific Ag, Serum       
                          6.740   High
   0.9
 uIU/mL
 ng/mL
  0.450-4.500
    0.0-4.0
     Roche ECLIA methodology.
     According to the American Urological Association, Serum PSA should
     decrease and remain at undetectable levels after radical
     prostatectomy. The AUA defines biochemical recurrence as an initial
     PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory
     PSA value 0.2 ng/mL or greater.
     Values obtained with different assay methods or kits cannot be used
     interchangeably. Results cannot be interpreted as absolute evidence
     of the presence or absence of malignant disease.
 Triiodothyronine (T3)       
Ambig Abbrev CMP14 Default
          109
 ng/dL
     71-180
     A hand-written panel/profile was received from your office. In
     accordance with the LabCorp Ambiguous Test Code Policy dated July
     2003, we have completed your order by using the closest currently
     or formerly recognized AMA panel.  We have assigned Comprehensive
     Metabolic Panel (14), Test Code #322000 to this request.  If this
     is not the testing you wished to receive on this specimen, please
     contact the LabCorp Client Inquiry/Technical Services Department
     to clarify the test order.  We appreciate your business.
 01 TA
 02 ES
 LabCorp Tampa
 5610 W LaSalle Street, Tampa, FL 33607-1770
 Dir: Sean Farrier, MD
 01
 01
 01
 01
 Esoterix Inc
 4301 Lost Hills Road, Calabasas Hills, CA 91301-5358
 For inquiries, the physician may contact Branch: 800-877-5227 Lab: 800-877-5227
 Dir: Samuel Pepkowitz, MD
 Date Issued: 01/20/21 1811 ET
 FINAL REPORT
 This document contains private and confidential health information protected by state and federal law.
 If you have received this document in error, please call 800-877-5227
 Page 2 of 2
 © 1995-2021 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version:          
1.00Weixelbaum, Lee S
 DOB: 06/20/1958
 Patient Report
 Patient ID: 106008419028
 Specimen ID: 305-443-1331-0
 Age: 66
 Sex: Male
 Account Number: 09521990
 Ordering Physician: F KOMAL
 Date Collected: 10/31/2024
 Date Received: 10/31/2024
 Date Reported: 11/06/2024
 Ordered Items: Hgb+Hct; Testosterone,Free and Total; Thyroxine (T4) Free, Direct; TSH; Venipuncture
 Fasting: No
 Date Collected: 10/31/2024
 Hgb+Hct
 Test
 Hemoglobin 01
 Hematocrit 01
 Current Result and Flag
 13.5
 Previous Result and Date
 13.8
 06/03/2024
 Units
 Reference Interval
 g/dL
 41.0
 Testosterone,Free and Total
 Test
 Testosterone 01
 Current Result and Flag
 375
 40.9
 06/03/2024
 Previous Result and Date
 410
 07/12/2024
 Adult male reference interval is based on a population of
 healthy nonobese males (BMI <30) between 19 and 39 years old.
 Travison, et.al. JCEM 2017,102;1161-1173. PMID: 28324103.
 %
 Units
 ng/dL
 13.0-17.7
 37.5-51.0
 Reference Interval
 264-916
 Free Testosterone(Direct) 02
 Thyroxine (T4) Free, Direct
 Test
 T4,Free(Direct) 01
 3.8
 Low
 Current Result and Flag
 1.05
 5.0
 07/12/2024
 Previous Result and Date
 pg/mL
 Units
 6.6-18.1
 Reference Interval
 1.10
 TSH
 Test
 Current Result and Flag
 07/07/2023
 Previous Result and Date
 TSH 01
 3.040
 ng/dL
 Units
 0.82-1.77
 Reference Interval
 5.370
 Disclaimer
 07/12/2024
 uIU/mL
 0.450-4.500
 The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to
 match the result to the patient. Results from certain tests are excluded from the Previous Result display.
 Icon Legend
 Out of Reference Range     
Performing Labs
 Critical or Alert
 01: TA - Labcorp Tampa, 5610 W LaSalle Street, Tampa, FL 33607-1770 Dir: Sean Farrier, MD
 02: BN - Labcorp Burlington, 1447 York Court, Burlington, NC 27215-3361 Dir: Sanjai Nagendra, MD
 For inquiries, the physician may contact Branch: 800-877-5227 Lab: 800-877-5227
 ©2024 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  11/06/24 1311 ET   Final Report  Page 1 of 2
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee S
 DOB: 06/20/1958
 Patient Report
 Patient ID: 106008419028
 Specimen ID: 305-443-1331-0
 Age: 66
 Sex: Male
 Account Number: 09521990
 Ordering Physician: F KOMAL
 Patient Details
 Weixelbaum, Lee S
 2811 WINDING TRAIL DR, VALRICO, FL, 33596
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Date of Birth: 06/20/1958
 Age: 66
 Sex: Male
 Patient ID: 106008419028
 Alternate Patient ID: 301181250
 Physician Details
 F KOMAL
 Endocrinology at Bloomingdale
 2470 Bloomingdale Ave Ste 123, Valrico, FL,
 33596
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Account Number: 09521990
 Physician ID: 1235616541
 NPI: 1235616541
 Specimen Details
 Specimen ID: 305-443-1331-0
 Control ID: 10600841902
 Alternate Control Number:
 106008419028L83451
 Date Collected: 10/31/2024 1400  Local
 Date Received: 10/31/2024 0000  ET
 Date Entered: 10/31/2024 1607  ET
 Date Reported: 11/06/2024 1308  ET
 ©2024 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  11/06/24 1311 ET   Final Report  Page 2 of 2
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee S
 Patient ID:
 Specimen ID: 261-216-1980-0
 DOB: 06/20/1958
 Age: 66
 Sex: Male
 Patient Report
 Account Number: 09349605
 Ordering Physician: A ROSSI
 Date Collected: 09/17/2024
 Date Received: 09/17/2024
 Date Reported: 09/18/2024
 Ordered Items: Basic Metabolic Panel (8); Litholink CKD Program; Venipuncture
 Basic Metabolic Panel (8)
 Test
 Glucose 01
 BUN 01
 Creatinine 01
 eGFR
 BUN/Creatinine Ratio
 Sodium 01
 Potassium 01
 Chloride 01
 Carbon Dioxide, Total 01
 Calcium 01
 Litholink CKD Program
 Test
 Current Result and Flag
 90
 20
 1.46
 53
 14
 140
 4.3
 105
 22
 9.2
 High
 Low
 Current Result and Flag
 Previous Result and Date
 84
 21
 1.50
 51
 14
 140
 4.5
 104
 23
 9.3
 07/12/2024
 07/12/2024
 07/12/2024
 07/12/2024
 07/12/2024
 07/12/2024
 07/12/2024
 07/12/2024
 07/12/2024
 07/12/2024
 Previous Result and Date
 Interpretation 02
 Note
 Note
 06/03/2024------------------------------
CHRONIC KIDNEY DISEASE:
 EGFR, BLOOD PRESSURE, AND PROTEINURIA ASSESSMENT
 The overall regression of eGFR with time is not
 statistically significant. Current eGFR is 53 mL/min/1.73mE2
 corresponding to CKD stage 3a. Potassium is within goal and
 has decreased, was 4.8 and now is 4.3 mmol/L.
 EGFR, BLOOD PRESSURE, AND PROTEINURIA TREATMENT SUGGESTIONS
Guidelines recommend a target blood pressure of 120/80 mmHg
 or less to reduce cardiovascular risk and CKD progression.
 Assessment of albuminuria (urine albumin:creatinine ratio or
 urine protein:creatinine ratio preferred) is recommended at
 least annually in CKD patients for staging and disease
 prognosis.
 EGFR, BLOOD PRESSURE, AND PROTEINURIA FOLLOW-UP
fasting Renal Panel within 12 months; Spot Urine Panel
 (Albumin preferred) is recommended by guidelines, at least
 yearly;
 BONE and MINERAL ASSESSMENT
 Calcium is within goal and has not changed significantly,
 was 9.1 and now is 9.2 mg/dL. Carbon Dioxide is within goal
 and has not changed significantly, was 22 and now is 22
 mmol/L. Vitamin D is adequate (42.0 ng/mL 6/3/2024) .
 BONE and MINERAL TREATMENT SUGGESTIONS
Interpretations require simultaneous measurements of serum
 calcium and phosphorus.
 BONE and MINERAL FOLLOW-UP
Fasting: Yes
 Date Collected: 09/17/2024
 Units
 mg/dL
 mg/dL
 mg/dL
 mL/min/1.73
 mmol/L
 mmol/L
 mmol/L
 mmol/L
 mg/dL
 Units
 Reference Interval
 70-99
 8-27
 0.76-1.27
 >59
 10-24
 134-144
 3.5-5.2
 96-106
 20-29
 8.6-10.2
 Reference Interval
 ©2024 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  09/18/24 0822 ET   Final Report  Page 1 of 4
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee S DOB: 06/20/1958 Patient Report
 Patient ID: Age: 66 Account Number: 09349605
 Specimen ID: 261-216-1980-0 Sex: Male Ordering Physician: A ROSSI
 Date Collected: 09/17/2024
 Litholink CKD Program (Cont.)
 25-Hydroxy Vitamin D within 9 months; fasting PTH with Renal
 Panel is due;
 LIPIDS ASSESSMENT
 Most recent order does not include a fasting Lipid Panel.
 LIPIDS FOLLOW-UP
 
 fasting Lipid Panel is due;
 ANEMIA ASSESSMENT
 Most recent order does not include a CBC Panel or iron
 studies.
 ANEMIA FOLLOW-UP
 
 CBC within 9 months;
 ------------------------------
 DISCLAIMER
 These assessments and treatment suggestions are provided as
 a convenience in support of the physician-patient
 relationship and are not intended to replace the physician's
 clinical judgment. They are derived from national guidelines
 in addition to other evidence and expert opinion. The
 clinician should consider this information within the
 context of clinical opinion and the individual patient.
 SEE GUIDANCE FOR CHRONIC KIDNEY DISEASE PROGRAM: Kidney
 Disease Improving Global Outcomes (KDIGO) clinical practice
 guidelines are at http://kdigo.org/home/guidelines/.
 National Kidney Foundation Kidney Disease Outcomes Quality
 Initiative (KDOQI (TM)), with its limitations and
 disclaimers, are at www.kidney.org/professionals/KDOQI. This
 program is intended for patients who have been diagnosed
 with stages 3, 4, or pre-dialysis 5 CKD. It is not intended
 for children, pregnant patients, or transplant patients.
 PDF 02 . Not applicable 06/03/2024
 
Disclaimer
 The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to
 match the result to the patient. Results from certain tests are excluded from the Previous Result display.
 
Icon Legend
 Out of Reference Range      Critical or Alert
 
Performing Labs
 01: TA - Labcorp Tampa, 5610 W LaSalle Street, Tampa, FL 33607-1770 Dir: Sean Farrier, MD
 02: LITNC - Labcorp Clinical / Digital, 10 Moore Drive, Durham, NC 27709-0009 Dir: Jennifer Ennis, MD
 For Inquiries, the physician may contact Branch: 800-877-5227 Lab: 800-877-5227
 
Date Created and Stored  09/18/24 0822 ET   Final Report  Page 2 of 4
 ©2024 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee S
 DOB: 06/20/1958
 Patient Report
 Patient ID:
 Specimen ID: 261-216-1980-0
 Age: 66
 Sex: Male
 Account Number: 09349605
 Ordering Physician: A ROSSI
 Patient Details
 Weixelbaum, Lee S
 2811 WINDING TRAIL DR, VALRICO, FL, 33596
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Date of Birth: 06/20/1958
 Age: 66
 Sex: Male
 Patient ID:
 Alternate Patient ID:
 Physician Details
 A ROSSI
 HEALTH POINT MED- OB GYN PLANT
 1601 W Timberlane Dr Ste 300, PLANT CITY,
 FL, 33566
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Account Number: 09349605
 Physician ID:
 NPI: 1811153737
 Specimen Details
 Specimen ID: 261-216-1980-0
 Control ID: 30185009313
 Alternate Control Number:
 Date Collected: 09/17/2024 0751  Local
 Date Received: 09/17/2024 0000  ET
 Date Entered: 09/17/2024 1118  ET
 Date Reported: 09/18/2024 0815  ET
 ©2024 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  09/18/24 0822 ET   Final Report  Page 3 of 4
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee S
 Patient ID:
 Specimen ID: 261-216-1980-0
 Historical Results & Insights
 DOB: 06/20/1958
 Age: 66
 Sex: Male
 Patient Report
 Account Number: 09349605
 Ordering Physician: A ROSSI
 Labcorp offers historical lab results data with easy-to-interpret visualizations to provide a more complete picture of a patient’s lab history and improve patient care.
 Creatinine
 Current Result: 1.46 mg/dL
 1.47
 1.63
 1.44
 1.37
 1.46
 1.29
 1.27
 1.32
 1.21
 eGFR
 Current Result: 53 mL/min/1.73
 CKD Evaluation
 60
 58
 67
 60
 Sep 8, 2022
 Nov 21, 2022
 53
 62
 54
 53
 Feb 6, 2023
 Mar 10, 2023
 Apr 28, 2023
 47
 45
 Sep 8, 2022
 Nov 21, 2022
 Feb 6, 2023
 Mar 10, 2023
 Apr 28, 2023
 Jul 7, 2023
 HIGH
 1.53
 1.46
 1.50
 Reference Interval: 0.76-1.27 mg/dL
 MILDLY DECREASED
 50 51 53
 Stage 3a
 Jul 7, 2023
 Nov 28, 2023
 Nov 28, 2023
 ©2024 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  09/18/24 0822 ET   Final Report  Page 4 of 4
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
 Jun 3, 2024
 Jul 12, 2024
 Sep 17, 2024
 Jun 3, 2024
 Jul 12, 2024
 Sep 17, 2024
PATIENT
 WEIXELBAUM, LEE
 Accessions: 26121619800
 DATE OF BIRTH
 06/20/1958
 GENDER CKD STAGE DATE OF SERVICE
 M
 3a
 09/17/2024
 PHYSICIAN
 Litholink Patient Results Report
 LabCorp Account #: 09349605
 DISCLAIMER: These assessments and treatment suggestions are provided as a convenience in support of the physician-patient relationship and are not intended to
 replace the physician’s clinical judgment.  They are derived from national guidelines in addition to other evidence and expert opinion.  The clinician should consider
 this information within the context of clinical opinion and the individual patient.
 SEE GUIDANCE FOR CHRONIC KIDNEY DISEASE PROGRAM: Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines are at
 http://kdigo.org/home/guidelines/. National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI (TM)), with its limitations and disclaimers, are at
 www.kidney.org/professionals/KDOQI. This program is intended for patients who have been diagnosed with stages 3, 4, or pre-dialysis 5 CKD. It is not intended for
 children, pregnant patients, or transplant patients.
 Note:  Please refer to your LabCorp Report for all results as well as any test-specific and specimen-specific comments.
 Chronic Kidney Disease
 Analysis & Treatment Suggestions
 GENDER
 DIABETES
 CURRENT eGFR
 MOST RECENT CKD STAGE
 M
 ?
 53
 3a
 Prognosis of CKD by GFR And Albuminuria Categories
 GFR Categories: (ml/min/1.73m  )
 2
 G1
 >=90
 60-89
 45-59
 30-44
 15-29
 <15
 G2
 G3a
 G3b
 G4
 G5
 NORMAL OR HIGH
 MILDLY DECREASED
 MILDLY TO MODERATELY DECREASED
 MODERATELY TO SEVERELY DECREASED
 SEVERELY DECREASED
 KIDNEY FAILURE
 A1
 eGFR, Blood Pressure, and Proteinuria
 The overall regression of eGFR with time is not statistically significant.
 Current eGFR is 53 mL/min/1.73mE2 corresponding to CKD stage 3a.
 Potassium is within goal and has decreased, was 4.8 and now is 4.3
 mmol/L.
 Persistent Albuminura Categories
 A2
 A3
 = NORMAL TO MILDLY INCREASED; ACR <30 ug/mg; PCR <=200 mg/g
 = MODERATELY INCREASED; ACR 30-300 ug/mg; PCR 201-500 mg/g
 = SEVERELY INCREASED; ACR >300 ug/mg; PCR >500 mg/g
 A1
 A2
 A3
 = LOW RISK
 = HIGH RISK
 = PATIENT'S RESULT
 = MODERATELY INCREASED RISK
 = VERY HIGH RISK
 Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012
 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney
 Disease.                                      2013; 3: 1-150.
 Kidney inter.; Suppl.
 Treatment Suggestions
 Guidelines recommend a target blood pressure of 120/80 mmHg or
 less to reduce cardiovascular risk and CKD progression.  Assessment
 of albuminuria (urine albumin:creatinine ratio or urine
 protein:creatinine ratio preferred) is recommended at least annually in
 CKD patients for staging and disease prognosis.
 Bone & Mineral
 Calcium is within goal and has not changed significantly, was 9.1 and
 now is 9.2 mg/dL.  Carbon Dioxide is within goal and has not changed
 significantly, was 22 and now is 22 mmol/L.  Vitamin D is adequate
 (42.0 ng/mL 6/3/2024) .
 Treatment Suggestions
 Interpretations require simultaneous measurements of serum calcium
 and phosphorus.
 Lipids
 Most recent order does not include a fasting Lipid Panel.
 Anemia
 Most recent order does not include a CBC Panel or iron studies.
 Follow-Up Suggestions for CKD
 Recommended by guidelines, at
 least yearly
 Spot Urine Panel (Albumin preferred)
 Due
 Fasting PTH with Renal Panel
 Fasting Lipid Panel
 9 months
 25-Hydroxy Vitamin D
 CBC
 12 months
 Fasting Renal Panel
 © 1995-2021 Laboratory Corporation of America® Holdings
 All RIghts Reserved - Enterprise Report Version 2.00
 Date Issued 09/17/2024 11:22 PM
 Page: 1 of 1
 This document contains private and confidential health information protected by state and federal law.
 If you have received this document in error, please call 336-222-7566.
PATIENT
 WEIXELBAUM, LEE
 Your Test Results
 Test
 DATE OF BIRTH
 06/20/1958
 GENDER CKD STAGE DATE OF SERVICE
 M
 3a
 Your Results
 09/17/2024
 PHYSICIAN
 Litholink Patient Results Report
 LabCorp Account #: 09349605
 Comments
 Kidney Health
 eGFR estimates how well your kidneys
 are filtering blood.  The higher the
 number, the better your kidneys are
 working.
 53
 Ref Range: >59
 mL/min/1.73mE2
 YOU ARE IN STAGE 3a CHRONIC KIDNEY
 DISEASE (CKD). There are 5 stages of CKD. See
 below for more information.
 POTASSIUM helps keep your heart and
 muscles working properly. High or low
 levels can be dangerous.
 4.3
 Ref. Range: 3.5 to 5.2 mmol/L
 YOUR POTASSIUM IS NORMAL. To keep it in
 the normal range, make sure you avoid foods high
 in potassium. For more information, visit
 www.kidney.org/atoz/content/potassium.cfm.
 YOUR eGFR IS 53, YOU ARE IN STAGE 3a CKD. THINGS YOU NEED TO KNOW:
 · CKD means your kidneys show decreased function which may be caused by aging, diabetes, high blood
 pressure, or many other diseases. CKD can lead to heart disease.
 · Even if you feel fine, you may be at risk for problems such as high blood pressure, high cholesterol, anemia,
 and bone disease.  Your doctor should test you for these problems.
 · Avoid taking NSAIDs (e.g. ibuprofen, Advil®, Motrin®, Aleve®) as these may worsen your kidney function.
 · To learn more, visit the National Kidney Foundation’s website: www.kidney.org/kidneydisease.
 DISCLAIMER: You should discuss this information with your physician. Labcorp does not have a doctor-patient relationship with you, nor does it have access to a complete
 medical history or physical examination conducted by a physician that would be necessary for a complete diagnosis and comprehensive treatment plan. Neither you nor your
 physician should rely solely on this guidance. Bolded result descriptions in "Comments" consider either the reference range or target range for the test result. Reference range
 refers to the Labcorp reference interval. Target range refers to the guideline-suggested goal. REFERENCES:National Kidney Foundation Kidney Disease Outcomes Quality
 Initiative (KDOQI) at www.Kidney.org and Kidney Disease Improving Global Outcomes (KDIGO) at http://kdigo.org. Adapted from: https://www.niddk.nih.gov/-/media/Files/Health-Information/Health-Professionals/Kidney-Disease/Your_Kidney_Test_Results_EN.pdf.
 © 1995-2021 Laboratory Corporation of America® Holdings
 All RIghts Reserved - Enterprise Report Version 2.00
 Date Issued 09/17/2024 11:22 PM
 Page: 1 of 1
 This document contains private and confidential health information protected by state and federal law.
 If you have received this document in error, please call 336-222-7566.
Weixelbaum, Lee S
 Patient ID:
 Specimen ID: 194-216-2928-0
 DOB: 06/20/1958
 Age: 66
 Sex: Male
 Patient Report
 Account Number: 09241500
 Ordering Physician: A HENRY
 Date Collected: 07/12/2024
 Date Received: 07/12/2024
 Date Reported: 07/21/2024
 Fasting: No
 Ordered Items: Comp. Metabolic Panel (14); Testosterone,Free and Total; Free T4 by Dialysis/Mass Spec; TSH; Prostate-Specific Ag;
 Vitamin D, 25-Hydroxy; Triiodothyronine (T3); Venipuncture
 Date Collected: 07/12/2024
 Comp. Metabolic Panel (14)
 Test
 Glucose 01
 BUN 01
 Creatinine 01
 eGFR
 BUN/Creatinine Ratio
 Sodium 01
 Potassium 01
 Chloride 01
 Carbon Dioxide, Total 01
 Calcium 01
 Protein, Total 01
 Albumin 01
 Globulin, Total
 Bilirubin, Total 01
 Alkaline Phosphatase 01
 AST (SGOT) 01
 ALT (SGPT) 01
 Testosterone,Free and Total
 Test
 Testosterone 01
 Free Testosterone(Direct) 02
 Free T4 by Dialysis/Mass Spec
 Test
 Free T4 by Dialysis/Mass Spec 03
 TSH
 Test
 TSH 01
 Current Result and Flag
 84
 21
 1.50
 51
 14
 140
 4.5
 104
 23
 9.3
 6.7
 4.2
 2.5
 0.8
 71
 24
 21
 High
 Low
 Current Result and Flag
 410
 Previous Result and Date
 89
 29
 1.53
 50
 19
 138
 4.8
 104
 22
 9.1
 6.7
 4.4
 2.3
 1.1
 62
 26
 18
 06/03/2024
 06/03/2024
 06/03/2024
 06/03/2024
 06/03/2024
 06/03/2024
 06/03/2024
 06/03/2024
 06/03/2024
 06/03/2024
 06/03/2024
 06/03/2024
 06/03/2024
 06/03/2024
 06/03/2024
 06/03/2024
 06/03/2024
 Previous Result and Date
 447
 01/12/2024
 Adult male reference interval is based on a population of
 healthy nonobese males (BMI <30) between 19 and 39 years old.
 Travison, et.al. JCEM 2017,102;1161-1173. PMID: 28324103.
 5.0
 Low
 Current Result and Flag
 0.96
 7.7
 01/12/2024
 Previous Result and Date
 0.97
 01/12/2024
 This test was developed and its performance characteristics
 determined by Labcorp. It has not been cleared or approved
 by the Food and Drug Administration.
 Reference Range:
 Pubertal Children and Adults:
 0.8 - 1.7
 Current Result and Flag
 5.370
 High
 Previous Result and Date
 3.860
 01/12/2024
 Units
 mg/dL
 mg/dL
 mg/dL
 mL/min/1.73
 mmol/L
 mmol/L
 mmol/L
 mmol/L
 mg/dL
 g/dL
 g/dL
 g/dL
 mg/dL
 IU/L
 IU/L
 IU/L
 Units
 ng/dL
 pg/mL
 Units
 ng/dL
 Units
 uIU/mL
 Reference Interval
 70-99
 8-27
 0.76-1.27
 >59
 10-24
 134-144
 3.5-5.2
 96-106
 20-29
 8.6-10.2
 6.0-8.5
 3.9-4.9
 1.5-4.5
 0.0-1.2
 44-121
 0-40
 0-44
 Reference Interval
 264-916
 6.6-18.1
 Reference Interval
 Reference Interval
 0.450-4.500
 ©2024 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  07/21/24 0811 ET   Final Report  Page 1 of 4
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee S DOB: 06/20/1958 Patient Report
 Patient ID: Age: 66 Account Number: 09241500
 Specimen ID: 194-216-2928-0 Sex: Male Ordering Physician: A HENRY
 Date Collected: 07/12/2024
 Prostate-Specific Ag
 Test Current Result and Flag Previous Result and Date Units Reference Interval
 Prostate Specific Ag 01 2.8 2.3 06/03/2024 ng/mL 0.0-4.0
 Roche ECLIA methodology.
 According to the American Urological Association, Serum PSA should
 decrease and remain at undetectable levels after radical
 prostatectomy. The AUA defines biochemical recurrence as an initial
 PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory
 PSA value 0.2 ng/mL or greater.
 Values obtained with different assay methods or kits cannot be used
 interchangeably. Results cannot be interpreted as absolute evidence
 of the presence or absence of malignant disease.
 Vitamin D, 25-Hydroxy
 Test Current Result and Flag Previous Result and Date Units Reference Interval
 Vitamin D, 25-Hydroxy 01 38.0 42.0 06/03/2024 ng/mL 30.0-100.0
 Vitamin D deficiency has been defined by the Institute of
 Medicine and an Endocrine Society practice guideline as a
 level of serum 25-OH vitamin D less than 20 ng/mL (1,2).
 The Endocrine Society went on to further define vitamin D
 insufficiency as a level between 21 and 29 ng/mL (2).
 1. IOM (Institute of Medicine). 2010. Dietary reference
    intakes for calcium and D. Washington DC: The
    National Academies Press.
 2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al.
    Evaluation, treatment, and prevention of vitamin D
    deficiency: an Endocrine Society clinical practice
    guideline. JCEM. 2011 Jul; 96(7):1911-30.
 Triiodothyronine (T3)
 Test Current Result and Flag Previous Result and Date Units Reference Interval
 Triiodothyronine (T3) 01 86 99 01/12/2024 ng/dL 71-180
 
Disclaimer
 The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to
 match the result to the patient. Results from certain tests are excluded from the Previous Result display.
 
Icon Legend
 Out of Reference Range      Critical or Alert
 
Performing Labs
 01: TA - Labcorp Tampa, 5610 W LaSalle Street, Tampa, FL 33607-1770 Dir: Sean Farrier, MD
 02: RN - Labcorp Raritan, 69 First Avenue, Raritan, NJ 08869-1800 Dir: Liza Jodry, MD
 03: ES - Esoterix Inc, 4301 Lost Hills Road, Calabasas Hills, CA 91301-5358 Dir: Brian Poirier, MD
 For Inquiries, the physician may contact Branch: 800-877-5227 Lab: 800-877-5227
 
Date Created and Stored  07/21/24 0811 ET   Final Report  Page 2 of 4
 ©2024 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee S
 DOB: 06/20/1958
 Patient Report
 Patient ID:
 Specimen ID: 194-216-2928-0
 Age: 66
 Sex: Male
 Account Number: 09241500
 Ordering Physician: A HENRY
 Patient Details
 Weixelbaum, Lee S
 2811 WINDING TRAIL DR, VALRICO, FL, 33596
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Date of Birth: 06/20/1958
 Age: 66
 Sex: Male
 Patient ID:
 Alternate Patient ID:
 Physician Details
 A HENRY
 Andrew Henry MD
 9260 BAY PLAZA BLVD, STE 502, Tampa, FL,
 33619
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Account Number: 09241500
 Physician ID:
 NPI: 1194892141
 Specimen Details
 Specimen ID: 194-216-2928-0
 Control ID: 30185005377
 Alternate Control Number:
 Date Collected: 07/12/2024 0812  Local
 Date Received: 07/12/2024 0000  ET
 Date Entered: 07/12/2024 1104  ET
 Date Reported: 07/21/2024 0807  ET
 ©2024 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  07/21/24 0811 ET   Final Report  Page 3 of 4
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee S
 Patient ID:
 Specimen ID: 194-216-2928-0
 Historical Results & Insights
 DOB: 06/20/1958
 Age: 66
 Sex: Male
 Patient Report
 Account Number: 09241500
 Ordering Physician: A HENRY
 Labcorp offers historical lab results data with easy-to-interpret visualizations to provide a more complete picture of a patient’s lab history and improve patient care.
 Creatinine
 Current Result: 1.50 mg/dL
 1.27
 1.27
 1.63
 1.47
 1.46
 1.44
 1.37
 1.32
 1.21
 eGFR
 Current Result: 51 mL/min/1.73
 CKD Evaluation
 63
 58
 67
 May 20, 2022
 60
 Sep 8, 2022
 Nov 21, 2022
 60
 45
 53
 62
 54
 53
 47
 May 20, 2022
 Sep 8, 2022
 Nov 21, 2022
 Feb 6, 2023
 Mar 10, 2023
 Apr 28, 2023
 Jul 7, 2023
 HIGH
 1.53
 1.50
 Reference Interval: 0.76-1.27 mg/dL
 MILDLY DECREASED
 Feb 6, 2023
 Mar 10, 2023
 Apr 28, 2023
 50 51
 Stage 3a
 Jul 7, 2023
 Nov 28, 2023
 ©2024 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Nov 28, 2023
 Date Created and Stored  07/21/24 0811 ET   Final Report  Page 4 of 4
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
 Jun 3, 2024
 Jul 12, 2024
 Jun 3, 2024
 Jul 12, 2024
Weixelbaum, Lee S DOB: 06/20/1958 Patient Report
 Patient ID: 106010275168 Age: 65 Account Number: 09621402
 Specimen ID: 155-216-2001-0 Sex: Male Ordering Physician: S STEVENSON
 Date Collected: 06/03/2024 Date Received: 06/03/2024 Date Reported: 06/04/2024 Fasting: No
 Ordered Items: CBC With Differential/Platelet; Comp. Metabolic Panel (14); Lipid Panel; Litholink CKD Program; Hemoglobin A1c;
 Prostate-Specific Ag; Vitamin D, 25-Hydroxy; Thyroid Cascade Profile; Venipuncture
 Date Collected: 06/03/2024
 CBC With Differential/Platelet
 Test Current Result and Flag Previous Result and Date Units Reference Interval
 WBC 01 7.1 5.7 04/28/2023 x10E3/uL 3.4-10.8
 RBC 01 4.46 4.56 04/28/2023 x10E6/uL 4.14-5.80
 Hemoglobin 01 13.8 14.1 04/28/2023 g/dL 13.0-17.7
 Hematocrit 01 40.9 41.1 04/28/2023 % 37.5-51.0
 MCV 01 92 90 04/28/2023 fL 79-97
 MCH 01 30.9 30.9 04/28/2023 pg 26.6-33.0
 MCHC 01 33.7 34.3 04/28/2023 g/dL 31.5-35.7
 RDW 01 13.7 13.2 04/28/2023 % 11.6-15.4
 Platelets 01 193 196 04/28/2023 x10E3/uL 150-450
 Neutrophils 01 57 53 04/28/2023 % Not Estab.
 Lymphs 01 29 32 04/28/2023 % Not Estab.
 Monocytes 01 9 8 04/28/2023 % Not Estab.
 Eos 01 4 6 04/28/2023 % Not Estab.
 Basos 01 1 1 04/28/2023 % Not Estab.
 Neutrophils (Absolute) 01 4.0 3.0 04/28/2023 x10E3/uL 1.4-7.0
 Lymphs (Absolute) 01 2.0 1.8 04/28/2023 x10E3/uL 0.7-3.1
 Monocytes(Absolute) 01 0.6 0.4 04/28/2023 x10E3/uL 0.1-0.9
 Eos (Absolute) 01 0.3 0.4 04/28/2023 x10E3/uL 0.0-0.4
 Baso (Absolute) 01 0.1 0.1 04/28/2023 x10E3/uL 0.0-0.2
 Immature Granulocytes 01 0 0 04/28/2023 % Not Estab.
 Immature Grans (Abs) 01 0.0 0.0 04/28/2023 x10E3/uL 0.0-0.1
 Comp. Metabolic Panel (14)
 Test Current Result and Flag Previous Result and Date Units Reference Interval
 Glucose 01 89 90 11/28/2023 mg/dL 70-99
 BUN 01 29 High 24 11/28/2023 mg/dL 8-27
 Creatinine 01 1.53 High 1.46 11/28/2023 mg/dL 0.76-1.27
 eGFR 50 Low 53 11/28/2023 mL/min/1.73 >59
 BUN/Creatinine Ratio 19 16 11/28/2023 10-24
 Sodium 01 138 139 11/28/2023 mmol/L 134-144
 Potassium 01 4.8 4.3 11/28/2023 mmol/L 3.5-5.2
 Chloride 01 104 103 11/28/2023 mmol/L 96-106
 Carbon Dioxide, Total 01 22 21 11/28/2023 mmol/L 20-29
 Calcium 01 9.1 8.9 11/28/2023 mg/dL 8.6-10.2
 Protein, Total 01 6.7 6.5 11/28/2023 g/dL 6.0-8.5
 Albumin 01 4.4 4.1 11/28/2023 g/dL 3.9-4.9
 Globulin, Total 2.3 2.4 11/28/2023 g/dL 1.5-4.5
 Date Created and Stored  06/04/24 0622 ET   Final Report  Page 1 of 7
 ©2024 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee S DOB: 06/20/1958 Patient Report
 Patient ID: 106010275168 Age: 65 Account Number: 09621402
 Specimen ID: 155-216-2001-0 Sex: Male Ordering Physician: S STEVENSON
 Date Collected: 06/03/2024
 Comp. Metabolic Panel (14) (Cont.)
 A/G Ratio 1.9 1.7 11/28/2023 1.2-2.2
 Bilirubin, Total 01 1.1 0.6 11/28/2023 mg/dL 0.0-1.2
 Alkaline Phosphatase 01 62 77 11/28/2023 IU/L 44-121
 AST (SGOT) 01 26 23 11/28/2023 IU/L 0-40
 ALT (SGPT) 01 18 19 11/28/2023 IU/L 0-44
 Lipid Panel
 Test Current Result and Flag Previous Result and Date Units Reference Interval
 Cholesterol, Total 01 170 174 04/28/2023 mg/dL 100-199
 Triglycerides 01 114 103 04/28/2023 mg/dL 0-149
 HDL Cholesterol 01 35 Low 42 04/28/2023 mg/dL >39
 VLDL Cholesterol Cal 21 19 04/28/2023 mg/dL 5-40
 LDL Chol Calc (NIH) 114 High 113 04/28/2023 mg/dL 0-99
 Litholink CKD Program
 Test Current Result and Flag Previous Result and Date Units Reference Interval
 Interpretation 02 Note Note 11/28/2023
 ------------------------------
 CHRONIC KIDNEY DISEASE:
 EGFR, BLOOD PRESSURE, AND PROTEINURIA ASSESSMENT
 The overall regression of eGFR with time is not
 statistically significant. Current eGFR is 50 mL/min/1.73mE2
 corresponding to CKD stage 3a. Potassium is within goal and
 has risen, was 4.3 and now is 4.8 mmol/L. Hemoglobin A1C is
 5.3 %; diabetic status is unknown. Refer to ADA guidelines
 for clinical practice recommendations.
 EGFR, BLOOD PRESSURE, AND PROTEINURIA TREATMENT SUGGESTIONS
 
 Guidelines recommend a target blood pressure of 120/80 mmHg
 or less to reduce cardiovascular risk and CKD progression.
 Assessment of albuminuria (urine albumin:creatinine ratio or
 urine protein:creatinine ratio preferred) is recommended at
 least annually in CKD patients for staging and disease
 prognosis.
 EGFR, BLOOD PRESSURE, AND PROTEINURIA FOLLOW-UP
 
 fasting Renal Panel within 12 months; Spot Urine Panel
 (Albumin preferred) is recommended by guidelines, at least
 yearly;
 BONE and MINERAL ASSESSMENT
 Calcium is within goal and has not changed significantly,
 was 8.9 and now is 9.1 mg/dL. Carbon Dioxide is within goal
 and has risen, was 21 and now is 22 mmol/L. Vitamin D is
 adequate (was 45.6 and now is 42.0 ng/mL).
 BONE and MINERAL TREATMENT SUGGESTIONS
 
 Interpretations require simultaneous measurements of serum
 calcium and phosphorus.
 BONE and MINERAL FOLLOW-UP
 
 25-Hydroxy Vitamin D within 12 months; fasting PTH with
 Date Created and Stored  06/04/24 0622 ET   Final Report  Page 2 of 7
 ©2024 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee S DOB: 06/20/1958 Patient Report
 Patient ID: 106010275168 Age: 65 Account Number: 09621402
 Specimen ID: 155-216-2001-0 Sex: Male Ordering Physician: S STEVENSON
 Date Collected: 06/03/2024
 Litholink CKD Program (Cont.)
 Renal Panel is due;
 LIPIDS ASSESSMENT
 Blood was non-fasting; interpret these results with caution.
 LDL-C is borderline high and has not changed significantly,
 was 113 and now is 114 mg/dL. Triglyceride is normal and has
 not changed significantly, was 103 and now is 114 mg/dL.
 Non-HDL Cholesterol is borderline high and has not changed
 significantly, was 132 and now is 135 mg/dL. HDL-C is low
 and has decreased, was 42 and now is 35 mg/dL.
 LIPIDS TREATMENT SUGGESTIONS
 
 Therapeutic lifestyle changes are always valuable to
 maintain optimal blood lipid status (diet, exercise, weight
 management). Begin statin. If statin already in use,
 consider increasing dose to achieve at least a 50% LDL
 reduction from baseline. Moderate or high intensity statin
 is preferred. If statin cannot be tolerated or increased,
 alternatives include use of an intestinal agent (ezetimibe
 or bile acid sequestrant) or niacin.
 LIPIDS FOLLOW-UP
 
 fasting Lipid Panel within 3 months;
 ANEMIA ASSESSMENT
 Hemoglobin is normal and has not changed significantly, was
 14.1 and now is 13.8 g/dL. Hemoglobin target assumes ESA is
 not in use.
 ANEMIA TREATMENT SUGGESTIONS
 
 No specific change of treatment is indicated at this time.
 ANEMIA FOLLOW-UP
 
 CBC within 12 months;
 ------------------------------
 DISCLAIMER
 These assessments and treatment suggestions are provided as
 a convenience in support of the physician-patient
 relationship and are not intended to replace the physician's
 clinical judgment. They are derived from national guidelines
 in addition to other evidence and expert opinion. The
 clinician should consider this information within the
 context of clinical opinion and the individual patient.
 SEE GUIDANCE FOR CHRONIC KIDNEY DISEASE PROGRAM: Kidney
 Disease Improving Global Outcomes (KDIGO) clinical practice
 guidelines are at http://kdigo.org/home/guidelines/.
 National Kidney Foundation Kidney Disease Outcomes Quality
 Initiative (KDOQI (TM)), with its limitations and
 disclaimers, are at www.kidney.org/professionals/KDOQI. This
 program is intended for patients who have been diagnosed
 with stages 3, 4, or pre-dialysis 5 CKD. It is not intended
 for children, pregnant patients, or transplant patients.
 PDF 02 Not applicable Not applicable 11/28/2023
 Hemoglobin A1c
 Test Current Result and Flag Previous Result and Date Units Reference Interval
 Hemoglobin A1c 01 5.3 5.0 04/28/2023 % 4.8-5.6
 Date Created and Stored  06/04/24 0622 ET   Final Report  Page 3 of 7
 ©2024 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee S DOB: 06/20/1958 Patient Report
 Patient ID: 106010275168 Age: 65 Account Number: 09621402
 Specimen ID: 155-216-2001-0 Sex: Male Ordering Physician: S STEVENSON
 Date Collected: 06/03/2024
 Hemoglobin A1c (Cont.)
 Please Note: 01
          Prediabetes: 5.7 - 6.4
          Diabetes: >6.4
          Glycemic control for adults with diabetes: <7.0
 Prostate-Specific Ag
 Test Current Result and Flag Previous Result and Date Units Reference Interval
 Prostate Specific Ag 01 2.3 0.8 03/10/2023 ng/mL 0.0-4.0
 Roche ECLIA methodology.
 According to the American Urological Association, Serum PSA should
 decrease and remain at undetectable levels after radical
 prostatectomy. The AUA defines biochemical recurrence as an initial
 PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory
 PSA value 0.2 ng/mL or greater.
 Values obtained with different assay methods or kits cannot be used
 interchangeably. Results cannot be interpreted as absolute evidence
 of the presence or absence of malignant disease.
 Vitamin D, 25-Hydroxy
 Test Current Result and Flag Previous Result and Date Units Reference Interval
 Vitamin D, 25-Hydroxy 01 42.0 31.4 01/12/2024 ng/mL 30.0-100.0
 Vitamin D deficiency has been defined by the Institute of
 Medicine and an Endocrine Society practice guideline as a
 level of serum 25-OH vitamin D less than 20 ng/mL (1,2).
 The Endocrine Society went on to further define vitamin D
 insufficiency as a level between 21 and 29 ng/mL (2).
 1. IOM (Institute of Medicine). 2010. Dietary reference
    intakes for calcium and D. Washington DC: The
    National Academies Press.
 2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al.
    Evaluation, treatment, and prevention of vitamin D
    deficiency: an Endocrine Society clinical practice
    guideline. JCEM. 2011 Jul; 96(7):1911-30.
 Thyroid Cascade Profile
 Test Current Result and Flag Previous Result and Date Units Reference Interval
 TSH 01 4.610 High 3.910 04/28/2023 uIU/mL 0.450-4.500
 T4,Free (Direct) 01 1.00 0.91 06/28/2021 ng/dL 0.82-1.77
 Thyroid Peroxidase (TPO)
 Ab 01 67 High 166 06/28/2021 IU/mL 0-34
 Interpretive Comment
 An elevation of TSH with a normal FT4 in the presence of antithyroid
 peroxidase antibody is suggestive of Subclinical Hypothyroidism.
 
Disclaimer
 The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to
 match the result to the patient. Results from certain tests are excluded from the Previous Result display.
 
Icon Legend
 Out of Reference Range      Critical or Alert
 Date Created and Stored  06/04/24 0622 ET   Final Report  Page 4 of 7
 ©2024 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee S
 DOB: 06/20/1958
 Patient Report
 Patient ID: 106010275168
 Specimen ID: 155-216-2001-0
 Age: 65
 Sex: Male
 Account Number: 09621402
 Ordering Physician: S STEVENSON
 Performing Labs
 01: TA - Labcorp Tampa, 5610 W LaSalle Street, Tampa, FL 33607-1770 Dir: Sean Farrier, MD
 02: LITNC - Labcorp Clinical / Digital, 10 Moore Drive, Durham, NC 27709-0009 Dir: Jennifer Ennis, MD
 For Inquiries, the physician may contact Branch: 800-877-5227 Lab: 800-877-5227
 Patient Details
 Weixelbaum, Lee S
 2811 WINDING TRAIL DR, VALRICO, FL, 33596
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Date of Birth: 06/20/1958
 Age: 65
 Sex: Male
 Patient ID: 106010275168
 Alternate Patient ID: 301181250
 Physician Details
 S STEVENSON
 BayCare Medical Group
 2470 Bloomingdale Ave Ste 123, Valrico, FL,
 33596
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Account Number: 09621402
 Physician ID: 1952866097
 NPI: 1952866097
 Specimen Details
 Specimen ID: 155-216-2001-0
 Control ID: 10601027516
 Alternate Control Number:
 106010275168L44609
 Date Collected: 06/03/2024 0802  Local
 Date Received: 06/03/2024 0000  ET
 Date Entered: 06/03/2024 1158  ET
 Date Reported: 06/04/2024 0610  ET
 ©2024 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  06/04/24 0622 ET   Final Report  Page 5 of 7
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee S
 Patient ID: 106010275168
 Specimen ID: 155-216-2001-0
 Historical Results & Insights
 DOB: 06/20/1958
 Age: 65
 Sex: Male
 Patient Report
 Account Number: 09621402
 Ordering Physician: S STEVENSON
 Labcorp offers historical lab results data with easy-to-interpret visualizations to provide a more complete picture of a patient’s lab history and improve patient care.
 Creatinine
 Current Result: 1.53 mg/dL
 1.47
 1.43
 1.63
 1.47
 1.44
 1.37
 1.27
 1.27
 1.32
 1.21
 eGFR
 Nov 15, 2021
 Current Result: 50 mL/min/1.73
 CKD Evaluation
 63
 60
 67
 58
 May 20, 2022
 60
 53
 62
 54
 47
 45
 May 20, 2022
 Sep 8, 2022
 Nov 21, 2022
 Feb 6, 2023
 Mar 10, 2023
 Apr 28, 2023
 Jul 7, 2023
 HIGH
 1.53
 1.46
 53
 Sep 8, 2022
 Nov 21, 2022
 Reference Interval: 0.76-1.27 mg/dL
 MILDLY DECREASED
 50
 Stage 3a
 Feb 6, 2023
 Mar 10, 2023
 Apr 28, 2023
 Jul 7, 2023
 ©2024 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  06/04/24 0622 ET   Final Report  Page 6 of 7
 Nov 28, 2023
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
 Nov 28, 2023
 Jun 3, 2024
 Jun 3, 2024
Weixelbaum, Lee S
 DOB: 06/20/1958
 Patient Report
 Patient ID: 106010275168
 Specimen ID: 155-216-2001-0
 Age: 65
 Sex: Male
 Account Number: 09621402
 Ordering Physician: S STEVENSON
 Cardiovascular Tests
 Date
 06/03/2024
 04/28/2023†
 05/20/2022
 06/28/2021†
 09/21/2020†
 Ref. Interval
 Units
 † Fasting
 Total
 Chol.
 170
 174
 180
 208
 182
 TG
 114
 103
 111
 157
 147
 HDL-C
 35
 42
 VLDL
 LDL-C
 21
 19
 35
 37
 37
 100-199
 mg/dL
 0-149
 mg/dL
 >39
 mg/dL
 20
 28
 26
 5-40
 mg/dL
 114
 113
 125
 143
 119
 0-99
 mg/dL
 ©2024 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  06/04/24 0622 ET   Final Report  Page 7 of 7
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee S DOB: 06/20/1958 Patient Report
 Patient ID: Age: 65 Account Number: 09241500
 Specimen ID: 012-216-2120-0 Sex: Male Ordering Physician: A HENRY
 Date Collected: 01/12/2024 Date Received: 01/12/2024 Date Reported: 01/22/2024 Fasting: Yes
 Ordered Items: Testosterone,Free and Total; Free T4 by Dialysis/Mass Spec; TSH; Vitamin D, 25-Hydroxy; Triiodothyronine (T3);
 Venipuncture
 Date Collected: 01/12/2024
 Testosterone,Free and Total
 Test Current Result and Flag Previous Result and Date Units Reference Interval
 Testosterone 01 447 372 07/07/2023 ng/dL 264-916
 Adult male reference interval is based on a population of
 healthy nonobese males (BMI <30) between 19 and 39 years old.
 Travison, et.al. JCEM 2017,102;1161-1173. PMID: 28324103.
 Free Testosterone(Direct) 02 7.7 6.5 07/07/2023 pg/mL 6.6-18.1
 Free T4 by Dialysis/Mass Spec
 Test Current Result and Flag Previous Result and Date Units Reference Interval
 Free T4 by Dialysis/Mass Spec 03 0.97 1.0 03/10/2023 ng/dL
 This test was developed and its performance characteristics
 determined by Labcorp. It has not been cleared or approved
 by the Food and Drug Administration.
 Reference Range:
 Pubertal Children and Adults:
 0.8 - 1.7
 TSH
 Test Current Result and Flag Previous Result and Date Units Reference Interval
 TSH 01 3.860 3.690 07/07/2023 uIU/mL 0.450-4.500
 Vitamin D, 25-Hydroxy
 Test Current Result and Flag Previous Result and Date Units Reference Interval
 Vitamin D, 25-Hydroxy 01 31.4 41.7 07/07/2023 ng/mL 30.0-100.0
 Vitamin D deficiency has been defined by the Institute of
 Medicine and an Endocrine Society practice guideline as a
 level of serum 25-OH vitamin D less than 20 ng/mL (1,2).
 The Endocrine Society went on to further define vitamin D
 insufficiency as a level between 21 and 29 ng/mL (2).
 1. IOM (Institute of Medicine). 2010. Dietary reference
    intakes for calcium and D. Washington DC: The
    National Academies Press.
 2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al.
    Evaluation, treatment, and prevention of vitamin D
    deficiency: an Endocrine Society clinical practice
    guideline. JCEM. 2011 Jul; 96(7):1911-30.
 Triiodothyronine (T3)
 Test Current Result and Flag Previous Result and Date Units Reference Interval
 Triiodothyronine (T3) 01 99 89 07/07/2023 ng/dL 71-180
 Date Created and Stored  01/22/24 1211 ET   Final Report  Page 1 of 2
 ©2024 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee S
 DOB: 06/20/1958
 Patient Report
 Patient ID:
 Specimen ID: 012-216-2120-0
 Age: 65
 Sex: Male
 Account Number: 09241500
 Ordering Physician: A HENRY
 Disclaimer
 The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to
 match the result to the patient. Results from certain tests are excluded from the Previous Result display.
 Icon Legend
 Out of Reference Range     
Performing Labs
 Critical or Alert
 01: TA - Labcorp Tampa, 5610 W LaSalle Street, Tampa, FL 33607-1770 Dir: Sean Farrier, MD
 02: BN - Labcorp Burlington, 1447 York Court, Burlington, NC 27215-3361 Dir: Sanjai Nagendra, MD
 03: ES - Esoterix Inc, 4301 Lost Hills Road, Calabasas Hills, CA 91301-5358 Dir: Brian Poirier, MD
 For Inquiries, the physician may contact Branch: 800-877-5227 Lab: 800-877-5227
 Patient Details
 Weixelbaum, Lee S
 2811 WINDING TRAIL DR, VALRICO, FL, 33596
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Date of Birth: 06/20/1958
 Age: 65
 Sex: Male
 Patient ID:
 Alternate Patient ID:
 Physician Details
 A HENRY
 Andrew Henry MD
 9260 BAY PLAZA BLVD, STE 502, Tampa, FL,
 33619
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Account Number: 09241500
 Physician ID:
 NPI: 1194892141
 Specimen Details
 Specimen ID: 012-216-2120-0
 Control ID: 30185094659
 Alternate Control Number:
 Date Collected: 01/12/2024 0756  Local
 Date Received: 01/12/2024 0000  ET
 Date Entered: 01/12/2024 1127  ET
 Date Reported: 01/22/2024 1208  ET
 ©2024 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  01/22/24 1211 ET   Final Report  Page 2 of 2
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee S
 Patient ID:
 Specimen ID: 188-216-1987-0
 DOB: 06/20/1958
 Age: 65
 Sex: Male
 Patient Report
 Account Number: 09241500
 Ordering Physician: A HENRY
 Date Collected: 07/07/2023
 Date Received: 07/07/2023
 Date Reported: 07/11/2023
 Fasting: Yes
 Ordered Items: Comp. Metabolic Panel (14); Thyroxine (T4) Free, Direct; Testosterone; TSH; Vitamin D, 25-Hydroxy; Testosterone,
 Free, Direct; Triiodothyronine (T3); Ambig Abbrev CMP14 Default; Venipuncture
 General Comments & Additional Information
 A courtesy copy of this report has been sent to
 8136760237.
 Comp. Metabolic Panel (14)
 Test
 Glucose 01
 BUN 01
 Creatinine 01
 eGFR
 BUN/Creatinine Ratio
 Sodium 01
 Potassium 01
 Chloride 01
 Carbon Dioxide, Total 01
 Calcium 01
 Protein, Total 01
 Albumin 01
 Current Result and Flag
 88
 19
 1.32
 60
 14
 142
 4.3
 103
 24
 9.1
 6.6
 4.3
 Date Collected: 07/07/2023
 Previous Result and Date
 91
 17
 High
 1.44
 54
 12
 139
 4.7
 104
 24
 9.6
 6.5
 4.6
 04/28/2023
 04/28/2023
 04/28/2023
 04/28/2023
 04/28/2023
 04/28/2023
 04/28/2023
 04/28/2023
 04/28/2023
 04/28/2023
 04/28/2023
 04/28/2023
 Units
 mg/dL
 mg/dL
 mg/dL
 mL/min/1.73
 mmol/L
 mmol/L
 mmol/L
 mmol/L
 mg/dL
 g/dL
 g/dL
               **Effective July 10, 2023 Albumin reference interval**
                 will be changing to:
                            Age                  Male          Female
                           0 -   7 days       3.6 - 4.9      3.6 - 4.9
                           8 -  30 days       3.5 - 4.6      3.5 - 4.6
                           1 -   6 months     3.7 - 4.8      3.7 - 4.8
                    7 months -   2 years      4.0 - 5.0      4.0 - 5.0
                           3 -   5 years      4.1 - 5.0      4.1 - 5.0
                           6 -  12 years      4.2 - 5.0      4.2 - 5.0
                          13 -  30 years      4.3 - 5.2      4.0 - 5.0
                          31 -  50 years      4.1 - 5.1      3.9 - 4.9
                          51 -  60 years      3.8 - 4.9      3.8 - 4.9
                          61 -  70 years      3.9 - 4.9      3.9 - 4.9
                          71 -  80 years      3.8 - 4.8      3.8 - 4.8
                          81 -  89 years      3.7 - 4.7      3.7 - 4.7
                          90 - 199 years      3.6 - 4.6      3.6 - 4.6
 Globulin, Total
 A/G Ratio
 Bilirubin, Total 01
 Alkaline Phosphatase 01
 AST (SGOT) 01
 ALT (SGPT) 01
 2.3
 1.9
 1.4
 73
 19
 15
 1.9
 2.4
 High
 1.2
 77
 20
 13
 04/28/2023
 04/28/2023
 04/28/2023
 04/28/2023
 04/28/2023
 04/28/2023
 g/dL
 mg/dL
 IU/L
 IU/L
 IU/L
 Reference Interval
 70-99
 8-27
 0.76-1.27
 >59
 10-24
 134-144
 3.5-5.2
 96-106
 20-29
 8.6-10.2
 6.0-8.5
 3.8-4.8
 1.5-4.5
 1.2-2.2
 0.0-1.2
 44-121
 0-40
 0-44
 ©2023 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  07/11/23 1614 ET   Final Report  Page 1 of 4
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee S DOB: 06/20/1958 Patient Report
 Patient ID: Age: 65 Account Number: 09241500
 Specimen ID: 188-216-1987-0 Sex: Male Ordering Physician: A HENRY
 Date Collected: 07/07/2023
 Thyroxine (T4) Free, Direct
 Test Current Result and Flag Previous Result and Date Units Reference Interval
 T4,Free(Direct) 01 1.10 1.11 09/08/2022 ng/dL 0.82-1.77
 Testosterone
 Test Current Result and Flag Previous Result and Date Units Reference Interval
 Testosterone 01 372 155 06/09/2023 ng/dL 264-916
 Adult male reference interval is based on a population of
 healthy nonobese males (BMI <30) between 19 and 39 years old.
 Travison, et.al. JCEM 2017,102;1161-1173. PMID: 28324103.
 TSH
 Test Current Result and Flag Previous Result and Date Units Reference Interval
 TSH 01 3.690 2.660 03/10/2023 uIU/mL 0.450-4.500
 Vitamin D, 25-Hydroxy
 Test Current Result and Flag Previous Result and Date Units Reference Interval
 Vitamin D, 25-Hydroxy 01 41.7 45.6 04/28/2023 ng/mL 30.0-100.0
 Vitamin D deficiency has been defined by the Institute of
 Medicine and an Endocrine Society practice guideline as a
 level of serum 25-OH vitamin D less than 20 ng/mL (1,2).
 The Endocrine Society went on to further define vitamin D
 insufficiency as a level between 21 and 29 ng/mL (2).
 1. IOM (Institute of Medicine). 2010. Dietary reference
    intakes for calcium and D. Washington DC: The
    National Academies Press.
 2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al.
    Evaluation, treatment, and prevention of vitamin D
    deficiency: an Endocrine Society clinical practice
    guideline. JCEM. 2011 Jul; 96(7):1911-30.
 Testosterone, Free, Direct
 Test Current Result and Flag Previous Result and Date Units Reference Interval
 Free Testosterone(Direct) 02 6.5 Low 4.8 06/09/2023 pg/mL 6.6-18.1
 Triiodothyronine (T3)
 Test Current Result and Flag Previous Result and Date Units Reference Interval
 Triiodothyronine (T3) 01 89 109 03/10/2023 ng/dL 71-180
 Ambig Abbrev CMP14 Default
 Test Current Result and Flag Previous Result and Date Units Reference Interval
 Ambig Abbrev CMP14 Default 01
 A hand-written panel/profile was received from your office. In
 accordance with the LabCorp Ambiguous Test Code Policy dated July
 2003, we have completed your order by using the closest currently
 or formerly recognized AMA panel.  We have assigned Comprehensive
 Metabolic Panel (14), Test Code #322000 to this request.  If this
 is not the testing you wished to receive on this specimen, please
 contact the LabCorp Client Inquiry/Technical Services Department
 Date Created and Stored  07/11/23 1614 ET   Final Report  Page 2 of 4
 ©2023 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee S
 DOB: 06/20/1958
 Patient Report
 Patient ID:
 Specimen ID: 188-216-1987-0
 Age: 65
 Sex: Male
 Account Number: 09241500
 Ordering Physician: A HENRY
 Date Collected: 07/07/2023
 Ambig Abbrev CMP14 Default (Cont.)
 to clarify the test order.  We appreciate your business.
 Disclaimer
 The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to
 match the result to the patient. Results from certain tests are excluded from the Previous Result display.
 Icon Legend
 Out of Reference Range     
Performing Labs
 Critical or Alert
 01: TA - Labcorp Tampa 5610 W LaSalle Street, Tampa, FL, 33607-1770 Dir: Sean Farrier, MD
 02: BN - Labcorp Burlington 1447 York Court, Burlington, NC, 27215-3361 Dir: Sanjai Nagendra, MD
 For Inquiries, the physician may contact Branch: 800-877-5227 Lab: 800-877-5227
 Patient Details
 Weixelbaum, Lee S
 2811 WINDING TRAIL DR, VALRICO, FL, 33596
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Date of Birth: 06/20/1958
 Age: 65
 Sex: Male
 Patient ID:
 Alternate Patient ID:
 Physician Details
 A HENRY
 Andrew Henry MD
 9260 BAY PLAZA BLVD, STE 502, Brandon, FL,
 33619
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Account Number: 09241500
 Physician ID:
 NPI: 1194892141
 Specimen Details
 Specimen ID: 188-216-1987-0
 Control ID: 30185084553
 Alternate Control Number:
 Date Collected: 07/07/2023 0742  Local
 Date Received: 07/07/2023 0000  ET
 Date Entered: 07/07/2023 1203  ET
 Date Reported: 07/11/2023 1609  ET
 ©2023 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  07/11/23 1614 ET   Final Report  Page 3 of 4
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee S
 Patient ID:
 Specimen ID: 188-216-1987-0
 Historical Results & Insights
 DOB: 06/20/1958
 Age: 65
 Sex: Male
 Patient Report
 Account Number: 09241500
 Ordering Physician: A HENRY
 Labcorp offers historical lab results data with easy-to-interpret visualizations to provide a more complete picture of a patient’s lab history and improve patient care.
 Creatinine
 Current Result: 1.32 mg/dL
 1.51
 1.63
 1.47
 1.44
 1.43
 1.47
 1.27
 1.27
 eGFR
 Current Result: 60 mL/min/1.73
 63
 Jun 28, 2021
 Jul 28, 2021
 67
 Nov 15, 2021
 60
 58
 53
 62
 47
 May 20, 2022
 Sep 8, 2022
 Nov 21, 2022
 HIGH
 1.44
 1.37
 1.29
 1.21
 1.32
 Reference Interval: 0.76-1.27 mg/dL
 60
 54
 May 20, 2022
 Sep 8, 2022
 Reference Interval: >59 mL/min/1.73
 Feb 6, 2023
 Nov 21, 2022
 ©2023 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Mar 10, 2023
 Date Created and Stored  07/11/23 1614 ET   Final Report  Page 4 of 4
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
 Apr 28, 2023
 Feb 6, 2023
 Mar 10, 2023
 Apr 28, 2023
 Jul 7, 2023
 Jul 7, 2023
Weixelbaum, Lee S
 DOB: 06/20/1958
 Patient Report
 Patient ID:
 Specimen ID: 160-216-2666-0
 Age: 64
 Sex: Male
 Account Number: 09521990
 Ordering Physician: R PATEL
 Date Collected: 06/09/2023
 Date Received: 06/09/2023
 Date Reported: 06/14/2023
 Ordered Items: FSH and LH; Testosterone,Free and Total; Estradiol; Venipuncture
 Fasting: Yes
 Date Collected: 06/09/2023
 FSH and LH
 Test
 LH 01
 FSH 01
 Current Result and Flag
 8.8
 High
 Previous Result and Date
 7.2
 07/02/2020
 Units
 Reference Interval
 14.3
 Testosterone,Free and Total
 Test
 High
 Current Result and Flag
 Testosterone 01
 155
 Low
 14.0
 07/02/2020
 Previous Result and Date
 332
 03/10/2023
 Adult male reference interval is based on a population of
 healthy nonobese males (BMI <30) between 19 and 39 years old.
 Travison, et.al. JCEM 2017,102;1161-1173. PMID: 28324103.
 mIU/mL
 mIU/mL
 Units
 ng/dL
 1.7-8.6
 1.5-12.4
 Reference Interval
 264-916
 Free Testosterone(Direct) 02
 Estradiol
 Test
 Estradiol 01
 4.8
 Low
 Current Result and Flag
 16.9
 5.4
 03/10/2023
 Previous Result and Date
 pg/mL
 Units
 6.6-18.1
 Reference Interval
 pg/mL
 Roche ECLIA methodology
 7.6-42.6
 Disclaimer
 The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to
 match the result to the patient. Results from certain tests are excluded from the Previous Result display.
 Icon Legend
 Out of Reference Range     
Performing Labs
 Critical or Alert
 01: TA - Labcorp Tampa 5610 W LaSalle Street, Tampa, FL, 33607-1770 Dir: Sean Farrier, MD
 02: BN - Labcorp Burlington 1447 York Court, Burlington, NC, 27215-3361 Dir: Sanjai Nagendra, MD
 For Inquiries, the physician may contact Branch: 800-877-5227 Lab: 800-877-5227
 Patient Details
 Weixelbaum, Lee S
 2811 WINDING TRAIL DR, VALRICO, FL, 33596
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Date of Birth: 06/20/1958
 Age: 64
 Sex: Male
 Patient ID:
 Alternate Patient ID:
 Physician Details
 R PATEL
 Endocrinology at Bloomingdale
 2470 Bloomingdale Ave Ste 123, Valrico, FL,
 33596
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Account Number: 09521990
 Physician ID:
 NPI: 1457776577
 Specimen Details
 Specimen ID: 160-216-2666-0
 Control ID: 30185083082
 Alternate Control Number:
 Date Collected: 06/09/2023 0801  Local
 Date Received: 06/09/2023 0000  ET
 Date Entered: 06/09/2023 1132  ET
 Date Reported: 06/14/2023 1308  ET
 ©2023 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  06/14/23 1315 ET   Final Report  Page 1 of 1
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee S DOB: 06/20/1958 Patient Report
 Patient ID: 106004834489 Age: 64 Account Number: 09621402
 Specimen ID: 118-216-2375-0 Sex: Male Ordering Physician: S STEVENSON
 Date Collected: 04/28/2023 Date Received: 04/28/2023 Date Reported: 04/29/2023 Fasting: Yes
 Ordered Items: CBC With Differential/Platelet; Comp. Metabolic Panel (14); Lipid Panel; Litholink CKD Program; Hemoglobin A1c;
 Vitamin D, 25-Hydroxy; Thyroid Cascade Profile; Venipuncture
 Date Collected: 04/28/2023
 CBC With Differential/Platelet
 Test Current Result and Flag Previous Result and Date Units Reference Interval
 WBC 01 5.7 5.9 02/06/2023 x10E3/uL 3.4-10.8
 RBC 01 4.56 4.88 02/06/2023 x10E6/uL 4.14-5.80
 Hemoglobin 01 14.1 14.5 03/10/2023 g/dL 13.0-17.7
 Hematocrit 01 41.1 42.6 03/10/2023 % 37.5-51.0
 MCV 01 90 90 02/06/2023 fL 79-97
 MCH 01 30.9 30.7 02/06/2023 pg 26.6-33.0
 MCHC 01 34.3 34.0 02/06/2023 g/dL 31.5-35.7
 RDW 01 13.2 14.0 02/06/2023 % 11.6-15.4
 Platelets 01 196 212 02/06/2023 x10E3/uL 150-450
 Neutrophils 01 53 52 02/06/2023 % Not Estab.
 Lymphs 01 32 35 02/06/2023 % Not Estab.
 Monocytes 01 8 8 02/06/2023 % Not Estab.
 Eos 01 6 4 02/06/2023 % Not Estab.
 Basos 01 1 1 02/06/2023 % Not Estab.
 Neutrophils (Absolute) 01 3.0 3.0 02/06/2023 x10E3/uL 1.4-7.0
 Lymphs (Absolute) 01 1.8 2.1 02/06/2023 x10E3/uL 0.7-3.1
 Monocytes(Absolute) 01 0.4 0.5 02/06/2023 x10E3/uL 0.1-0.9
 Eos (Absolute) 01 0.4 0.3 02/06/2023 x10E3/uL 0.0-0.4
 Baso (Absolute) 01 0.1 0.1 02/06/2023 x10E3/uL 0.0-0.2
 Immature Granulocytes 01 0 0 02/06/2023 % Not Estab.
 Immature Grans (Abs) 01 0.0 0.0 02/06/2023 x10E3/uL 0.0-0.1
 Comp. Metabolic Panel (14)
 Test Current Result and Flag Previous Result and Date Units Reference Interval
 Glucose 01 91 86 03/10/2023 mg/dL 70-99
 BUN 01 17 15 03/10/2023 mg/dL 8-27
 Creatinine 01 1.44 High 1.29 03/10/2023 mg/dL 0.76-1.27
 eGFR 54 Low 62 03/10/2023 mL/min/1.73 >59
 BUN/Creatinine Ratio 12 12 03/10/2023 10-24
 Sodium 01 139 140 03/10/2023 mmol/L 134-144
 Potassium 01 4.7 4.8 03/10/2023 mmol/L 3.5-5.2
 Chloride 01 104 105 03/10/2023 mmol/L 96-106
 Carbon Dioxide, Total 01 24 23 03/10/2023 mmol/L 20-29
 Calcium 01 9.6 9.2 03/10/2023 mg/dL 8.6-10.2
 Protein, Total 01 6.5 7.0 03/10/2023 g/dL 6.0-8.5
 Albumin 01 4.6 4.4 03/10/2023 g/dL 3.8-4.8
 Globulin, Total 1.9 2.6 03/10/2023 g/dL 1.5-4.5
 Date Created and Stored  04/29/23 0719 ET   Final Report  Page 1 of 5
 ©2023 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee S DOB: 06/20/1958 Patient Report
 Patient ID: 106004834489 Age: 64 Account Number: 09621402
 Specimen ID: 118-216-2375-0 Sex: Male Ordering Physician: S STEVENSON
 Date Collected: 04/28/2023
 Comp. Metabolic Panel (14) (Cont.)
 A/G Ratio 2.4 High 1.7 03/10/2023 1.2-2.2
 Bilirubin, Total 01 1.2 1.5 03/10/2023 mg/dL 0.0-1.2
 Alkaline Phosphatase 01 77 74 03/10/2023 IU/L 44-121
 AST (SGOT) 01 20 21 03/10/2023 IU/L 0-40
 ALT (SGPT) 01 13 17 03/10/2023 IU/L 0-44
 Lipid Panel
 Test Current Result and Flag Previous Result and Date Units Reference Interval
 Cholesterol, Total 01 174 180 05/20/2022 mg/dL 100-199
 Triglycerides 01 103 111 05/20/2022 mg/dL 0-149
 HDL Cholesterol 01 42 35 05/20/2022 mg/dL >39
 VLDL Cholesterol Cal 19 20 05/20/2022 mg/dL 5-40
 LDL Chol Calc (NIH) 113 High 125 05/20/2022 mg/dL 0-99
 Litholink CKD Program
 Test Current Result and Flag Previous Result and Date Units Reference Interval
 Interpretation 02 Note Note 02/06/2023
 ------------------------------
 CHRONIC KIDNEY DISEASE:
 EGFR, BLOOD PRESSURE, AND PROTEINURIA ASSESSMENT
 The overall regression of eGFR with time is not
 statistically significant. Current eGFR is 54 mL/min/1.73mE2
 corresponding to CKD stage 3a. Potassium is within goal and
 has not changed significantly, was 4.6 and now is 4.7
 mmol/L. Hemoglobin A1C is 5.0 %; diabetic status is unknown.
 Refer to ADA guidelines for clinical practice
 recommendations.
 EGFR, BLOOD PRESSURE, AND PROTEINURIA TREATMENT SUGGESTIONS
 
 Guidelines recommend a target blood pressure of 120/80 mmHg
 or less to reduce cardiovascular risk and CKD progression.
 Assessment of albuminuria (urine albumin:creatinine ratio or
 urine protein:creatinine ratio preferred) is recommended at
 least annually in CKD patients for staging and disease
 prognosis.
 EGFR, BLOOD PRESSURE, AND PROTEINURIA FOLLOW-UP
 
 fasting Renal Panel within 12 months; Spot Urine Panel
 (Albumin preferred) is recommended by guidelines, at least
 yearly;
 BONE and MINERAL ASSESSMENT
 Calcium is within goal and has not changed significantly,
 was 9.7 and now is 9.6 mg/dL. Carbon Dioxide is within goal
 and has not changed significantly, was 24 and now is 24
 mmol/L. Vitamin D is adequate (was 16.2 and now is 45.6
 ng/mL).
 BONE and MINERAL TREATMENT SUGGESTIONS
 
 Interpretations require simultaneous measurements of serum
 calcium and phosphorus.
 BONE and MINERAL FOLLOW-UP
 Date Created and Stored  04/29/23 0719 ET   Final Report  Page 2 of 5
 ©2023 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee S DOB: 06/20/1958 Patient Report
 Patient ID: 106004834489 Age: 64 Account Number: 09621402
 Specimen ID: 118-216-2375-0 Sex: Male Ordering Physician: S STEVENSON
 Date Collected: 04/28/2023
 Litholink CKD Program (Cont.)
 
 25-Hydroxy Vitamin D within 12 months; fasting PTH with
 Renal Panel is due;
 LIPIDS ASSESSMENT
 LDL-C is borderline high and has decreased, was 143 and now
 is 113 mg/dL. Triglyceride is normal and has decreased, was
 157 and now is 103 mg/dL. Non-HDL Cholesterol is borderline
 high and has decreased, was 171 and now is 132 mg/dL. HDL-C
 is normal and has risen, was 37 and now is 42 mg/dL.
 LIPIDS TREATMENT SUGGESTIONS
 
 Therapeutic lifestyle changes are always valuable to
 maintain optimal blood lipid status (diet, exercise, weight
 management). Begin statin. If statin already in use,
 consider increasing dose to achieve at least a 50% LDL
 reduction from baseline. Moderate or high intensity statin
 is preferred. If statin cannot be tolerated or increased,
 alternatives include use of an intestinal agent (ezetimibe
 or bile acid sequestrant) or niacin.
 LIPIDS FOLLOW-UP
 
 fasting Lipid Panel within 3 months;
 ANEMIA ASSESSMENT
 Hemoglobin is normal and has decreased, was 15.0 and now is
 14.1 g/dL. Hemoglobin target assumes ESA is not in use.
 ANEMIA TREATMENT SUGGESTIONS
 
 No specific change of treatment is indicated at this time.
 ANEMIA FOLLOW-UP
 
 CBC within 12 months;
 ------------------------------
 DISCLAIMER
 These assessments and treatment suggestions are provided as
 a convenience in support of the physician-patient
 relationship and are not intended to replace the physician's
 clinical judgment. They are derived from national guidelines
 in addition to other evidence and expert opinion. The
 clinician should consider this information within the
 context of clinical opinion and the individual patient.
 SEE GUIDANCE FOR CHRONIC KIDNEY DISEASE PROGRAM: Kidney
 Disease Improving Global Outcomes (KDIGO) clinical practice
 guidelines are at http://kdigo.org/home/guidelines/.
 National Kidney Foundation Kidney Disease Outcomes Quality
 Initiative (KDOQI (TM)), with its limitations and
 disclaimers, are at www.kidney.org/professionals/KDOQI. This
 program is intended for patients who have been diagnosed
 with stages 3, 4, or pre-dialysis 5 CKD. It is not intended
 for children, pregnant patients, or transplant patients.
 PDF 02 Not applicable Not applicable 02/06/2023
 Hemoglobin A1c
 Test Current Result and Flag Previous Result and Date Units Reference Interval
 Hemoglobin A1c 01 5.0 5.0 03/10/2023 % 4.8-5.6
 Please Note: 01
 Date Created and Stored  04/29/23 0719 ET   Final Report  Page 3 of 5
 ©2023 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee S
 DOB: 06/20/1958
 Patient Report
 Patient ID: 106004834489
 Specimen ID: 118-216-2375-0
 Age: 64
 Sex: Male
 Account Number: 09621402
 Ordering Physician: S STEVENSON
 Date Collected: 04/28/2023
 Hemoglobin A1c (Cont.)
         Prediabetes: 5.7 - 6.4
         Diabetes: >6.4
         Glycemic control for adults with diabetes: <7.0
 Vitamin D, 25-Hydroxy
 Test
 Vitamin D, 25-Hydroxy 01
 Current Result and Flag
 45.6
 Previous Result and Date
 Units
 Reference Interval
 55.5
 03/10/2023
 Vitamin D deficiency has been defined by the Institute of
 Medicine and an Endocrine Society practice guideline as a
 level of serum 25-OH vitamin D less than 20 ng/mL (1,2).
 The Endocrine Society went on to further define vitamin D
 insufficiency as a level between 21 and 29 ng/mL (2).
 1. IOM (Institute of Medicine). 2010. Dietary reference
   intakes for calcium and D. Washington DC: The
   National Academies Press.
 2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al.
   Evaluation, treatment, and prevention of vitamin D
   deficiency: an Endocrine Society clinical practice
   guideline. JCEM. 2011 Jul; 96(7):1911-30.
 ng/mL
 30.0-100.0
 Thyroid Cascade Profile
 Test
 TSH 01
 Current Result and Flag
 3.910
 Previous Result and Date
 Units
 Reference Interval
 7.670
 06/28/2021
 uIU/mL
 No apparent thyroid disorder. Additional testing not indicated. In
 rare instances, Secondary Hypothyroidism as well as Subclinical
 Hypothyroidism have been reported in some patients with normal TSH
 values.
 0.450-4.500
 Disclaimer
 The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to
 match the result to the patient. Results from certain tests are excluded from the Previous Result display.
 Icon Legend
 Out of Reference Range     
Performing Labs
 Critical or Alert
 01: TA - Labcorp Tampa 5610 W LaSalle Street, Tampa, FL, 33607-1770 Dir: Sean Farrier, MD
 02: LITIL - Litholink Corporation 150 Spring Lake Dr Ste A, Itasca, IL, 60143-2091 Dir: Pawan Vohra, PhD
 For Inquiries, the physician may contact Branch: 800-877-5227 Lab: 800-877-5227
 ©2023 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  04/29/23 0719 ET   Final Report  Page 4 of 5
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee S
 DOB: 06/20/1958
 Patient Report
 Patient ID: 106004834489
 Specimen ID: 118-216-2375-0
 Age: 64
 Sex: Male
 Account Number: 09621402
 Ordering Physician: S STEVENSON
 Patient Details
 Weixelbaum, Lee S
 2811 WINDING TRAIL DR, VALRICO, FL, 33596
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Date of Birth: 06/20/1958
 Age: 64
 Sex: Male
 Patient ID: 106004834489
 Alternate Patient ID: 301181250
 Physician Details
 S STEVENSON
 BayCare Medical Group
 2470 Bloomingdale Ave Ste 123, Valrico, FL,
 33596
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Account Number: 09621402
 Physician ID: 1952866097
 NPI: 1952866097
 Specimen Details
 Specimen ID: 118-216-2375-0
 Control ID: 10600483448
 Alternate Control Number:
 106004834489L15121
 Date Collected: 04/28/2023 0757  Local
 Date Received: 04/28/2023 0000  ET
 Date Entered: 04/28/2023 1139  ET
 Date Reported: 04/29/2023 0708  ET
 ©2023 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  04/29/23 0719 ET   Final Report  Page 5 of 5
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee S
 DOB: 06/20/1958
 Patient Report
 Patient ID:
 Specimen ID: 072-443-4264-0
 Age: 64
 Sex: Male
 Account Number: 09372020
 Ordering Physician: R LORCH
 Date Collected: 03/13/2023
 Date Received: 03/13/2023
 Date Reported: 03/14/2023
 Ordered Items: CreatU+Prot U
 Fasting: No
 General Comments & Additional Information
 Total Volume: 2150 ml
 CreatU+Prot U
 Test
 Creatinine, Urine 01
 Creatinine, Ur 24hr
 Prot,24hr calculated
 Protein,Total,Urine 01
 Protein/Creat Ratio
 Current Result and Flag
 88.9
 1911
 108
 Date Collected: 03/13/2023
 Previous Result and Date
 25.8
 02/06/2023
 Units
 Reference Interval
 5.0
 56
 Disclaimer
 <4.0
 02/06/2023
 mg/dL
 mg/24 hr
 mg/24 hr
 mg/dL
 mg/g creat
 Not Estab.
 1000-2000
 30-150
 Not Estab.
 0-200
 The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to
 match the result to the patient. Results from certain tests are excluded from the Previous Result display.
 Icon Legend
 Out of Reference Range     
Performing Labs
 Critical or Alert
 01: TA - Labcorp Tampa 5610 W LaSalle Street, Tampa, FL, 33607-1770 Dir: Sean Farrier, MD
 For Inquiries, the physician may contact Branch: 800-877-5227 Lab: 800-877-5227
 Patient Details
 Weixelbaum, Lee S
 2811 WINDING TRAIL DR, VALRICO, FL, 33596
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Date of Birth: 06/20/1958
 Age: 64
 Sex: Male
 Patient ID:
 Alternate Patient ID:
 Physician Details
 R LORCH
 BRANDON NEPHROLOGY
 3140 S Falkenburg Rd STE 201, Riverview,
 FL, 33578
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Account Number: 09372020
 Physician ID:
 NPI: 1932596525
 Specimen Details
 Specimen ID: 072-443-4264-0
 Control ID: 30185078072
 Alternate Control Number:
 Date Collected: 03/13/2023 0700  Local
 Date Received: 03/13/2023 0000  ET
 Date Entered: 03/13/2023 1724  ET
 Date Reported: 03/14/2023 1610  ET
 ©2023 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  03/14/23 1618 ET   Final Report  Page 1 of 1
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee S
 Patient ID:
 Specimen ID: 069-216-8425-0
 DOB: 06/20/1958
 Age: 64
 Sex: Male
 Patient Report
 Account Number: 09241500
 Ordering Physician: A HENRY
 Date Collected: 03/10/2023
 Date Received: 03/10/2023
 Date Reported: 03/20/2023
 Fasting: Yes
 Ordered Items: Comp. Metabolic Panel (14); Free T4 by Dialysis/Mass Spec; Hemoglobin A1c; Testosterone; TSH; Prostate-Specific
 Ag; Vitamin D, 25-Hydroxy; Testosterone, Free, Direct; Triiodothyronine (T3); Ambig Abbrev CMP14 Default
 General Comments & Additional Information
 A courtesy copy of this report has been sent to
 8136760237.
 Comp. Metabolic Panel (14)
 Test
 Glucose 01
 BUN 01
 Creatinine 01
 eGFR
 BUN/Creatinine Ratio
 Sodium 01
 Potassium 01
 Chloride 01
 Carbon Dioxide, Total 01
 Calcium 01
 Protein, Total 01
 Albumin 01
 Globulin, Total
 A/G Ratio
 Bilirubin, Total 01
 Alkaline Phosphatase 01
 AST (SGOT) 01
 ALT (SGPT) 01
 Free T4 by Dialysis/Mass Spec
 Test
 Free T4 by Dialysis/Mass Spec 02
 Current Result and Flag
 86
 15
 1.29
 62
 12
 140
 4.8
 105
 23
 9.2
 7.0
 4.4
 2.6
 1.7
 1.5
 74
 21
 17
 Current Result and Flag
 1.0
 This test was developed and its performance characteristics
 determined by Labcorp. It has not been cleared or approved
 by the Food and Drug Administration.
 Reference Range:
 Pubertal Children and Adults:
 0.8 - 1.7
 Hemoglobin A1c
 Test
 Hemoglobin A1c 01
 Please Note: 01
 Current Result and Flag
 5.0
         Prediabetes: 5.7 - 6.4
 Date Collected: 03/10/2023
 Previous Result and Date
 87
 16
 High
 High
 1.37
 58
 12
 139
 4.6
 102
 24
 9.7
 7.2
 4.5
 2.7
 1.7
 1.4
 80
 23
 20
 02/06/2023
 02/06/2023
 02/06/2023
 02/06/2023
 02/06/2023
 02/06/2023
 02/06/2023
 02/06/2023
 02/06/2023
 02/06/2023
 02/06/2023
 02/06/2023
 02/06/2023
 02/06/2023
 02/06/2023
 02/06/2023
 02/06/2023
 02/06/2023
 Previous Result and Date
 1.2
 03/15/2022
 Previous Result and Date
 5.1
 11/21/2022
 Units
 mg/dL
 mg/dL
 mg/dL
 mL/min/1.73
 mmol/L
 mmol/L
 mmol/L
 mmol/L
 mg/dL
 g/dL
 g/dL
 g/dL
 mg/dL
 IU/L
 IU/L
 IU/L
 Units
 ng/dL
 Units
 %
 Reference Interval
 70-99
 8-27
 0.76-1.27
 >59
 10-24
 134-144
 3.5-5.2
 96-106
 20-29
 8.6-10.2
 6.0-8.5
 3.8-4.8
 1.5-4.5
 1.2-2.2
 0.0-1.2
 44-121
 0-40
 0-44
 Reference Interval
 Reference Interval
 4.8-5.6
 ©2023 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  03/20/23 1213 ET   Final Report  Page 1 of 3
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee S DOB: 06/20/1958 Patient Report
 Patient ID: Age: 64 Account Number: 09241500
 Specimen ID: 069-216-8425-0 Sex: Male Ordering Physician: A HENRY
 Date Collected: 03/10/2023
 Hemoglobin A1c (Cont.)
          Diabetes: >6.4
          Glycemic control for adults with diabetes: <7.0
 Testosterone
 Test Current Result and Flag Previous Result and Date Units Reference Interval
 Testosterone 01 332 411 09/08/2022 ng/dL 264-916
 Adult male reference interval is based on a population of
 healthy nonobese males (BMI <30) between 19 and 39 years old.
 Travison, et.al. JCEM 2017,102;1161-1173. PMID: 28324103.
 **Verified by repeat analysis**
 TSH
 Test Current Result and Flag Previous Result and Date Units Reference Interval
 TSH 01 2.660 3.740 09/08/2022 uIU/mL 0.450-4.500
 Prostate-Specific Ag
 Test Current Result and Flag Previous Result and Date Units Reference Interval
 Prostate Specific Ag 01 0.8 0.9 03/15/2022 ng/mL 0.0-4.0
 Roche ECLIA methodology.
 According to the American Urological Association, Serum PSA should
 decrease and remain at undetectable levels after radical
 prostatectomy. The AUA defines biochemical recurrence as an initial
 PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory
 PSA value 0.2 ng/mL or greater.
 Values obtained with different assay methods or kits cannot be used
 interchangeably. Results cannot be interpreted as absolute evidence
 of the presence or absence of malignant disease.
 Vitamin D, 25-Hydroxy
 Test Current Result and Flag Previous Result and Date Units Reference Interval
 Vitamin D, 25-Hydroxy 01 55.5 50.9 09/08/2022 ng/mL 30.0-100.0
 Vitamin D deficiency has been defined by the Institute of
 Medicine and an Endocrine Society practice guideline as a
 level of serum 25-OH vitamin D less than 20 ng/mL (1,2).
 The Endocrine Society went on to further define vitamin D
 insufficiency as a level between 21 and 29 ng/mL (2).
 1. IOM (Institute of Medicine). 2010. Dietary reference
    intakes for calcium and D. Washington DC: The
    National Academies Press.
 2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al.
    Evaluation, treatment, and prevention of vitamin D
    deficiency: an Endocrine Society clinical practice
    guideline. JCEM. 2011 Jul; 96(7):1911-30.
 Testosterone, Free, Direct
 Test Current Result and Flag Previous Result and Date Units Reference Interval
 Free Testosterone(Direct) 03 5.4 Low 8.5 09/08/2022 pg/mL 6.6-18.1
 Date Created and Stored  03/20/23 1213 ET   Final Report  Page 2 of 3
 ©2023 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee S
 DOB: 06/20/1958
 Patient Report
 Patient ID:
 Specimen ID: 069-216-8425-0
 Age: 64
 Sex: Male
 Account Number: 09241500
 Ordering Physician: A HENRY
 Date Collected: 03/10/2023
 Triiodothyronine (T3)
 Test
 Triiodothyronine (T3) 01
 Current Result and Flag
 109
 Previous Result and Date
 96
 Units
 Reference Interval
 09/08/2022
 Ambig Abbrev CMP14 Default
 Test
 Ambig Abbrev CMP14 Default 01
 Current Result and Flag
 Previous Result and Date
 ng/dL
 Units
 71-180
 Reference Interval
 A hand-written panel/profile was received from your office. In
 accordance with the LabCorp Ambiguous Test Code Policy dated July
 2003, we have completed your order by using the closest currently
 or formerly recognized AMA panel.  We have assigned Comprehensive
 Metabolic Panel (14), Test Code #322000 to this request.  If this
 is not the testing you wished to receive on this specimen, please
 contact the LabCorp Client Inquiry/Technical Services Department
 to clarify the test order.  We appreciate your business.
 Disclaimer
 The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to
 match the result to the patient. Results from certain tests are excluded from the Previous Result display.
 Icon Legend
 Out of Reference Range     
Performing Labs
 Critical or Alert
 01: TA - Labcorp Tampa 5610 W LaSalle Street, Tampa, FL, 33607-1770 Dir: Sean Farrier, MD
 02: ES - Esoterix Inc 4301 Lost Hills Road, Calabasas Hills, CA, 91301-5358 Dir: Brian Poirier, MD
 03: BN - Labcorp Burlington 1447 York Court, Burlington, NC, 27215-3361 Dir: Sanjai Nagendra, MD
 For Inquiries, the physician may contact Branch: 800-877-5227 Lab: 800-877-5227
 Patient Details
 Weixelbaum, Lee S
 2811 WINDING TRAIL DR, VALRICO, FL, 33596
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Date of Birth: 06/20/1958
 Age: 64
 Sex: Male
 Patient ID:
 Alternate Patient ID:
 Physician Details
 A HENRY
 Andrew Henry MD
 9260 BAY PLAZA BLVD, STE 502, Brandon, FL,
 33619
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Account Number: 09241500
 Physician ID:
 NPI: 1194892141
 Specimen Details
 Specimen ID: 069-216-8425-0
 Control ID: 30185077945
 Alternate Control Number:
 Date Collected: 03/10/2023 1056  Local
 Date Received: 03/10/2023 0000  ET
 Date Entered: 03/10/2023 1730  ET
 Date Reported: 03/20/2023 1208  ET
 ©2023 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  03/20/23 1213 ET   Final Report  Page 3 of 3
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee S
 Patient ID: 772340
 Specimen ID: 069-216-8149-0
 DOB: 06/20/1958
 Age: 64
 Sex: Male
 Patient Report
 Account Number: 09372020
 Ordering Physician: R LORCH
 Date Collected: 03/10/2023
 Date Received: 03/10/2023
 Date Reported: 03/11/2023
 Fasting: Yes
 Ordered Items: Urinalysis, Complete; Renal Panel (10); Hgb+Hct; Vitamin D, 25-Hydroxy; PTH, Intact; Venipuncture
 Date Collected: 03/10/2023
 Urinalysis, Complete
 Test
 Urinalysis Gross Exam 01
 Specific Gravity 01
 pH 01
 Urine-Color 01
 Appearance 01
 WBC Esterase 01
 Protein 01
 Glucose 01
 Ketones 01
 Occult Blood 01
 Bilirubin 01
 Urobilinogen,Semi-Qn 01
 Nitrite, Urine 01
 Microscopic Examination 01
 Microscopic Examination 01
 WBC 01
 RBC 01
 Epithelial Cells (non renal) 01
 Casts 01
 Bacteria 01
 Renal Panel (10)
 Test
 Glucose 01
 BUN 01
 Creatinine 01
 eGFR
 BUN/Creatinine Ratio
 Sodium 01
 Potassium 01
 Chloride 01
 Carbon Dioxide, Total 01
 Calcium 01
 Phosphorus 01
 Albumin 01
 Current Result and Flag
 1.006
 7.5
 Yellow
 Clear
 Negative
 Negative
 Negative
 Negative
 Negative
 Negative
 0.2
 Negative
 Microscopic follows if indicated.
 See below:
 Previous Result and Date
 <=1.005
 6.5
 Yellow
 Clear
 Negative
 Negative
 Negative
 Negative
 Negative
 Negative
 0.2
 Negative
 See below:
 Microscopic was indicated and was performed.
 None seen
 None seen
 None seen
 None seen
 None seen
 Current Result and Flag
 None seen
 None seen
 None seen
 None seen
 None seen
 02/10/2023
 02/10/2023
 02/10/2023
 02/10/2023
 02/10/2023
 02/10/2023
 02/10/2023
 02/10/2023
 02/10/2023
 02/10/2023
 02/10/2023
 02/10/2023
 02/10/2023
 02/10/2023
 02/10/2023
 02/10/2023
 02/10/2023
 02/10/2023
 Previous Result and Date
 84
 15
 1.21
 67
 12
 140
 4.6
 103
 24
 9.0
 3.2
 4.6
 87
 16
 1.37
 58
 12
 139
 4.6
 102
 24
 9.7
 4.5
 02/06/2023
 02/06/2023
 02/06/2023
 02/06/2023
 02/06/2023
 02/06/2023
 02/06/2023
 02/06/2023
 02/06/2023
 02/06/2023
 02/06/2023
 Units
 mg/dL
 /hpf
 /hpf
 /hpf
 /lpf
 Units
 mg/dL
 mg/dL
 mg/dL
 mL/min/1.73
 mmol/L
 mmol/L
 mmol/L
 mmol/L
 mg/dL
 mg/dL
 g/dL
 Reference Interval
 1.005-1.030
 5.0-7.5
 Yellow
 Clear
 Negative
 Negative/Trace
 Negative
 Negative
 Negative
 Negative
 0.2-1.0
 Negative
 0 -  5
 0 -  2
 0 - 10
 None seen
 None seen/Few
 Reference Interval
 70-99
 8-27
 0.76-1.27
 >59
 10-24
 134-144
 3.5-5.2
 96-106
 20-29
 8.6-10.2
 2.8-4.1
 3.8-4.8
 ©2023 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  03/11/23 1018 ET   Final Report  Page 1 of 2
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee S
 DOB: 06/20/1958
 Patient Report
 Patient ID: 772340
 Specimen ID: 069-216-8149-0
 Age: 64
 Sex: Male
 Account Number: 09372020
 Ordering Physician: R LORCH
 Date Collected: 03/10/2023
 Hgb+Hct
 Test
 Hemoglobin 01
 Hematocrit 01
 Current Result and Flag
 14.5
 42.6
 Previous Result and Date
 15.0
 02/06/2023
 Units
 Reference Interval
 44.1
 Vitamin D, 25-Hydroxy
 Test
 Current Result and Flag
 02/06/2023
 Previous Result and Date
 Vitamin D, 25-Hydroxy 01
 50.3
 g/dL
 %
 Units
 13.0-17.7
 37.5-51.0
 Reference Interval
 50.9
 09/08/2022
 Vitamin D deficiency has been defined by the Institute of
 Medicine and an Endocrine Society practice guideline as a
 level of serum 25-OH vitamin D less than 20 ng/mL (1,2).
 The Endocrine Society went on to further define vitamin D
 insufficiency as a level between 21 and 29 ng/mL (2).
 1. IOM (Institute of Medicine). 2010. Dietary reference
   intakes for calcium and D. Washington DC: The
   National Academies Press.
 2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al.
   Evaluation, treatment, and prevention of vitamin D
   deficiency: an Endocrine Society clinical practice
   guideline. JCEM. 2011 Jul; 96(7):1911-30.
 ng/mL
 30.0-100.0
 PTH, Intact
 Test
 PTH, Intact 01
 Current Result and Flag
 42
 Previous Result and Date
 Units
 Reference Interval
 41
 Disclaimer
 01/12/2021
 pg/mL
 15-65
 The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to
 match the result to the patient. Results from certain tests are excluded from the Previous Result display.
 Icon Legend
 Out of Reference Range     
Performing Labs
 Critical or Alert
 01: TA - Labcorp Tampa 5610 W LaSalle Street, Tampa, FL, 33607-1770 Dir: Sean Farrier, MD
 For Inquiries, the physician may contact Branch: 800-877-5227 Lab: 800-877-5227
 Patient Details
 Weixelbaum, Lee S
 2811 WINDING TRAIL DR, VALRICO, FL, 33596
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Date of Birth: 06/20/1958
 Age: 64
 Sex: Male
 Patient ID: 772340
 Alternate Patient ID: 772340
 Physician Details
 R LORCH
 BRANDON NEPHROLOGY
 3140 S Falkenburg Rd STE 201, Riverview,
 FL, 33578
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Account Number: 09372020
 Physician ID: 1932596525
 NPI: 1932596525
 Specimen Details
 Specimen ID: 069-216-8149-0
 Control ID: 583432CE156
 Alternate Control Number: 583432CE15644
 Date Collected: 03/10/2023 1055  Local
 Date Received: 03/10/2023 0000  ET
 Date Entered: 03/10/2023 1730  ET
 Date Reported: 03/11/2023 1009  ET
 ©2023 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  03/11/23 1018 ET   Final Report  Page 2 of 2
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Litholink Laboratory Reporting SystemTM
 Patient Results Report
 PATIENT
 Weixelbaum, Lee
 MRN:
 Gabriel  Coimbra APRN
 University of South Florida Health
 EDI-USF
 13330 USF Laurel Drive
 Morsani Building
 Tampa, FL 33612
 Current Test Overview
 DATE OF BIRTH
 06/20/1958
 GENDER
 M
 PHYSICIAN
 Coimbra, Gabriel
 RESULTS
 TURNAROUND
 (IN DAYS)
 SAMPLE ID
 PATIENT
 COLLECTION
 DATE
 LAB
 RECEIPT
 DATE
 DATE
 COMPLETED
 SAMPLE BARCODE
 S27285504
 4
 02/13/2023
 02/14/2023 02/17/2023
 S27285504_23741472
 No medical history was taken on this patient and will be reflected in the interpretive algorithms sections of the report.
 If you would like to update our records, we can rerun the interpretive paragraphs to reflect any changes made.
 Pawan K. Vohra, Ph.D.
 Laboratory Director
 Litholink's computer generated comments are based upon the patient's most recent laboratory results without taking into account concurrent use of medication or dietary therapy. They are
 intended solely as a guide for the treating physician. Litholink does not have a doctor-patient relationship with the individuals for whom tests are ordered, nor does it have access to a complete
 medical history, which is required for both a definitive diagnosis and treatment plan. Cys 24, Cys Capacity, Sulfate, and Citrate were developed and their performance characteristics determined by
 Litholink Corporation. It has not been cleared or approved by the US Food and Drug Administration.
 Page 1 of 4
 Version:9.6.3.10
 Date Reported: 02/20/2023
 Pawan K. Vohra, Ph.D.
 Laboratory Director
 CLIA# 14D0897314
 Litholink Corporation
 150 Spring Lake Dr., Suite A
 Itasca, IL  60143
 800 338 4333 Telephone
 <PRESIDIO_ANONYMIZED_PHONE_NUMBER> Facsimile
 www.litholink.com
PATIENT DATE OF BIRTH PHYSICIAN
 Weixelbaum, Lee 06/20/1958 Coimbra, Gabriel
 Litholink Laboratory Reporting SystemTM
 Patient Results Report
 MRN:
 GENDER
 M
 DECREASED RISK INCREASING RISK FOR STONE FORMATION
 Summary Stone Risk Factors
 ANALYTE
 SAMPLE ID: PATIENT COLLECTION DATE: S27285504 02/13/2023
 Values larger, bolder and more towards red indicate increasing risk for kidney stone formation.
 Urine Volume
 SS CaOx
 (liters/day)
 Urine Calcium (mg/day)
 (mg/day) Urine Oxalate
 Urine Citrate (mg/day)
 24 Hour Urine pH
 SS CaP
 SS Uric Acid
 Urine Uric Acid (g/day)
 3.04
 4.30
 293
 39
 784
 0.26
 5.353
 1.67
 0.908
 Interpretation Of Laboratory Results
 Hypercalciuria.  Exclude hypercalcemia, Vit D excess, sarcoidosis, hyperthyroidism and malignant neoplasm.
 Treat with diet sodium 2300 to 3500 mg/day, calcium 800-1200 mg/day from food; protein 0.8 to 1.3
 gm/kg/day (see PCR value on Dietary Factors table). Thiazide if needed. Recheck at 6 weeks.
 Borderline hyperoxaluria.  May contribute to calcium oxalate stone risk. Can be caused by high oxalate or low
 calcium diet, or vitamin C supplements. Treat with low oxalate diet and diet calcium of 800 to 1200 mg/day.
 Recheck at 6 weeks.
 Low urine pH.  Is common with renal insufficiency, diarrheal diseases, diabetes and gout. Low urine pH is the
 main risk factor for uric acid stones. Consider potassium citrate, 20 - 60 mEq/day in 2-3 doses (check serum
 potassium). If unable to tolerate potassium loads consider sodium bicarbonate. Recheck at 6 weeks including
 serum potassium.
 Mild hyperuricosuria  Can cause calcium oxalate stones. Reduce poultry, fish and meat protein to 0.8 to 1.3
 gm/kg/day (see PCR value on Dietary Factors table). Recheck at 6 weeks. If stones are clinically active and diet
 measures fail consider allopurinol 150 - 300 mg daily.
 Mild uric acid supersaturation.  If stones are uric acid manage volume and pH to reduce SS below 1. If uric
 acid excretion low and urine pH is low, consider crystallization has occurred and uric acid excretion and SS are
 falsely low.
 Page 2 of 4 Date Reported: 02/20/2023
 Pawan K. Vohra, Ph.D.
 Laboratory Director
 CLIA# 14D0897314
 Litholink Corporation
 150 Spring Lake Dr., Suite A
 Itasca, IL  60143
 800 338 4333 Telephone
 <PRESIDIO_ANONYMIZED_PHONE_NUMBER> Facsimile
 www.litholink.com
 Version:9.6.3.10
PATIENT DATE OF BIRTH PHYSICIAN
 Weixelbaum, Lee 06/20/1958 Coimbra, Gabriel
 Litholink Laboratory Reporting SystemTM
 Patient Results Report
 MRN:
 GENDER
 M
 Stone Risk Factors /Cystine Screening:
 DATE SAMPLE ID Vol 24 SS CaOx Ox 24 Cit 24 Ca 24 pH SS UA UA 24 SS CaP
 Negative (02/15/2023)
 Values larger, bolder and more towards red indicate increasing risk for kidney stone formation. See
 reverse for further details.
 02/13/23 S27285504 3.04 4.30 293 39 784 0.26 5.353 1.67 0.908
 REFERENCE RANGE 0.5 - 4L 6 - 10 male <250
 female <200 20 - 40 male >450
 female >550 0.5 - 2 5.8 - 6.2 0 - 1 male <0.800
 female <0.750
 Dietary Factors
 DATE SAMPLE ID Na 24 K 24 P 24 Nh4 24 Mg 24 Sul 24 UUN 24 PCR Cl 24
 02/13/23 S27285504 113 79 223 1.560 44 110 70 18.91 1.1
 REFERENCE RANGE 50 - 150 20 - 100 30 - 120 0.6 - 1.2 15 - 60 70 - 250 20 - 80 6 - 14 0.8 - 1.4
 Normalized Values
 DATE SAMPLE ID WEIGHT Cr 24 Ca 24/Kg Cr 24/Kg Ca 24/Cr 24
 02/13/23 S27285504 129.7 2738 21.1 2.3 107
 REFERENCE RANGE male 11.9-24.4
 female 8.7-20.3 <4 male 34-196
 female 51-262
 Page 3 of 4 Date Reported: 02/20/2023
 Pawan K. Vohra, Ph.D.
 Laboratory Director
 CLIA# 14D0897314
 Litholink Corporation
 150 Spring Lake Dr., Suite A
 Itasca, IL  60143
 800 338 4333 Telephone
 <PRESIDIO_ANONYMIZED_PHONE_NUMBER> Facsimile
 www.litholink.com
 Version:9.6.3.10
PATIENT DATE OF BIRTH PHYSICIAN
 Weixelbaum, Lee 06/20/1958 Coimbra, Gabriel
 Litholink Laboratory Reporting SystemTM
 Patient Results Report
 MRN:
 GENDER
 M
 Stone Risk Factors /Cystine Screening
 Dietary Factors
 Normalized Urine Values
 ABBR. ANALYTE
 Vol 24
 REFERENCE RANGE COMMENTS
 Urine Volume 0.5 - 4 L/d; Raise vol to at least 2L .
 SS CaOx Supersaturation CaOx 6 - 10 Raise urine vol and cit, lower ox and ca.
 Ca 24 Urine Calcium male <250, female <200 idiopathic hypercalciuria, consider hydrochlorothiazide 25 mg bid or
 chlorthalidone 12.5 - 25 mg qam, urine Na <100.
 Ox 24 Urine Oxalate 20 - 40 usually dietary; if enteric, consider cholestyramine, oral calcium 1-2 gm with
 meals; if >80, may be primary hyperoxauria.
 Cit 24 Urine Citrate male >450, female >550 consider K citrate 20 - 30 mEq BID; if from RTA (urine pH > 6.5) also use K
 citrate.
 SS CaP Supersaturation CaP 0.5 - 2 Urine usually pH > 6.5, idiopathic hypercalciuria common.
 pH 24 Hour Urine pH 5.8 - 6.2 <5.8 consider K or Na citrate 25-30 mEq BID; 6.5, RTA if citrate is low; >8,
 urea splitting infection.
 SS UA Supersaturation Uric Acid 0 - 1 Urine pH <6, creates UA stones. Treated with alkali.
 UA 24 Urine Uric Acid male <0.800,  female <
 0.750;
 g/d; dietary; if stones are severe and low protein diet fails try allopurinol
 200 mg/d.
 ** Cystine Screening: positive result may be seen in patients with homozygous cystinuria and cystine stone disease, some individuals
 heterozygous for cystinuria without cystine stone disease, or in patients taking medications such as captopril or penicillamine.
 ABBR. ANALYTE
 Na 24
 REFERENCE RANGE COMMENTS
 Urine Sodium mmol/d; 50 - 150 When high raises urine Ca, and K loss from thiazide; ideal is <100.
 K 24 Urine Potassium mmol /d; 20 - 100 <20, consider bowel disease, diuretics, laxatives.
 Mg 24 Urine Magnesium mg/d; 30 - 120 Low with poor nutrition, some laxatives, malabsorption syndrome.
 P 24 Urine Phosphorus g/d; 0.6 - 1.2 Low in bowel disease, malnutrition, high with large food intake.
 Nh4 24 Urine Ammonium mmol/d; 15 - 60 High + pH>7, urea splitting infection; low + pH <5.5, renal disease, UA stones, Gout.
 Cl 24 Urine Chloride mmol/d; 70 - 250 Varies with sodium and potassium intake.
 Sul 24 Urine Sulfate
 UUN 24 Urine Urea Nitrogen g/d; 6 - 14 This measures urea production from diet protein.
 PCR Protein Catabolic Rate
 meq/d; 20 - 80 When high shows high protein diet.
 g/kg/d; 0.8 - 1.4 This measure protein intake per kg body weight.
 Creatinine/Kg
 ABBR. ANALYTE
 Weight
 COMMENTS
 Body Weight in Kg Obtained from treating physician or patient.
 Cr 24 Urine Creatinine mg/d; varies with body weight; check for day to day consistency of urine collection.
 Cr 24/Kg mg/kg/d; male 11.9 - 24.4, female 8.7 - 20.3; low in obesity or incomplete urine collection, high in
 people with large muscle mass or over-collection of urine.
 Ca 24/Kg Calcium/Kg mg/kg/d; <4.00; when high, treated as if Ca 24 mg/d were high.
 Ca 24/Cr 24 Calcium/Creatinine mg/g; male 34-196, female 51-262; when high, treated as if Ca 24 mg/d were high.
 Page 4 of 4 Date Reported: 02/20/2023
 Pawan K. Vohra, Ph.D.
 Laboratory Director
 CLIA# 14D0897314
 Litholink Corporation
 150 Spring Lake Dr., Suite A
 Itasca, IL  60143
 800 338 4333 Telephone
 <PRESIDIO_ANONYMIZED_PHONE_NUMBER> Facsimile
 www.litholink.com
 Version:9.6.3.10
Weixelbaum, Lee
 Patient ID: E327502
 Specimen ID: 041-755-4617-0
 DOB: 06/20/1958
 Age: 64
 Sex: Male
 Patient Report
 Account Number: 09394340
 Ordering Physician: E NORBY
 Ordered Items: UA/M w/rflx Culture, Routine
 Date Collected: 02/10/2023
 Date Received: 02/10/2023
 General Comments & Additional Information
 Clinical Info: SRC:URINE
 UA/M w/rflx Culture, Routine
 Test
 Urinalysis Gross Exam 01
 Specific Gravity 01
 pH 01
 Urine-Color 01
 Appearance 01
 WBC Esterase 01
 Protein 01
 Glucose 01
 Ketones 01
 Occult Blood 01
 Bilirubin 01
 Urobilinogen,Semi-Qn 01
 Nitrite, Urine 01
 Microscopic Examination 01
 Current Result and Flag
 <=1.005
 6.5
 Yellow
 Clear
 Negative
 Negative
 Negative
 Negative
 Negative
 Negative
 0.2
 Negative
 Date Reported: 02/11/2023
 Previous Result and Date
 Abnormal
 Microscopic follows if indicated.
 Microscopic Examination 01
 See below:
 <=1.005
 5.5
 Yellow
 Clear
 Negative
 Negative
 Negative
 Negative
 Negative
 Negative
 0.2
 Negative
 See below:
 Microscopic was indicated and was performed.
 WBC 01
 RBC 01
 Epithelial Cells (non renal) 01
 Casts 01
 Bacteria 01
 Urinalysis Reflex 01
 None seen
 None seen
 None seen
 None seen
 None seen
 None seen
 None seen
 None seen
 None seen
 None seen
 02/06/2023
 02/06/2023
 02/06/2023
 02/06/2023
 02/06/2023
 02/06/2023
 02/06/2023
 02/06/2023
 02/06/2023
 02/06/2023
 02/06/2023
 02/06/2023
 02/06/2023
 02/06/2023
 02/06/2023
 02/06/2023
 02/06/2023
 02/06/2023
 This specimen will not reflex to a Urine Culture.
 Disclaimer
 Fasting: Not Given
 Units
 mg/dL
 /hpf
 /hpf
 /hpf
 /lpf
 Reference Interval
 1.005-1.030
 5.0-7.5
 Yellow
 Clear
 Negative
 Negative/Trace
 Negative
 Negative
 Negative
 Negative
 0.2-1.0
 Negative
 0 -  5
 0 -  2
 0 - 10
 None seen
 None seen/Few
 The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to
 match the result to the patient. Results from certain tests are excluded from the Previous Result display.
 Icon Legend
 Out of Reference Range     
Performing Labs
 Critical or Alert
 01: TA - Labcorp Tampa 5610 W LaSalle Street, Tampa, FL, 33607-1770 Dir: Sean Farrier, MD
 For Inquiries, the physician may contact Branch: 800-877-5227 Lab: 800-877-5227
 ©2023 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  02/11/23 0414 ET   Final Report  Page 1 of 2
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee
 DOB: 06/20/1958
 Patient Report
 Patient ID: E327502
 Specimen ID: 041-755-4617-0
 Age: 64
 Sex: Male
 Account Number: 09394340
 Ordering Physician: E NORBY
 Patient Details
 Weixelbaum, Lee
 2811 WINDING TRAIL DRIVE, VALRICO, FL,
 33596
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Date of Birth: 06/20/1958
 Age: 64
 Sex: Male
 Patient ID: E327502
 Alternate Patient ID: E327502
 Physician Details
 E NORBY
 USFH STC URO SC4
 2 TAMPA GENERAL CIRCLE, TAMPA, FL,
 33606
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Account Number: 09394340
 Physician ID:
 NPI: 1134775489
 Specimen Details
 Specimen ID: 041-755-4617-0
 Control ID: 326377074BU
 Alternate Control Number: 326377074BU
 Date Collected: 02/10/2023 0927  Local
 Date Received: 02/10/2023 0000  ET
 Date Entered: 02/10/2023 2308  ET
 Date Reported: 02/11/2023 0407  ET
 Rte: 00
 ©2023 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  02/11/23 0414 ET   Final Report  Page 2 of 2
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee
 Patient ID: 772340
 Specimen ID: 037-443-1350-0
 DOB: 06/20/1958
 Age: 64
 Sex: Male
 Patient Report
 Account Number: 09372020
 Ordering Physician: R LORCH
 Ordered Items: IFE, PE and FLC, Serum; CMP14+eGFR; CBC With Differential/Platelet; Urinalysis, Complete; Acute Hepatitis;
 Prot+CreatU (Random); Albumin/Creat Ratio, Random Ur; Litholink CKD Program; Cystatin C with eGFR; Venipuncture
 Date Collected: 02/06/2023
 IFE, PE and FLC, Serum
 Test
 . 01
 IFE and PE, Serum 01
 Immunoglobulin G, Qn,
 Serum 01
 Immunoglobulin A, Qn,
 Serum 01
 Immunoglobulin M, Qn,
 Serum 01
 Protein, Total 01
 Albumin 01
 Alpha-1-Globulin 01
 Alpha-2-Globulin 01
 Beta Globulin 01
 Gamma Globulin 01
 M-Spike 01
 Globulin, Total
 A/G Ratio
 Immunofixation Result,
 Serum 01
 Please note: 01
 PDF 01
 Free Kappa Lt Chains,S 01
 Free Lambda Lt Chains,S 01
 Kappa/Lambda Ratio,S 01
 CMP14+eGFR
 Test
 Glucose 01
 BUN 01
 Creatinine 01
 eGFR
 BUN/Creatinine Ratio
 Sodium 01
 Potassium 01
 Chloride 01
 Carbon Dioxide, Total 01
 Date Received: 02/06/2023
 Current Result and Flag
 1043
 320
 132
 7.2
 4.3
 0.2
 0.6
 1.1
 1.1
 Not Observed
 2.9
 1.5
 Date Reported: 02/14/2023
 Previous Result and Date
 6.3
 11/21/2022
 The immunofixation pattern appears unremarkable. Evidence of
 monoclonal protein is not apparent.
 Protein electrophoresis scan will follow via computer, mail, or
 courier delivery.
 .
 23.4
 16.2
 1.44
 High
 Current Result and Flag
 87
 16
 1.37
 58
 12
 139
 4.6
 102
 24
 High
 Low
 Previous Result and Date
 88
 17
 1.63
 47
 10
 141
 4.5
 105
 22
 11/21/2022
 11/21/2022
 11/21/2022
 11/21/2022
 11/21/2022
 11/21/2022
 11/21/2022
 11/21/2022
 11/21/2022
 Fasting: Yes
 Units
 mg/dL
 mg/dL
 mg/dL
 g/dL
 g/dL
 g/dL
 g/dL
 g/dL
 g/dL
 g/dL
 g/dL
 mg/L
 mg/L
 Units
 mg/dL
 mg/dL
 mg/dL
 mL/min/1.73
 mmol/L
 mmol/L
 mmol/L
 mmol/L
 Reference Interval
 603-1613
 61-437
 20-172
 6.0-8.5
 2.9-4.4
 0.0-0.4
 0.4-1.0
 0.7-1.3
 0.4-1.8
 Not Observed
 2.2-3.9
 0.7-1.7
 3.3-19.4
 5.7-26.3
 0.26-1.65
 Reference Interval
 70-99
 8-27
 0.76-1.27
 >59
 10-24
 134-144
 3.5-5.2
 96-106
 20-29
 ©2023 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  02/14/23 0824 ET   Final Report  Page 1 of 5
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee
 Patient ID: 772340
 Specimen ID: 037-443-1350-0
 CMP14+eGFR (Cont.)
 Calcium 01
 Albumin 01
 Globulin, Total
 A/G Ratio
 Bilirubin, Total 01
 Alkaline Phosphatase 01
 AST (SGOT) 01
 ALT (SGPT) 01
 CBC With Differential/Platelet
 Test
 WBC 01
 RBC 01
 Hemoglobin 01
 Hematocrit 01
 MCV 01
 MCH 01
 MCHC 01
 RDW 01
 Platelets 01
 Neutrophils 01
 Lymphs 01
 Monocytes 01
 Eos 01
 Basos 01
 Neutrophils (Absolute) 01
 Lymphs (Absolute) 01
 Monocytes(Absolute) 01
 Eos (Absolute) 01
 Baso (Absolute) 01
 Immature Granulocytes 01
 Immature Grans (Abs) 01
 Urinalysis, Complete
 Test
 Urinalysis Gross Exam 01
 Specific Gravity 01
 pH 01
 Urine-Color 01
 Appearance 01
 WBC Esterase 01
 Protein 01
 Glucose 01
 Ketones 01
 Occult Blood 01
 DOB: 06/20/1958
 Age: 64
 Sex: Male
 9.7
 4.5
 2.7
 1.7
 1.4
 80
 23
 20
 High
 Current Result and Flag
 5.9
 4.88
 15.0
 44.1
 90
 30.7
 34.0
 14.0
 212
 52
 35
 8
 4
 1
 3.0
 2.1
 0.5
 0.3
 0.1
 0
 0.0
 Current Result and Flag
 <=1.005
 5.5
 Yellow
 Clear
 Negative
 Negative
 Negative
 Negative
 Negative
 Abnormal
 Patient Report
 Account Number: 09372020
 Ordering Physician: R LORCH
 9.5
 4.5
 1.8
 2.5
 1.0
 62
 23
 15
 11/21/2022
 11/21/2022
 11/21/2022
 11/21/2022
 11/21/2022
 11/21/2022
 11/21/2022
 11/21/2022
 Previous Result and Date
 7.2
 09/08/2022
 4.57
 13.8
 40.7
 89
 30.2
 33.9
 14.4
 222
 64
 23
 8
 4
 1
 4.6
 1.6
 0.6
 0.3
 0.1
 0
 0.0
 09/08/2022
 09/08/2022
 09/08/2022
 09/08/2022
 09/08/2022
 09/08/2022
 09/08/2022
 09/08/2022
 09/08/2022
 09/08/2022
 09/08/2022
 09/08/2022
 09/08/2022
 09/08/2022
 09/08/2022
 09/08/2022
 09/08/2022
 09/08/2022
 09/08/2022
 09/08/2022
 Previous Result and Date
 1.014
 7.0
 Yellow
 Clear
 Negative
 Negative
 Negative
 Negative
 Negative
 09/21/2020
 09/21/2020
 09/21/2020
 09/21/2020
 09/21/2020
 09/21/2020
 09/21/2020
 09/21/2020
 09/21/2020
 mg/dL
 g/dL
 g/dL
 mg/dL
 IU/L
 IU/L
 IU/L
 Units
 x10E3/uL
 x10E6/uL
 g/dL
 %
 fL
 pg
 g/dL
 %
 x10E3/uL
 %
 %
 %
 %
 %
 x10E3/uL
 x10E3/uL
 x10E3/uL
 x10E3/uL
 x10E3/uL
 %
 x10E3/uL
 Units
 8.6-10.2
 3.8-4.8
 1.5-4.5
 1.2-2.2
 0.0-1.2
 44-121
 0-40
 0-44
 Reference Interval
 3.4-10.8
 4.14-5.80
 13.0-17.7
 37.5-51.0
 79-97
 26.6-33.0
 31.5-35.7
 11.6-15.4
 150-450
 Not Estab.
 Not Estab.
 Not Estab.
 Not Estab.
 Not Estab.
 1.4-7.0
 0.7-3.1
 0.1-0.9
 0.0-0.4
 0.0-0.2
 Not Estab.
 0.0-0.1
 Reference Interval
 1.005-1.030
 5.0-7.5
 Yellow
 Clear
 Negative
 Negative/Trace
 Negative
 Negative
 Negative
 ©2023 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  02/14/23 0824 ET   Final Report  Page 2 of 5
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee
 Patient ID: 772340
 Specimen ID: 037-443-1350-0
 Urinalysis, Complete (Cont.)
 Bilirubin 01
 Urobilinogen,Semi-Qn 01
 Nitrite, Urine 01
 Microscopic Examination 01
 Microscopic Examination 01
 WBC 01
 RBC 01
 Epithelial Cells (non renal) 01
 Casts 01
 Bacteria 01
 Acute Hepatitis
 Test
 Hep A Ab, IgM 01
 HBsAg Screen 01
 Hep B Core Ab, IgM 01
 HCV Ab 01
 Interpretation: 01
 Prot+CreatU (Random)
 Test
 Creatinine, Urine 01
 Protein,Total,Urine 01
 Protein/Creat Ratio
 DOB: 06/20/1958
 Age: 64
 Sex: Male
 Negative
 0.2
 Negative
 Patient Report
 Account Number: 09372020
 Ordering Physician: R LORCH
 Negative
 0.2
 Negative
 Microscopic follows if indicated.
 See below:
 Microscopic was indicated and was performed.
 None seen
 None seen
 None seen
 None seen
 None seen
 Current Result and Flag
 09/21/2020
 09/21/2020
 09/21/2020
 Previous Result and Date
 Negative
 Negative
 Negative
 <0.1
 0.1
 06/28/2021
 mg/dL
 /hpf
 /hpf
 /hpf
 /lpf
 Units
 s/co ratio
 Negative
 Not infected with HCV, unless recent infection is suspected or other
 evidence exists to indicate HCV infection.
 Current Result and Flag
 25.8
 <4.0
 **Verified by repeat analysis**
 Abnormal
 Previous Result and Date
 Units
 mg/dL
 mg/dL
 mg/g creat
 This result is below the assay's limit of quantitation indicating a
 dilute specimen, potentially due to diurnal variation.  Consider
 recollection at a time likely to provide a more concentrated urine.
 Albumin/Creat Ratio, Random Ur
 Test
 Albumin, Urine 01
 Alb/Creat Ratio
 Litholink CKD Program
 Test
 Interpretation 02
 Current Result and Flag
 **Verified by repeat analysis**
 Current Result and Flag
 Previous Result and Date
 <3.0
 <12
 Units
 ug/mL
 mg/g creat
                                      Normal:                0 -  29
                                      Moderately increased: 30 - 300
                                      Severely increased:       >300
 Previous Result and Date
 Note
 Note
 11/21/2022
 Units
 Negative
 0.2-1.0
 Negative
 0 -  5
 0 -  2
 0 - 10
 None seen
 None seen/Few
 Reference Interval
 Negative
 Negative
 Negative
 0.0-0.9
 Reference Interval
 Not Estab.
 Not Estab.
 0-200
 Reference Interval
 Not Estab.
 0-29
 Reference Interval
 ©2023 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  02/14/23 0824 ET   Final Report  Page 3 of 5
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee DOB: 06/20/1958 Patient Report
 Patient ID: 772340 Age: 64 Account Number: 09372020
 Specimen ID: 037-443-1350-0 Sex: Male Ordering Physician: R LORCH
 Litholink CKD Program (Cont.)
 ------------------------------
 CHRONIC KIDNEY DISEASE:
 EGFR, BLOOD PRESSURE, AND PROTEINURIA ASSESSMENT
 Estimated GFR has risen, was 47 and now is 58
 mL/min/1.73mE2. Current eGFR corresponds to CKD stage 3a.
 Cystatin C eGFR derived from the CKD-EPI creatinine-cystatin
 C 2021 equation is 78 mL/min/1.73mE2. Potassium is within
 goal and has not changed significantly, was 4.5 and now is
 4.6 mmol/L. Urine albumin is undetectable. If no other
 markers of kidney damage are present consider measurement of
 cystatin C to confirm diagnosis of CKD. Hemoglobin A1C is
 5.1 % (measured on 11/21/2022); diabetic status is unknown.
 Refer to ADA guidelines for clinical practice
 recommendations.
 EGFR, BLOOD PRESSURE, AND PROTEINURIA TREATMENT SUGGESTIONS
 
 Based on current eGFR and absence of significant
 proteinuria, patient is at moderately increased risk for
 adverse outcomes such as CKD progression, CVD, and
 mortality. Guidelines recommend a target blood pressure of
 120/80 mmHg or less to reduce cardiovascular risk and CKD
 progression.
 EGFR, BLOOD PRESSURE, AND PROTEINURIA FOLLOW-UP
 
 Spot Urine Panel (Albumin preferred) and fasting Renal Panel
 within 12 months;
 BONE and MINERAL ASSESSMENT
 Calcium is within goal and has not changed significantly,
 was 9.5 and now is 9.7 mg/dL. Carbon Dioxide is within goal
 and has risen, was 22 and now is 24 mmol/L. Guidelines
 recommend the measurement of 25-hydroxy vitamin D in
 patients with CKD.
 BONE and MINERAL TREATMENT SUGGESTIONS
 
 Interpretations require simultaneous measurements of serum
 calcium and phosphorus.
 BONE and MINERAL FOLLOW-UP
 
 fasting PTH with Renal Panel and 25-Hydroxy Vitamin D are
 due;
 LIPIDS ASSESSMENT
 Most recent order does not include a fasting Lipid Panel.
 LIPIDS FOLLOW-UP
 
 fasting Lipid Panel is due;
 ANEMIA ASSESSMENT
 Hemoglobin is normal and has not changed significantly, was
 15.1 and now is 15.0 g/dL. Hemoglobin target assumes ESA is
 not in use.
 ANEMIA TREATMENT SUGGESTIONS
 
 No specific change of treatment is indicated at this time.
 ANEMIA FOLLOW-UP
 
 CBC within 12 months;
 ------------------------------
 DISCLAIMER
 These assessments and treatment suggestions are provided as
 Date Created and Stored  02/14/23 0824 ET   Final Report  Page 4 of 5
 ©2023 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee
 DOB: 06/20/1958
 Patient Report
 Patient ID: 772340
 Specimen ID: 037-443-1350-0
 Age: 64
 Sex: Male
 Account Number: 09372020
 Ordering Physician: R LORCH
 Litholink CKD Program (Cont.)
 a convenience in support of the physician-patient
 relationship and are not intended to replace the physician's
 clinical judgment. They are derived from national guidelines
 in addition to other evidence and expert opinion. The
 clinician should consider this information within the
 context of clinical opinion and the individual patient.
 SEE GUIDANCE FOR CHRONIC KIDNEY DISEASE PROGRAM: Kidney
 Disease Improving Global Outcomes (KDIGO) clinical practice
 guidelines are at http://kdigo.org/home/guidelines/.
 National Kidney Foundation Kidney Disease Outcomes Quality
 Initiative (KDOQI (TM)), with its limitations and
 disclaimers, are at www.kidney.org/professionals/KDOQI. This
 program is intended for patients who have been diagnosed
 with stages 3, 4, or pre-dialysis 5 CKD. It is not intended
 for children, pregnant patients, or transplant patients.
 PDF 02
 Not applicable
 Not applicable
 Cystatin C with eGFR
 Test
 Current Result and Flag
 11/21/2022
 Previous Result and Date
 Cystatin C 03
 eGFR
 0.87
 Units
 Reference Interval
 92
 Disclaimer
 mg/L
 mL/min/1.73
 0.72-1.16
 >59
 The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to
 match the result to the patient. Results from certain tests are excluded from the Previous Result display.
 Icon Legend
 Out of Reference Range     
Performing Labs
 Critical or Alert
 01: TA - Labcorp Tampa 5610 W LaSalle Street, Tampa, FL, 33607-1770 Dir: Sean Farrier, MD
 02: LITIL - Litholink Corporation 150 Spring Lake Dr Ste A, Itasca, IL, 60143-2091 Dir: Pawan Vohra, PhD
 03: BN - Labcorp Burlington 1447 York Court, Burlington, NC, 27215-3361 Dir: Sanjai Nagendra, MD
 For Inquiries, the physician may contact Branch: 800-877-5227 Lab: 800-877-5227
 Patient Details
 Weixelbaum, Lee
 2811 WINDING TRAIL DR, VALRICO, FL, 33596
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Date of Birth: 06/20/1958
 Age: 64
 Sex: Male
 Patient ID: 772340
 Alternate Patient ID: 772340
 Physician Details
 R LORCH
 BRANDON NEPHROLOGY
 3140 S Falkenburg Rd STE 201, Riverview,
 FL, 33578
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Account Number: 09372020
 Physician ID: 1932596525
 NPI: 1932596525
 Specimen Details
 Specimen ID: 037-443-1350-0
 Control ID: 583432CE156
 Alternate Control Number: 583432CE15644
 Date Collected: 02/06/2023 1219  Local
 Date Received: 02/06/2023 0000  ET
 Date Entered: 02/06/2023 1557  ET
 Date Reported: 02/14/2023 0812  ET
 Rte: 00
 ©2023 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  02/14/23 0824 ET   Final Report  Page 5 of 5
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Laboratory Corporation of America
 Special Chemistry Department
 Tampa, FL
 Electrophoresis
 Accession Number 037443135009
 Patient Name WEIXELBAU, LEE
 Total Protein 7.2
 Patient ID 1387.73.33
 Birthdate 6/20/1958
 Account No./ Name 09372020-BRANDON NEPHROLO...
 Physician ID LORCH    R
 Account Address 1
 Account Address 2 511 MEDICAL OAKS AVE
 Account Address 3 BRANDON, FL 33511
 Serum Proteins  Gel 000540211652  Sample 33  02/13/2023  10:47:32:32
 Albumin
 Alpha-1
 Alpha-2
 Beta
 Gamma
 Total
 Fraction
  59.1
   3.2
   8.1
  14.9
  14.6
 %
     4.3 
     0.2 
     0.6 
     1.1 
     1.1 
     7.2 
 g/dl
     2.9 to     4.4
     0.0 to     0.4
     0.4 to     1.0
     0.7 to     1.3
     0.4 to     1.8
 g/dl Range
 A/G
 Ratio
    1.4
 Interpretation
 The SPE pattern appears unremarkable. Evidence of monoclonal protein is not apparent.
Weixelbaum, Lee S
 DOB: 06/20/1958
 Patient Report
 Patient ID: 106002335274
 Specimen ID: 325-216-2836-0
 Age: 64
 Sex: Male
 Account Number: 09621402
 Ordering Physician: S STEVENSON
 Ordered Items: Comp. Metabolic Panel (14); Litholink CKD Program; Hemoglobin A1c; Venipuncture
 Date Collected: 11/21/2022
 Comp. Metabolic Panel (14)
 Test
 Glucose 01
 BUN 01
 Creatinine 01
 eGFR
 BUN/Creatinine Ratio
 Sodium 01
 Potassium 01
 Chloride 01
 Carbon Dioxide, Total 01
 Calcium 01
 Protein, Total 01
 Albumin 01
 Globulin, Total
 A/G Ratio
 Bilirubin, Total 01
 Alkaline Phosphatase 01
 AST (SGOT) 01
 ALT (SGPT) 01
 Test
 Date Received: 11/21/2022
 Current Result and Flag
 88
 17
 1.63
 47
 10
 141
 4.5
 105
 22
 9.5
 6.3
 4.5
 1.8
 High
 Low
 Date Reported: 11/22/2022
 Previous Result and Date
 96*
 14
 1.47
 53
 10
 142
 09/08/2022
 09/08/2022
 09/08/2022
 09/08/2022
 09/08/2022
 09/08/2022
 4.4
 106
 22
 9.0
 6.9
 4.4
 2.5
 2.5
 1.0
 62
 23
 15
 * Previous Reference Interval: (Glucose: 65-99 mg/dL)
 Litholink CKD Program
 High
 Current Result and Flag
 1.8
 1.4
 57
 31
 24
 09/08/2022
 09/08/2022
 09/08/2022
 09/08/2022
 09/08/2022
 09/08/2022
 09/08/2022
 09/08/2022
 09/08/2022
 09/08/2022
 09/08/2022
 09/08/2022
 Previous Result and Date
 Interpretation 02
 Note
 Note
 11/15/2021------------------------------
CHRONIC KIDNEY DISEASE:
 EGFR, BLOOD PRESSURE, AND PROTEINURIA ASSESSMENT
 We presume eGFR has been less than 60 mL/min/1.73mE2 on at
 least two occasions spaced at least 3 months apart. Current
 eGFR is 47 mL/min/1.73mE2 corresponding to CKD stage 3a.
 Potassium is within goal and has not changed significantly,
 was 4.5 and now is 4.5 mmol/L. Hemoglobin A1C is 5.1 %;
 diabetic status is unknown. Refer to ADA guidelines for
 clinical practice recommendations.
 EGFR, BLOOD PRESSURE, AND PROTEINURIA TREATMENT SUGGESTIONS
mL/min/1.73
 Guidelines recommend a target blood pressure of 120/80 mmHg
 or less to reduce cardiovascular risk and CKD progression.
 Assessment of albuminuria (urine albumin:creatinine ratio or
 urine protein:creatinine ratio preferred) is recommended at
 least annually in CKD patients for staging and disease
 prognosis.
 EGFR, BLOOD PRESSURE, AND PROTEINURIA FOLLOW-UP
fasting Renal Panel within 12 months; Spot Urine Panel is
 Fasting: Yes
 Units
 mg/dL
 mg/dL
 mg/dL
 mmol/L
 mmol/L
 mmol/L
 mmol/L
 mg/dL
 g/dL
 g/dL
 g/dL
 mg/dL
 IU/L
 IU/L
 IU/L
 Units
 Reference Interval
 70-99
 8-27
 0.76-1.27
 >59
 10-24
 134-144
 3.5-5.2
 96-106
 20-29
 8.6-10.2
 6.0-8.5
 3.8-4.8
 1.5-4.5
 1.2-2.2
 0.0-1.2
 44-121
 0-40
 0-44
 Reference Interval
 ©2022 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  11/22/22 0715 ET   Final Report  Page 1 of 3
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee S DOB: 06/20/1958 Patient Report
 Patient ID: 106002335274 Age: 64 Account Number: 09621402
 Specimen ID: 325-216-2836-0 Sex: Male Ordering Physician: S STEVENSON
 Litholink CKD Program (Cont.)
 recommended by guidelines, at least yearly;
 BONE and MINERAL ASSESSMENT
 Calcium is within goal and has risen, was 9.1 and now is 9.5
 mg/dL. Carbon Dioxide is within goal and has not changed
 significantly, was 24 and now is 22 mmol/L. Guidelines
 recommend the measurement of 25-hydroxy vitamin D in
 patients with CKD.
 BONE and MINERAL TREATMENT SUGGESTIONS
 
 Interpretations require simultaneous measurements of serum
 calcium and phosphorus.
 BONE and MINERAL FOLLOW-UP
 
 fasting PTH with Renal Panel and 25-Hydroxy Vitamin D are
 due;
 LIPIDS ASSESSMENT
 Most recent order does not include a fasting Lipid Panel.
 LIPIDS FOLLOW-UP
 
 fasting Lipid Panel is due;
 ANEMIA ASSESSMENT
 Most recent order does not include a CBC Panel or iron
 studies.
 ANEMIA FOLLOW-UP
 
 CBC is due;
 ------------------------------
 DISCLAIMER
 These assessments and treatment suggestions are provided as
 a convenience in support of the physician-patient
 relationship and are not intended to replace the physician's
 clinical judgment. They are derived from national guidelines
 in addition to other evidence and expert opinion. The
 clinician should consider this information within the
 context of clinical opinion and the individual patient.
 SEE GUIDANCE FOR CHRONIC KIDNEY DISEASE PROGRAM: Kidney
 Disease Improving Global Outcomes (KDIGO) clinical practice
 guidelines are at http://kdigo.org/home/guidelines/.
 National Kidney Foundation Kidney Disease Outcomes Quality
 Initiative (KDOQI (TM)), with its limitations and
 disclaimers, are at www.kidney.org/professionals/KDOQI. This
 program is intended for patients who have been diagnosed
 with stages 3, 4, or pre-dialysis 5 CKD. It is not intended
 for children, pregnant patients, or transplant patients.
 PDF 02 Not applicable Not applicable 11/15/2021
 Hemoglobin A1c
 Test Current Result and Flag Previous Result and Date Units Reference Interval
 Hemoglobin A1c 01 5.1 5.0 06/28/2021 % 4.8-5.6
 Please Note: 01
          Prediabetes: 5.7 - 6.4
          Diabetes: >6.4
          Glycemic control for adults with diabetes: <7.0
 Date Created and Stored  11/22/22 0715 ET   Final Report  Page 2 of 3
 ©2022 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
DOB: 06/20/1958
 Patient Report
 Weixelbaum, Lee S
 Patient ID: 106002335274
 Specimen ID: 325-216-2836-0
 Age: 64
 Sex: Male
 Account Number: 09621402
 Ordering Physician: S STEVENSON
 Disclaimer
 The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to
 match the result to the patient. Results from certain tests are excluded from the Previous Result display.
 Icon Legend
 Out of Reference Range     
Performing Labs
 Critical or Alert
 01: TA - Labcorp Tampa 5610 W LaSalle Street, Tampa, FL, 33607-1770 Dir: Sean Farrier, MD
 02: LITIL - Litholink Corporation 150 Spring Lake Dr Ste A, Itasca, IL, 60143-2091 Dir: Pawan Vohra, PhD
 For Inquiries, the physician may contact Branch: 800-877-5227 Lab: 800-877-5227
 Patient Details
 Weixelbaum, Lee S
 2811 WINDING TRAIL DR, VALRICO, FL, 33596
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Date of Birth: 06/20/1958
 Age: 64
 Sex: Male
 Patient ID: 106002335274
 Alternate Patient ID: 301181250
 Physician Details
 S STEVENSON
 BayCare Medical Group
 2470 Bloomingdale Ave Ste 123, Valrico, FL,
 33596
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Account Number: 09621402
 Physician ID: 1952866097
 NPI: 1952866097
 Specimen Details
 Specimen ID: 325-216-2836-0
 Control ID: 10600233527
 Alternate Control Number:
 106002335274L91723
 Date Collected: 11/21/2022 0829  Local
 Date Received: 11/21/2022 0000  ET
 Date Entered: 11/21/2022 1538  ET
 Date Reported: 11/22/2022 0708  ET
 Rte: 27
 ©2022 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  11/22/22 0715 ET   Final Report  Page 3 of 3
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee S DOB: 06/20/1958 Patient Report
 Patient ID: Age: 64 Account Number: 09241500
 Specimen ID: 251-216-2783-0 Sex: Male Ordering Physician: A HENRY
 
Ordered Items: CBC With Differential/Platelet; Comp. Metabolic Panel (14); Testosterone,Free and Total; Thyroxine (T4) Free,
 Direct; TSH; Vitamin D, 25-Hydroxy; Triiodothyronine (T3); Venipuncture; Handwritten Order
 
Date Collected: 09/08/2022 Date Received: 09/08/2022 Date Reported: 09/12/2022 Fasting: No
 General Comments & Additional Information
 A courtesy copy of this report has been sent to
 8136760237.
 
CBC With Differential/Platelet
 Test Current Result and Flag Previous Result and Date Units Reference Interval
 WBC 01 7.2 6.1 05/20/2022 x10E3/uL 3.4-10.8
 RBC 01 4.57 4.71 05/20/2022 x10E6/uL 4.14-5.80
 Hemoglobin 01 13.8 14.4 05/20/2022 g/dL 13.0-17.7
 Hematocrit 01 40.7 42.5 05/20/2022 % 37.5-51.0
 MCV 01 89 90 05/20/2022 fL 79-97
 MCH 01 30.2 30.6 05/20/2022 pg 26.6-33.0
 MCHC 01 33.9 33.9 05/20/2022 g/dL 31.5-35.7
 RDW 01 14.4 13.7 05/20/2022 % 11.6-15.4
 Platelets 01 222 212 05/20/2022 x10E3/uL 150-450
 Neutrophils 01 64 49 05/20/2022 % Not Estab.
 Lymphs 01 23 38 05/20/2022 % Not Estab.
 Monocytes 01 8 8 05/20/2022 % Not Estab.
 Eos 01 4 4 05/20/2022 % Not Estab.
 Basos 01 1 1 05/20/2022 % Not Estab.
 Neutrophils (Absolute) 01 4.6 3.0 05/20/2022 x10E3/uL 1.4-7.0
 Lymphs (Absolute) 01 1.6 2.3 05/20/2022 x10E3/uL 0.7-3.1
 Monocytes(Absolute) 01 0.6 0.5 05/20/2022 x10E3/uL 0.1-0.9
 Eos (Absolute) 01 0.3 0.2 05/20/2022 x10E3/uL 0.0-0.4
 Baso (Absolute) 01 0.1 0.1 05/20/2022 x10E3/uL 0.0-0.2
 Immature Granulocytes 01 0 0 05/20/2022 % Not Estab.
 Immature Grans (Abs) 01 0.0 0.0 05/20/2022 x10E3/uL 0.0-0.1
 Comp. Metabolic Panel (14)
 Test Current Result and Flag Previous Result and Date Units Reference Interval
 Glucose 01 96 87 05/20/2022 mg/dL 65-99
 BUN 01 14 15 05/20/2022 mg/dL 8-27
 Creatinine 01 1.47 High 1.27 05/20/2022 mg/dL 0.76-1.27
 eGFR 53 Low 63 05/20/2022 mL/min/1.73 >59
 BUN/Creatinine Ratio 10 12 05/20/2022 10-24
 Sodium 01 142 139 05/20/2022 mmol/L 134-144
 Potassium 01 4.4 4.4 05/20/2022 mmol/L 3.5-5.2
 Chloride 01 106 104 05/20/2022 mmol/L 96-106
 Carbon Dioxide, Total 01 22 20 05/20/2022 mmol/L 20-29
 Calcium 01 9.0 9.1 05/20/2022 mg/dL 8.6-10.2
 Date Created and Stored  09/12/22 1110 ET   Final Report  Page 1 of 3
 ©2022 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee S
 DOB: 06/20/1958
 Patient Report
 Patient ID:
 Specimen ID: 251-216-2783-0
 Age: 64
 Sex: Male
 Comp. Metabolic Panel (14) (Cont.)
 Protein, Total 01
 Albumin 01
 Globulin, Total
 A/G Ratio
 Bilirubin, Total 01
 Alkaline Phosphatase 01
 AST (SGOT) 01
 ALT (SGPT) 01
 Testosterone,Free and Total
 Test
 Testosterone 01
 6.9
 4.4
 2.5
 1.8
 1.4
 57
 31
 24
 Current Result and Flag
 411
 Account Number: 09241500
 Ordering Physician: A HENRY
 6.9
 4.7
 2.2
 2.1
 High
 0.9
 61
 22
 21
 05/20/2022
 05/20/2022
 05/20/2022
 05/20/2022
 05/20/2022
 05/20/2022
 05/20/2022
 05/20/2022
 Previous Result and Date
 449
 03/15/2022
 Adult male reference interval is based on a population of
 healthy nonobese males (BMI <30) between 19 and 39 years old.
 Travison, et.al. JCEM 2017,102;1161-1173. PMID: 28324103.
 Free Testosterone(Direct) 02
 Thyroxine (T4) Free, Direct
 Test
 T4,Free(Direct) 01
 TSH
 Test
 TSH 01
 Vitamin D, 25-Hydroxy
 Test
 Vitamin D, 25-Hydroxy 01
 8.5
 Current Result and Flag
 1.11
 Current Result and Flag
 3.740
 50.9
 9.6
 g/dL
 g/dL
 g/dL
 mg/dL
 IU/L
 IU/L
 IU/L
 Units
 ng/dL
 03/15/2022
 Previous Result and Date
 1.15
 11/15/2021
 Previous Result and Date
 2.67
 Current Result and Flag
 03/15/2022
 Previous Result and Date
 36.5
 03/15/2022
 Vitamin D deficiency has been defined by the Institute of
 Medicine and an Endocrine Society practice guideline as a
 level of serum 25-OH vitamin D less than 20 ng/mL (1,2).
 The Endocrine Society went on to further define vitamin D
 insufficiency as a level between 21 and 29 ng/mL (2).
 1. IOM (Institute of Medicine). 2010. Dietary reference
   intakes for calcium and D. Washington DC: The
   National Academies Press.
 2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al.
   Evaluation, treatment, and prevention of vitamin D
   deficiency: an Endocrine Society clinical practice
   guideline. JCEM. 2011 Jul; 96(7):1911-30.
 Triiodothyronine (T3)
 Test
 Triiodothyronine (T3) 01
 Current Result and Flag
 96
 Previous Result and Date
 116
 03/15/2022
 pg/mL
 Units
 ng/dL
 Units
 uIU/mL
 Units
 ng/mL
 Units
 ng/dL
 6.0-8.5
 3.8-4.8
 1.5-4.5
 1.2-2.2
 0.0-1.2
 44-121
 0-40
 0-44
 Reference Interval
 264-916
 6.6-18.1
 Reference Interval
 0.82-1.77
 Reference Interval
 0.450-4.500
 Reference Interval
 30.0-100.0
 Reference Interval
 71-180
 ©2022 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  09/12/22 1110 ET   Final Report  Page 2 of 3
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
DOB: 06/20/1958
 Patient Report
 Weixelbaum, Lee S
 Patient ID:
 Specimen ID: 251-216-2783-0
 Age: 64
 Sex: Male
 Account Number: 09241500
 Ordering Physician: A HENRY
 Disclaimer
 The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to
 match the result to the patient. Results from certain tests are excluded from the Previous Result display.
 Icon Legend
 Out of Reference Range     
Performing Labs
 Critical or Alert
 01: TA - Labcorp Tampa 5610 W LaSalle Street, Tampa, FL, 33607-1770 Dir: Sean Farrier, MD
 02: BN - Labcorp Burlington 1447 York Court, Burlington, NC, 27215-3361 Dir: Sanjai Nagendra, MD
 For Inquiries, the physician may contact Branch: 800-877-5227 Lab: 800-877-5227
 Patient Details
 Weixelbaum, Lee S
 2811 WINDING TRAIL DR, VALRICO, FL, 33596
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Date of Birth: 06/20/1958
 Age: 64
 Sex: Male
 Patient ID:
 Alternate Patient ID:
 Physician Details
 A HENRY
 Andrew Henry MD
 9260 BAY PLAZA BLVD, STE 502, Brandon, FL,
 33619
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Account Number: 09241500
 Physician ID:
 NPI: 1194892141
 Specimen Details
 Specimen ID: 251-216-2783-0
 Control ID: 30185068055
 Alternate Control Number:
 Date Collected: 09/08/2022 0821  Local
 Date Received: 09/08/2022 0000  ET
 Date Entered: 09/08/2022 1143  ET
 Date Reported: 09/12/2022 1108  ET
 Rte: 00
 ©2022 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  09/12/22 1110 ET   Final Report  Page 3 of 3
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee S DOB: 06/20/1958 Patient Report
 Patient ID: 106001072320 Age: 63 Account Number: 09621402
 Specimen ID: 140-216-9545-0 Sex: Male Ordering Physician: S STEVENSON
 
Ordered Items: CBC With Differential/Platelet; Comp. Metabolic Panel (14); Lipid Panel; Venipuncture
 
Date Collected: 05/20/2022 Date Received: 05/20/2022 Date Reported: 05/21/2022 Fasting: No
 CBC With Differential/Platelet
 Test Current Result and Flag Previous Result and Date Units Reference Interval
 WBC 01 6.1 6.3 06/28/2021 x10E3/uL 3.4-10.8
 RBC 01 4.71 4.88 06/28/2021 x10E6/uL 4.14-5.80
 Hemoglobin 01 14.4 15.1 06/28/2021 g/dL 13.0-17.7
 Hematocrit 01 42.5 44.0 06/28/2021 % 37.5-51.0
 MCV 01 90 90 06/28/2021 fL 79-97
 MCH 01 30.6 30.9 06/28/2021 pg 26.6-33.0
 MCHC 01 33.9 34.3 06/28/2021 g/dL 31.5-35.7
 RDW 01 13.7 14.1 06/28/2021 % 11.6-15.4
 Platelets 01 212 217 06/28/2021 x10E3/uL 150-450
 Neutrophils 01 49 60 06/28/2021 % Not Estab.
 Lymphs 01 38 26 06/28/2021 % Not Estab.
 Monocytes 01 8 8 06/28/2021 % Not Estab.
 Eos 01 4 5 06/28/2021 % Not Estab.
 Basos 01 1 1 06/28/2021 % Not Estab.
 Neutrophils (Absolute) 01 3.0 3.8 06/28/2021 x10E3/uL 1.4-7.0
 Lymphs (Absolute) 01 2.3 1.6 06/28/2021 x10E3/uL 0.7-3.1
 Monocytes(Absolute) 01 0.5 0.5 06/28/2021 x10E3/uL 0.1-0.9
 Eos (Absolute) 01 0.2 0.3 06/28/2021 x10E3/uL 0.0-0.4
 Baso (Absolute) 01 0.1 0.1 06/28/2021 x10E3/uL 0.0-0.2
 Immature Granulocytes 01 0 0 06/28/2021 % Not Estab.
 Immature Grans (Abs) 01 0.0 0.0 06/28/2021 x10E3/uL 0.0-0.1
 Comp. Metabolic Panel (14)
 Test Current Result and Flag Previous Result and Date Units Reference Interval
 Glucose 01 87 95 11/15/2021 mg/dL 65-99
 BUN 01 15 15 11/15/2021 mg/dL 8-27
 Creatinine 01 1.27 1.43 11/15/2021 mg/dL 0.76-1.27
 eGFR 63 mL/min/1.73 >59
 BUN/Creatinine Ratio 12 10 11/15/2021 10-24
 Sodium 01 139 142 11/15/2021 mmol/L 134-144
 Potassium 01 4.4 4.5 11/15/2021 mmol/L 3.5-5.2
 Chloride 01 104 106 11/15/2021 mmol/L 96-106
 Carbon Dioxide, Total 01 20 22 11/15/2021 mmol/L 20-29
 Calcium 01 9.1 9.1 11/15/2021 mg/dL 8.6-10.2
 Protein, Total 01 6.9 6.6 11/15/2021 g/dL 6.0-8.5
 Albumin 01 4.7 4.2 11/15/2021 g/dL 3.8-4.8
 Globulin, Total 2.2 2.4 11/15/2021 g/dL 1.5-4.5
 A/G Ratio 2.1 1.8 11/15/2021 1.2-2.2
 Bilirubin, Total 01 0.9 0.7 11/15/2021 mg/dL 0.0-1.2
 Date Created and Stored  05/21/22 0619 ET   Final Report  Page 1 of 2
 ©2022 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
Weixelbaum, Lee S DOB: 06/20/1958 Patient Report
 Patient ID: 106001072320 Age: 63 Account Number: 09621402
 Specimen ID: 140-216-9545-0 Sex: Male Ordering Physician: S STEVENSON
 Comp. Metabolic Panel (14) (Cont.)
 Alkaline Phosphatase 01 61 67 11/15/2021 IU/L 44-121
 AST (SGOT) 01 22 21 11/15/2021 IU/L 0-40
 ALT (SGPT) 01 21 18 11/15/2021 IU/L 0-44
 Lipid Panel
 Test Current Result and Flag Previous Result and Date Units Reference Interval
 Cholesterol, Total 01 180 208 06/28/2021 mg/dL 100-199
 Triglycerides 01 111 157 06/28/2021 mg/dL 0-149
 HDL Cholesterol 01 35 Low 37 06/28/2021 mg/dL >39
 VLDL Cholesterol Cal 20 28 06/28/2021 mg/dL 5-40
 LDL Chol Calc (NIH) 125 High 143 06/28/2021 mg/dL 0-99
 
Disclaimer
 The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to
 match the result to the patient. Results from certain tests are excluded from the Previous Result display.
 
Icon Legend
 Out of Reference Range      Critical or Alert
 
Performing Labs
 01: TA - Labcorp Tampa 5610 W LaSalle Street, Tampa, FL, 33607-1770 Dir: Sean Farrier, MD
 For Inquiries, the physician may contact Branch: 800-877-5227 Lab: 800-877-5227
 
Patient Details
 Weixelbaum, Lee S
 2811 WINDING TRAIL DR, VALRICO, FL, 33596
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Date of Birth: 06/20/1958
 Age: 63
 Sex: Male
 Patient ID: 106001072320
 Alternate Patient ID: 301181250
 Physician Details
 S STEVENSON
 BayCare Medical Group
 2470 Bloomingdale Ave Ste 123, Valrico, FL,
 33596
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Account Number: 09621402
 Physician ID: 1952866097
 NPI: 1952866097
 Specimen Details
 Specimen ID: 140-216-9545-0
 Control ID: 10600107232
 Alternate Control Number:
 106001072320L86283
 Date Collected: 05/20/2022 1255  Local
 Date Received: 05/20/2022 0000  ET
 Date Entered: 05/20/2022 1913  ET
 Date Reported: 05/21/2022 0608  ET
 Rte: 27
 Date Created and Stored  05/21/22 0619 ET   Final Report  Page 2 of 2
 ©2022 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
DOB: 06/20/1958
 Patient Report
 Weixelbaum, Lee S
 Patient ID:
 Specimen ID: 074-216-2087-0
 Age: 63
 Sex: Male
 Account Number: 09241500
 Ordering Physician: A HENRY
 Ordered Items: Testosterone,Free and Total; Free T4 by Dialysis/Mass Spec; TSH; Prostate-Specific Ag; Vitamin D, 25-Hydroxy;
 Triiodothyronine (T3); Venipuncture
 Date Collected: 03/15/2022
 Date Received: 03/15/2022
 Date Reported: 03/26/2022
 Testosterone,Free and Total
 Test
 Testosterone 01
 Current Result and Flag
 449
 Previous Result and Date
 367
 11/15/2021
 Adult male reference interval is based on a population of
 healthy nonobese males (BMI <30) between 19 and 39 years old.
 Travison, et.al. JCEM 2017,102;1161-1173. PMID: 28324103.
 Fasting: Yes
 Units
 ng/dL
 Reference Interval
 264-916
 Free Testosterone(Direct) 02
 Free T4 by Dialysis/Mass Spec
 Test
 Free T4 by Dialysis/Mass Spec 03
 9.6
 Current Result and Flag
 1.2
 10.9
 05/06/2021
 Previous Result and Date
 pg/mL
 Units
 6.6-18.1
 Reference Interval
 0.81
 05/06/2021
 This test was developed and its performance characteristics
 determined by LabCorp. It has not been cleared or approved
 by the Food and Drug Administration.
 Reference Range:
 Pubertal Children and Adults:
 0.8 - 1.7
 ng/dL
 TSH
 Test
 TSH 01
 Current Result and Flag
 2.670
 Previous Result and Date
 Units
 Reference Interval
 6.42
 Prostate-Specific Ag
 Test
 Current Result and Flag
 11/15/2021
 Previous Result and Date
 Prostate Specific Ag 01
 0.9
 uIU/mL
 Units
 0.450-4.500
 Reference Interval
 0.8
 10/07/2021
 ng/mL
 Roche ECLIA methodology.
 According to the American Urological Association, Serum PSA should
 decrease and remain at undetectable levels after radical
 prostatectomy. The AUA defines biochemical recurrence as an initial
 PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory
 PSA value 0.2 ng/mL or greater.
 Values obtained with different assay methods or kits cannot be used
 interchangeably. Results cannot be interpreted as absolute evidence
 of the presence or absence of malignant disease.
 0.0-4.0
 Vitamin D, 25-Hydroxy
 Test
 Vitamin D, 25-Hydroxy 01
 Current Result and Flag
 36.5
 Previous Result and Date
 Units
 Reference Interval
 39.7
 11/15/2021
 Vitamin D deficiency has been defined by the Institute of
 Medicine and an Endocrine Society practice guideline as a
 level of serum 25-OH vitamin D less than 20 ng/mL (1,2).
 ng/mL
 30.0-100.0
 ©2022 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  03/26/22 0837 ET   Final Report  Page 1 of 2
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-5227
DOB: 06/20/1958
 Patient Report
 Weixelbaum, Lee S
 Patient ID:
 Specimen ID: 074-216-2087-0
 Age: 63
 Sex: Male
 Account Number: 09241500
 Ordering Physician: A HENRY
 Vitamin D, 25-Hydroxy (Cont.)
 The Endocrine Society went on to further define vitamin D
 insufficiency as a level between 21 and 29 ng/mL (2).
 1. IOM (Institute of Medicine). 2010. Dietary reference
   intakes for calcium and D. Washington DC: The
   National Academies Press.
 2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al.
   Evaluation, treatment, and prevention of vitamin D
   deficiency: an Endocrine Society clinical practice
   guideline. JCEM. 2011 Jul; 96(7):1911-30.
 Triiodothyronine (T3)
 Test
 Triiodothyronine (T3) 01
 Current Result and Flag
 116
 Previous Result and Date
 Units
 Reference Interval
 120
 Disclaimer
 05/06/2021
 ng/dL
 71-180
 The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to
 match the result to the patient. Results from certain tests are excluded from the Previous Result display.
 Icon Legend
 Out of Reference Range     
Performing Labs
 Critical or Alert
 01: TA - Labcorp Tampa 5610 W LaSalle Street, Tampa, FL, 33607-1770 Dir: Sean Farrier, MD
 02: BN - Labcorp Burlington 1447 York Court, Burlington, NC, 27215-3361 Dir: Sanjai Nagendra, MD
 03: ES - Esoterix Inc 4301 Lost Hills Road, Calabasas Hills, CA, 91301-5358 Dir: Brian Poirier, MD
 For Inquiries, the physician may contact Branch: 800-877-5227 Lab: 800-877-5227
 PatientDetails
 Weixelbaum, Lee S
 2811 WINDING TRAIL DR, VALRICO, FL, 33596
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Date of Birth: 06/20/1958
 Age: 63
 Sex: Male
 Patient ID:
 Alternate Patient ID:
 Physician Details
 A HENRY
 Andrew Henry MD
 9260 BAY PLAZA BLVD, STE 502, Brandon, FL,
 33619
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Account Number: 09241500
 Physician ID:
 NPI: 1194892141
 Specimen Details
 Specimen ID: 074-216-2087-0
 Control ID: 30185056778
 Alternate Control Number:
 Date Collected: 03/15/2022 0754  Local
 Date Received: 03/15/2022 0000  ET
 Date Entered: 03/15/2022 1113  ET
 Date Reported: 03/26/2022 0812  ET
 Rte: 00
 ©2022 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version 2.00
 Date Created and Stored  03/26/22 0837 ET   Final Report  Page 2 of 2
 This document contains private and confidential health information protected by state and federal law.
              If you have received this document in error please call 800-877-52271 Patient Report   
Specimen ID:  263-216-3212-0
 Control ID: 27466067
 WEIXELBAUM, LEE S.
 2811 WINDING TRAIL DR
 VALRICO FL  33596
 (813) 445-1261
 Patient Details
 DOB: 06/20/1958
 Age(y/m/d): 060/03/00
 Gender:  M              
SSN:  ***-**-3210
 Patient ID: 40097.0
 Acct #: 09683682
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Bloomingdale Medical Assoc.
 13403 BOYETTE RD
 RIVERVIEW FL 33569
 Specimen Details
 Physician Details
 Rte: 30
 Date collected: 09/20/2018  0913 Local
 Date received: 09/20/2018
 Date entered: 09/20/2018
 Date reported: 09/21/2018  0307 ET
 General Comments & Additional Information
 Alternate Control Number: 27466067
 Ordering: J  CAMERON
 Referring:
 ID:     1720044027
 NPI:  1720044027
 Alternate Patient ID: 40097.0
 Total Volume: Not Provided
 Ordered Items
 Fasting: No
 Thyroxine (T4) Free, Direct, S; TSH; Thyroid Peroxidase (TPO) Ab; Triiodothyronine (T3), Free; Venipuncture
           TESTS              RESULT     FLAG      UNITS  REFERENCE INTERVAL  LAB
 Thyroxine (T4) Free, Direct, S
 T4,Free(Direct)       
TSH       
Thyroid Peroxidase (TPO) Ab       
Triiodothyronine (T3), Free       
              1.10
                          0.172    Low
    245   High
    2.9
 ng/dL
 uIU/mL
 IU/mL
 pg/mL
  0.82 - 1.77
 0.450 - 4.500
     0 - 34
   2.0 - 4.4
 01 TA
 LabCorp Tampa
 5610 W LaSalle Street, Tampa, FL 33607-1770
 01
 01
 01
 01
 Dir: Sean Farrier, MD
 For inquiries, the physician may contact Branch: 800-877-5227 Lab: 800-877-5227
 Date Issued: 06/21/19 0914 ET
 FINAL REPORT
 This document contains private and confidential health information protected by state and federal law.
 If you have received this document in error, please call 800-877-5227
 Page 1 of 1
 © 1995-2019 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version:          
1.00
 1 Patient Report   
Specimen ID:  184-216-5205-0 Acct #: 09241500 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER> Rte: 00
 Control ID: 30185025205
 Andrew Henry MD
 9260 BAY PLAZA BLVD, STE 502
 Brandon FL 33619
 WEIXELBAUM, LEE
 2811 WINDING TRAIL DR
 VALRICO FL  33596
 (813) 445-1261
 Patient Details
 DOB: 06/20/1958
 Age(y/m/d): 062/00/12
 Gender:  M
 Patient ID:
 Specimen Details
 Date collected: 07/02/2020  0953 Local
 Date received: 07/02/2020
 Date entered: 07/02/2020
 Date reported: 07/11/2020  1008 ET
 Physician Details
 Ordering: A  HENRY
 Referring:
 ID:
 NPI:  1194892141
 Date Issued: 08/13/21 0914 ET FINAL REPORT Page 1 of 2
 This document contains private and confidential health information protected by state and federal law.
 If you have received this document in error, please call 800-877-5227
 © 1995-2021 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version:          
General Comments & Additional Information
 Total Volume: Not Provided Fasting: Yes
 Ordered Items
 Free T4 by Dialysis/Mass Spec; Testosterone, Serum; TSH; Luteinizing Hormone(LH), S; FSH, Serum; Prostate-Specific Ag, Serum;
 Triiodothyronine (T3); Venipuncture; Handwritten Order
           TESTS              RESULT     FLAG      UNITS  REFERENCE INTERVAL  LAB
 Free T4 by Dialysis/Mass Spec
 0.89 ng/dL 01
     This test was developed and its performance characteristics
     determined by LabCorp. It has not been cleared or approved
     by the Food and Drug Administration.
     Reference Range:
     Pubertal Children and Adults:
     0.8 - 1.7
 Testosterone, Serum                   150    Low ng/dL    264-916 02
     Adult male reference interval is based on a population of
     healthy nonobese males (BMI <30) between 19 and 39 years old.
     Travison, et.al. JCEM 2017,102;1161-1173. PMID: 28324103.
 TSH                                 6.690   High uIU/mL  0.450-4.500 02
 Luteinizing Hormone(LH), S
  LH                                   7.2 mIU/mL    1.7-8.6 02
 FSH, Serum
  FSH                                 14.0   High mIU/mL    1.5-12.4 02
 Prostate-Specific Ag, Serum
  Prostate Specific Ag, Serum          1.3 ng/mL    0.0-4.0 02
     Roche ECLIA methodology.
     According to the American Urological Association, Serum PSA should
     decrease and remain at undetectable levels after radical
     prostatectomy. The AUA defines biochemical recurrence as an initial
     PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory
     PSA value 0.2 ng/mL or greater.
     Values obtained with different assay methods or kits cannot be used
     interchangeably. Results cannot be interpreted as absolute evidence
     of the presence or absence of malignant disease.
 Triiodothyronine (T3)                 100 ng/dL     71-180 02
 1.00
1 Patient Report   
Patient: WEIXELBAUM, LEE
 DOB: 06/20/1958
 Specimen ID: 184-216-5205-0
 Patient ID:
 Control ID: 30185025205
 Date collected: 07/02/2020  0953 Local
           TESTS              RESULT     FLAG      UNITS  REFERENCE INTERVAL  LAB
 01 ES
 02 TA
 Esoterix Inc
 4301 Lost Hills Road, Calabasas Hills, CA 91301-5358
 Dir: Samuel Pepkowitz, MD
 LabCorp Tampa
 5610 W LaSalle Street, Tampa, FL 33607-1770
 For inquiries, the physician may contact Branch: 800-877-5227 Lab: 800-444-9111
 Dir: Sean Farrier, MD
 Date Issued: 08/13/21 0914 ET
 FINAL REPORT
 This document contains private and confidential health information protected by state and federal law.
 If you have received this document in error, please call 800-877-5227
 Page 2 of 2
 © 1995-2021 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version:          
1.00
 1 Patient Report   
Specimen ID:  265-216-2090-0 Acct #: 09683682 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER> Rte: 30
 Control ID: 15156694CE1
 Bloomingdale Medical Assoc.
 13403 BOYETTE RD
 RIVERVIEW FL 33569
 WEIXELBAUM, LEE S.
 2811 WINDING TRAIL DR
 VALRICO FL  33596
 (813) 445-1261
 Patient Details
 DOB: 06/20/1958
 Age(y/m/d): 062/03/01
 Gender:  M
 Patient ID: 4352438
 Specimen Details
 Date collected: 09/21/2020  0758 Local
 Date received: 09/21/2020
 Date entered: 09/21/2020
 Date reported: 09/22/2020  0306 ET
 Physician Details
 Ordering: J  CAMERON
 Referring:
 ID:     1720044027
 NPI:  1720044027
 Date Issued: 09/22/20 0307 ET FINAL REPORT Page 1 of 3
 This document contains private and confidential health information protected by state and federal law.
 If you have received this document in error, please call 800-877-5227
 © 1995-2020 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version:          
General Comments & Additional Information
 Alternate Control Number: 15156694CE13122 Alternate Patient ID: 4352438
 Total Volume: Not Provided Fasting: Yes
 Ordered Items
 CBC With Differential/Platelet; Comp. Metabolic Panel (14); Urinalysis, Routine; Lipid Panel; Litholink CKD Program; TSH;
 Prostate-Specific Ag, Serum; Venipuncture
           TESTS              RESULT     FLAG      UNITS  REFERENCE INTERVAL  LAB
 CBC With Differential/Platelet
  WBC                                  7.0 x10E3/uL    3.4-10.8 01
  RBC                                 4.64 x10E6/uL   4.14-5.80 01
  Hemoglobin                          14.3 g/dL   13.0-17.7 01
  Hematocrit                          42.1 %   37.5-51.0 01
  MCV                                   91 fL     79-97 01
  MCH                                 30.8 pg   26.6-33.0 01
  MCHC                                34.0 g/dL   31.5-35.7 01
  RDW                                 14.1 %   11.6-15.4 01
  Platelets                            211 x10E3/uL    150-450 01
  Neutrophils                           66 %  Not Estab. 01
  Lymphs                                19 %  Not Estab. 01
  Monocytes                             10 %  Not Estab. 01
  Eos                                    4 %  Not Estab. 01
  Basos                                  1 %  Not Estab. 01
  Neutrophils (Absolute)               4.6 x10E3/uL    1.4-7.0 01
  Lymphs (Absolute)                    1.3 x10E3/uL    0.7-3.1 01
  Monocytes(Absolute)                  0.7 x10E3/uL    0.1-0.9 01
  Eos (Absolute)                       0.2 x10E3/uL    0.0-0.4 01
  Baso (Absolute)                      0.1 x10E3/uL    0.0-0.2 01
  Immature Granulocytes                  0 %  Not Estab. 01
  Immature Grans (Abs)                 0.0 x10E3/uL    0.0-0.1 01
 Comp. Metabolic Panel (14)
  Glucose                               84 mg/dL     65-99 01
  BUN                                   18 mg/dL      8-27 01
  Creatinine                          1.46   High mg/dL   0.76-1.27 01
  eGFR If NonAfricn Am                  51    Low mL/min/1.73        >59
  eGFR If Africn Am                     59    Low mL/min/1.73        >59
 1.00
 1 Patient Report   
Patient: WEIXELBAUM, LEE S. Specimen ID: 265-216-2090-0
 DOB: 06/20/1958 Patient ID: 4352438 Control ID: 15156694CE1 Date collected: 09/21/2020  0758 Local
 Date Issued: 09/22/20 0307 ET FINAL REPORT Page 2 of 3
 This document contains private and confidential health information protected by state and federal law.
 If you have received this document in error, please call 800-877-5227
 © 1995-2020 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version:          
           TESTS              RESULT     FLAG      UNITS  REFERENCE INTERVAL  LAB
  BUN/Creatinine Ratio                  12     10-24
  Sodium                               139 mmol/L    134-144 01
  Potassium                            4.3 mmol/L    3.5-5.2 01
  Chloride                             102 mmol/L     96-106 01
  Carbon Dioxide, Total                 21 mmol/L     20-29 01
  Calcium                              9.1 mg/dL    8.6-10.2 01
  Protein, Total                       6.5 g/dL    6.0-8.5 01
  Albumin                              4.2 g/dL    3.8-4.8 01
  Globulin, Total                      2.3 g/dL    1.5-4.5
  A/G Ratio                            1.8    1.2-2.2
  Bilirubin, Total                     1.7   High mg/dL    0.0-1.2 01
  Alkaline Phosphatase                  71 IU/L     39-117 01
  AST (SGOT)                            21 IU/L      0-40 01
  ALT (SGPT)                            17 IU/L      0-44 01
 Urinalysis, Routine
  Urinalysis Gross Exam 01
  Specific Gravity                   1.014  1.005-1.030 01
  pH                                   7.0    5.0-7.5 01
  Urine-Color                       Yellow    Yellow 01
  Appearance                         Clear     Clear 01
  WBC Esterase                    Negative   Negative 01
  Protein                         Negative Negative/Trace 01
  Glucose                         Negative   Negative 01
  Ketones                         Negative   Negative 01
  Occult Blood                    Negative   Negative 01
  Bilirubin                       Negative   Negative 01
  Urobilinogen,Semi-Qn                 0.2 mg/dL    0.2-1.0 01
  Nitrite, Urine                  Negative   Negative 01
 Microscopic Examination 01
     Microscopic not indicated and not performed.
 Lipid Panel
  Cholesterol, Total                   182 mg/dL    100-199 01
  Triglycerides                        147 mg/dL      0-149 01
  HDL Cholesterol                       37    Low mg/dL      >39 01
  VLDL Cholesterol Cal                  26 mg/dL      5-40
  LDL Chol Calc (NIH)                  119   High mg/dL      0-99
 Litholink CKD Program
  Interpretation                      Note 02
     Supplemental report is available.
  PDF                                    . 02
 1.00
1 Patient Report   
Patient: WEIXELBAUM, LEE S.
 DOB: 06/20/1958
 Patient ID: 4352438
 Specimen ID: 265-216-2090-0
 Control ID: 15156694CE1
 Date collected: 09/21/2020  0758 Local
           TESTS              RESULT     FLAG      UNITS  REFERENCE INTERVAL  LAB
 TSH       
Prostate-Specific Ag, Serum
 Prostate Specific Ag, Serum       
                          6.010   High
   0.9
 uIU/mL
 ng/mL
  0.450-4.500
    0.0-4.0
     Roche ECLIA methodology.
     According to the American Urological Association, Serum PSA should
     decrease and remain at undetectable levels after radical
     prostatectomy. The AUA defines biochemical recurrence as an initial
     PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory
     PSA value 0.2 ng/mL or greater.
     Values obtained with different assay methods or kits cannot be used
     interchangeably. Results cannot be interpreted as absolute evidence
     of the presence or absence of malignant disease.
 01 TA
 LabCorp Tampa
 5610 W LaSalle Street, Tampa, FL 33607-1770
 Dir: Sean Farrier, MD
 01
 01
 02 LITIL Litholink Corporation
 150 Spring Lake Dr Ste A, Itasca, IL 60143-2091
 For inquiries, the physician may contact Branch: 800-877-5227 Lab: 800-877-5227
 Dir: John Asplin, MD
 Date Issued: 09/22/20 0307 ET
 FINAL REPORT
 This document contains private and confidential health information protected by state and federal law.
 If you have received this document in error, please call 800-877-5227
 Page 3 of 3
 © 1995-2020 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version:          
1.00
Accessions: 26521620900
 DISCLAIMER:These assessments and treatment suggestions are provided as a convenience in support of the physician-patient relationship and are not intended to
 replace the physician’s clinical judgment.  They are derived from national guidelines in addition to other evidence and expert opinion.  The clinician should consider
 this information within the context of clinical opinion and the individual patient.
 SEE GUIDANCE FOR CHRONIC KIDNEY DISEASE PROGRAM: Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines are at
 http://kdigo.org/home/guidelines/. National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI (TM)), with its limitations and disclaimers, are at
 www.kidney.org/professionals/KDOQI. This program is intended for patients who have been diagnosed with stages 3, 4, or pre-dialysis 5 CKD. It is not intended for
 children, pregnant patients, or transplant patients.
 Note:  Please refer to your LabCorp Report for all results as well as any test-specific and specimen-specific comments.
 Current Laboratory Results
 Blood Draw Date: Date Received: 09/21/2020 Date Completed: 09/22/2020 09/21/2020 Fasting:YES
 Comp. Metabolic Panel (14)
 REF. INTERVAL RESULT ANALYTE LOW HIGH
 Glucose mg/dL 65-99 84
 BUN mg/dL 8-27 18
 Creatinine mg/dL 0.76-1.27 1.46H
 Sodium mmol/L 134-144 139
 Potassium mmol/L 3.5-5.2 4.3
 Chloride mmol/L 96-106 102
 Carbon Dioxide mmol/L 20-29 21
 Calcium mg/dL 8.6-10.2 9.1
 Protein, Total, Serum g/dL 6.0-8.5 6.5
 Albumin g/dL 3.8-4.8 4.2
 Globulin, Total g/dL 1.5-4.5 2.3
 A/G Ratio 1.2-2.2 1.8
 Bilirubin, Total mg/dL 0.0-1.2 1.7H
 Alkaline Phosphatase, S IU/L 39-117 71
 AST IU/L 0-40 21
 ALT IU/L 0-44 17
 BUN: Creatinine Ratio 10-24 12
 Anion Gap mmol/L 10 - 18 16
 estimated GFR
 mL/min/1.73mE2
 > 59 51
 Albumin testing performed on the Roche Modular using the ALB PLUS assay.
 Lipid Panel
 REF. INTERVAL RESULT ANALYTE LOW HIGH
 Total Cholesterol mg/dL 100-199 182
 Triglyceride mg/dL 0-149 147
 HDL-C mg/dL >39 37L
 VLDL mg/dL 5-40 26
 LDL(calc) mg/dL 0-99 119H
 non-HDL cholesterol  mg/dL 0 - 129 145H
 CBC With Differential/Platelet
 REF. INTERVAL RESULT ANALYTE LOW HIGH
 White Blood Count x10E3/uL 3.4-10.8 7.0
 Red Blood Count x10E6/uL 4.14-5.80 4.64
 Hemoglobin g/dL 13.0-17.7 14.3
 Hematocrit % 37.5-51.0 42.1
 MCV fL 79-97 91
 MCH pg 26.6-33.0 30.8
 MCHC g/dL 31.5-35.7 34.0
 RDW % 11.6-15.4 14.1
 Platelet Count x10E3/uL 150-450 211
 Neutrophils % Not Estab. 66
 Lymphocytes % Not Estab. 19
 Monocytes % Not Estab. 10
 Eosinophils % Not Estab. 4
 Basophils % Not Estab. 1
 Neutrophils (Abs) x10E3/uL 1.4-7.0 4.6
 Lymphocytes (Abs) x10E3/uL 0.7-3.1 1.3
 Monocytes (Abs) x10E3/uL 0.1-0.9 0.7
 Eosinophils (Abs) x10E3/uL 0.0-0.4 0.2
 Basophils (Abs) x10E3/uL 0.0-0.2 0.1
 Immature Granulocytes % Not Estab. 0
 Immature Grans (Abs)
 x10E3/uL
 0.0-0.1 0.0
 NRBC % 0 - 0
 L - Below Low Normal
 H - Above High Normal
 LL - Alert Low
 HH - Alert High
 < - Panic Low
 > - Panic High
 A - Abnormal (applies to non-numeric results)
 AA - Critical Abnormal (applies to non-numeric results)
 Legend for Abnormal Flags:
 CAMERON, JOHN E
 LabCorp Account #: 09683682
 09/21/2020 3a M 06/20/1958 WEIXELBAUM, LEE
 Litholink Patient Results Report PATIENT DATE OF BIRTH GENDER CKD STAGEDATE OF SERVICE PHYSICIAN
 9.3.6.6793 Version:
 Page: 1 of 4
 Printed: 09/22/2020 Laboratory Director
 CLIA# 14D0897314
 150 Spring Lake Dr., Suite A
 Itasca, Illinois 60143 www.litholink.com
 866 361 7939 Facsimile
 John Asplin, MD Litholink, A LabCorp Company 800 338 4333 Telephone
PATIENT
 WEIXELBAUM, LEE
 DATE OF BIRTH
 06/20/1958
 Chronic Kidney Disease
 Analysis & Treatment Suggestions
 GENDER
 DIABETES
 SELF-REPORTED RACE
 CURRENT eGFR
 GENDER CKD STAGE DATE OF SERVICE
 M
 3a
 MOST RECENT CKD STAGE
 09/21/2020
 M
 ?
 Missing
 51
 3a
 PHYSICIAN
 Litholink Patient Results Report
 CAMERON, JOHN E
 LabCorp Account #: 09683682
 Prognosis of CKD by GFR And Albuminuria Categories
 GFR Categories: (ml/min/1.73m  )
 2
 G1
 >=90
 60-89
 45-59
 30-44
 15-29
 <15
 G2
 G3a
 G3b
 G4
 G5
 NORMAL OR HIGH
 MILDLY DECREASED
 MILDLY TO MODERATELY DECREASED
 MODERATELY TO SEVERELY DECREASED
 SEVERELY DECREASED
 KIDNEY FAILURE
 A1
 A2
 eGFR, Blood Pressure, and Proteinuria
 Estimated GFR is falling significantly with time;  annualized rate of
 decline (all values) is -1.9 mL/min/year, p = 0.02.  Current eGFR is 51
 mL/min/1.73mE2 corresponding to CKD stage 3a.  Multiply eGFR by
 1.159 if patient is African American.  Potassium is within goal and has
 not changed significantly, was 4.5 and now is 4.3 mmol/L.
 Persistent Albuminura Categories
 A3
 = NORMAL TO MILDLY INCREASED; ACR <30 ug/mg; PCR <=200 mg/g
 = MODERATELY INCREASED; ACR 30-300 ug/mg; PCR 201-500 mg/g
 = SEVERELY INCREASED; ACR >300 ug/mg; PCR >500 mg/g
 A1
 A2
 A3
 = LOW RISK
 = HIGH RISK
 = PATIENT'S RESULT
 = MODERATELY INCREASED RISK
 = VERY HIGH RISK
 Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012
 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney
 Disease.                                      2013; 3: 1-150.
 Kidney inter.; Suppl.
 Treatment Suggestions
 Guidelines recommend a target blood pressure of 140/90 mmHg or
 less in CKD patients to reduce cardiovascular risk and CKD
 progression.  Assessment of albuminuria (urine albumin:creatinine
 ratio or urine protein:creatinine ratio preferred) is recommended at
 least annually in CKD patients for staging and disease prognosis.
 Bone & Mineral
 Calcium is within goal and has not changed significantly, was 9.4 and
 now is 9.1 mg/dL.  Carbon Dioxide is below goal and has not changed
 significantly, was 20 and now is 21 mmol/L.  Guidelines recommend
 the measurement of 25-hydroxy vitamin D in patients with CKD.
 Treatment Suggestions
 Interpretations require simultaneous measurements of serum calcium
 and phosphorus.  If not on alkali, begin sodium bicarbonate, one 650
 mg pill 2-3 times daily, otherwise increase dose.
 Lipids
 LDL-C is borderline high and has decreased, was 150 and now is 119
 mg/dL.  Triglyceride is normal and has not changed significantly, was
 152 and now is 147 mg/dL.  Non-HDL Cholesterol  is borderline high
 and has decreased, was 180 and now is 145 mg/dL.  HDL-C is low
 and has decreased, was 40 and now is 37 mg/dL.
 Treatment Suggestions
 Therapeutic lifestyle changes are always valuable to maintain optimal
 blood lipid status (diet, exercise, weight management).  Begin statin. If
 statin already in use, consider increasing dose to achieve at least a
 50% LDL reduction from baseline.  Moderate or high intensity statin is
 preferred.  If statin cannot be tolerated or increased, alternatives
 include use of an intestinal agent (ezetimibe or bile acid sequestrant)
 or niacin.
 Anemia
 Hemoglobin is normal and has decreased, was 14.9 and now is 14.3
 g/dL.  Hemoglobin target assumes ESA is not in use.
 Treatment Suggestions
 No specific change of treatment is indicated at this time.
 Follow-Up Suggestions for CKD
 Recommended by KDOQI guidelines,
 at least yearly
 Spot Urine Panel
 3 months
 Fasting Renal Panel
 Fasting Lipid Panel
 12 months
 CBC
 Fasting PTH with Renal Panel
 25-Hydroxy Vitamin D
 Graphs
 DISCLAIMER: These assessments and treatment suggestions are provided as a convenience and are neither comprehensive nor intended to replace the
 physician’s clinical judgment. They do not include information such as family history, personal history, or physical findings as would be obtained by the clinician
 during patient evaluation because LabCorp does not have access to the complete patient medical record.
 John Asplin, MD
 Laboratory Director
 CLIA# 14D0897314
 Litholink, A LabCorp Company
 150 Spring Lake Dr., Suite A
 Itasca, Illinois 60143
 800 338 4333 Telephone
 <PRESIDIO_ANONYMIZED_PHONE_NUMBER> Facsimile
 www.litholink.com
 Version:
 Printed:
 Page:
 9.3.6.6793
 09/22/2020
 2 of 4
CAMERON, JOHN E
 LabCorp Account #: 09683682
 09/21/2020 3a M 06/20/1958 WEIXELBAUM, LEE
 Litholink Patient Results Report PATIENT DATE OF BIRTH GENDER CKD STAGEDATE OF SERVICE PHYSICIAN
 months (since enrollment)
 eGFR
 months (since enrollment)
 = serum calcium result was corrected for low serum albumin
 Calcium
 months (since enrollment)
 Hemoglobin
 Test Results & Treatments
 The 8 most recent lab results as well as the treatments are reported.
 K BUN SCr Date eGFR Weight (kg) HB A1c
 Protein/Cr
 ACEI/ARB Diuretic (mg/g) (ug/mg)
 Alb/Cr 1 Date Meds Reported DBP SBP
 eGFR
 4.3 18 09/21/20 1.46 51 ? ? ? ? ? ?
 4.5 20 08/02/19 1.42 53 ? ? ? ? ? ?
 4.5 17 07/31/18 1.38 55 ? ? ? ? ? ?
    The CKD-EPI eGFR equation has only been validated for patients aged 18-70.  Self-reported race was not provided; eGFR was calculated as if the patient was not African American.
 Multiply eGFR by 1.159 if African American.
 1
 LPD Date PTH P 25-D K Ca PB CaPB C0 AVD Vit D Alkali 2
 Bone & Mineral
 ? 09/21/20 9.1 4.3 21 ? ? ? ? ?
 ? 08/02/19 9.4 4.5 20 ? ? ? ? ?
 ? 07/31/18 9.3 4.5 19 ? ? ? ? ?
 DISCLAIMER:These assessments and treatment suggestions are provided as a convenience and are neither comprehensive nor intended to replace the
 physician’s clinical judgment. They do not include information such as family history, personal history, or physical findings as would be obtained by the clinician
 during patient evaluation because LabCorp does not have access to the complete patient medical record.
 9.3.6.6793 Version:
 Page: 3 of 4
 Printed: 09/22/2020 Laboratory Director
 CLIA# 14D0897314
 150 Spring Lake Dr., Suite A
 Itasca, Illinois 60143 www.litholink.com
 866 361 7939 Facsimile
 John Asplin, MD Litholink, A LabCorp Company 800 338 4333 Telephone
PATIENT
 WEIXELBAUM, LEE
 Lipids
 Date
 09/21/20
 LDL
 119
 DATE OF BIRTH
 06/20/1958
 TG
 147
 non-HDL
 145
 Chol
 182
 GENDER CKD STAGE DATE OF SERVICE
 M
 HDL
 3a
 09/21/2020
 PHYSICIAN
 Litholink Patient Results Report
 CAMERON, JOHN E
 LabCorp Account #: 09683682
 Statin
 Fibrate
 Niacin
 Fasting
 37
 ?
 ?
 ?
 Yes
 08/02/19
 150
 152
 180
 220
 40
 ?
 ?
 ?
 Yes
 07/31/18
 87
 152
 117
 151
 34
 ?
 ?
 ?
 Yes
 Anemia
 Date
 Hb
 TSAT
 Ferritin
 Iron
 ESA
 09/21/20 14.3
 ?
 ?
 08/02/19 14.9
 ?
 ?
 07/31/18 14.1
 ?
 ?
 DISCLAIMER: These assessments and treatment suggestions are provided as a convenience and are neither comprehensive nor intended to replace the
 physician’s clinical judgment. They do not include information such as family history, personal history, or physical findings as would be obtained by the clinician
 during patient evaluation because LabCorp does not have access to the complete patient medical record.
 John Asplin, MD
 Laboratory Director
 CLIA# 14D0897314
 Litholink, A LabCorp Company
 150 Spring Lake Dr., Suite A
 Itasca, Illinois 60143
 800 338 4333 Telephone
 <PRESIDIO_ANONYMIZED_PHONE_NUMBER> Facsimile
 www.litholink.com
 Version:
 Printed:
 Page:
 9.3.6.6793
 09/22/2020
 4 of 4
PATIENT
 WEIXELBAUM, LEE
 Your Test Results
 Test
 DATE OF BIRTH
 06/20/1958
 GENDER CKD STAGE DATE OF SERVICE
 M
 3a
 Your Results
 09/21/2020
 PHYSICIAN
 Litholink Patient Results Report
 CAMERON, JOHN E
 LabCorp Account #: 09683682
 Comments
 Blood Lipids
 LDL CHOLESTEROL is the bad
 cholesterol that can clog your arteries.
 LOWERING LDL IS IMPORTANT to protect your
 119
 Ref. Range: 0 to 99 mg/dL
 heart and blood vessels. Your doctor may
 prescribe or increase medicine to lower your
 cholesterol. Remember to take all medicines as
 prescribed. Weight loss, exercise (at least 30
 minutes 5 times a week), eating less trans and
 saturated fats, and quitting smoking can also help
 to lower cholesterol.
 Kidney Health
 eGFR estimates how well your kidneys
 are filtering blood.  The higher the
 number, the better your kidneys are
 working.
 51
 Ref Range: >59
 mL/min/1.73mE2
 YOU ARE IN STAGE 3a CHRONIC KIDNEY
 DISEASE (CKD). There are 5 stages of CKD. See
 below for more information.
 POTASSIUM helps keep your heart and
 muscles working properly. High or low
 levels can be dangerous.
 4.3
 Ref. Range: 3.5 to 5.2 mmol/L
 YOUR POTASSIUM IS NORMAL. To keep it in
 the normal range, make sure you avoid foods high
 in potassium. For more information, visit
 www.kidney.org/atoz/content/potassium.cfm.
 HEMOGLOBIN is a test to look for
 anemia, or low blood count. Low
 hemoglobin levels may cause you to feel
 tired or have low energy.
 14.3
 Male Range: 13 to 17 g/dL
 YOUR HEMOGLOBIN IS NORMAL. Because
 low hemoglobin is common and can happen over
 time, it is important to follow up regularly with
 your doctor for continued monitoring.
 YOUR eGFR IS 51, YOU ARE IN STAGE 3a CKD. THINGS YOU NEED TO KNOW:
 · CKD means your kidneys show decreased function which may be caused by aging, diabetes, high blood
 pressure, or many other diseases. CKD can lead to heart disease.
 · Even if you feel fine, you may be at risk for problems such as high blood pressure, high cholesterol, anemia,
 and bone disease.  Your doctor should test you for these problems.
 · Avoid taking NSAIDs (e.g. ibuprofen, Advil®, Motrin®, Aleve®) as these may worsen your kidney function.
 · Your eGFR result may be slightly higher if you are African American.
 · To learn more, visit the National Kidney Foundation’s website: www.kidney.org/kidneydisease.
 DISCLAIMER: You should discuss this information with your physician. Litholink does not have a doctor-patient relationship with you, nor does it have access to a complete
 medical history or physical examination conducted by a physician that would be necessary for a complete diagnosis and comprehensive treatment plan. Neither you nor your
 physician should rely solely on this guidance. Bolded result descriptions in "Comments" consider either the reference range or target range for the test result. Reference range
 refers to the LabCorp reference interval. Target range refers to the guideline-suggested goal. REFERENCES:National Kidney Foundation Kidney Disease Outcomes Quality
 Initiative (KDOQI) at www.Kidney.org and Kidney Disease Improving Global Outcomes (KDIGO) at http://kdigo.org. Adapted from: http://nkdep.nih.gov/resources/nkdep-kidney
test-results-508.pdf.
 John Asplin, MD
 Laboratory Director
 CLIA# 14D0897314
 Litholink, A LabCorp Company
 150 Spring Lake Dr., Suite A
 Itasca, Illinois 60143
 800 338 4333 Telephone
 <PRESIDIO_ANONYMIZED_PHONE_NUMBER> Facsimile
 www.litholink.com
 Version:
 Printed:
 Page:
 9.3.6.6793
 09/22/2020
 1 of 1
 1 Patient Report   
Specimen ID:  214-216-4947-0 Acct #: 09683682 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER> Rte: 30
 Control ID: 30185013185
 Bloomingdale Medical Assoc.
 13403 BOYETTE RD
 RIVERVIEW FL 33569
 WEIXELBAUM, LEE
 2811 WINDING TRAIL DR
 VALRICO FL  33596
 (813) 445-1261
 Patient Details
 DOB: 06/20/1958
 Age(y/m/d): 061/01/13
 Gender:  M              SSN:
 Patient ID:
 Specimen Details
 Date collected: 08/02/2019  0933 Local
 Date received: 08/02/2019
 Date entered: 08/02/2019
 Date reported: 08/03/2019  0506 ET
 Physician Details
 Ordering: J  CAMERON
 Referring:
 ID:
 NPI:  1720044027
 Date Issued: 08/03/19 0511 ET FINAL REPORT Page 1 of 3
 This document contains private and confidential health information protected by state and federal law.
 If you have received this document in error, please call 800-877-5227
 © 1995-2019 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version:          
General Comments & Additional Information
 Total Volume: Not Provided Fasting: Yes
 Ordered Items
 CBC With Differential/Platelet; Comp. Metabolic Panel (14); Urinalysis, Routine; Lipid Panel With LDL/HDL Ratio; Litholink CKD
 Program; TSH; Prostate-Specific Ag, Serum; Venipuncture
           TESTS              RESULT     FLAG      UNITS  REFERENCE INTERVAL  LAB
 CBC With Differential/Platelet
  WBC                                  7.2 x10E3/uL   3.4 - 10.8 01
  RBC                                 4.77 x10E6/uL  4.14 - 5.80 01
  Hemoglobin                          14.9 g/dL  13.0 - 17.7 01
  Hematocrit                          42.5 %  37.5 - 51.0 01
  MCV                                   89 fL    79 - 97 01
  MCH                                 31.2 pg  26.6 - 33.0 01
  MCHC                                35.1 g/dL  31.5 - 35.7 01
  RDW                                 14.7 %  12.3 - 15.4 01
  Platelets                            225 x10E3/uL   150 - 450 01
  Neutrophils                           61 %  Not Estab. 01
  Lymphs                                27 %  Not Estab. 01
  Monocytes                              8 %  Not Estab. 01
  Eos                                    3 %  Not Estab. 01
  Basos                                  1 %  Not Estab. 01
  Neutrophils (Absolute)               4.4 x10E3/uL   1.4 - 7.0 01
  Lymphs (Absolute)                    2.0 x10E3/uL   0.7 - 3.1 01
  Monocytes(Absolute)                  0.6 x10E3/uL   0.1 - 0.9 01
  Eos (Absolute)                       0.2 x10E3/uL   0.0 - 0.4 01
  Baso (Absolute)                      0.1 x10E3/uL   0.0 - 0.2 01
  Immature Granulocytes                  0 %  Not Estab. 01
  Immature Grans (Abs)                 0.0 x10E3/uL   0.0 - 0.1 01
 Comp. Metabolic Panel (14)
  Glucose                               91 mg/dL    65 - 99 01
  BUN                                   20 mg/dL     8 - 27 01
  Creatinine                          1.42   High mg/dL  0.76 - 1.27 01
  eGFR If NonAfricn Am                  53    Low mL/min/1.73        >59
  eGFR If Africn Am                     61 mL/min/1.73        >59
  BUN/Creatinine Ratio                  14    10 - 24
 1.00
 1 Patient Report   
Patient: WEIXELBAUM, LEE Specimen ID: 214-216-4947-0
 DOB: 06/20/1958 Patient ID: Control ID: 30185013185 Date collected: 08/02/2019  0933 Local
 Date Issued: 08/03/19 0511 ET FINAL REPORT Page 2 of 3
 This document contains private and confidential health information protected by state and federal law.
 If you have received this document in error, please call 800-877-5227
 © 1995-2019 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version:          
           TESTS              RESULT     FLAG      UNITS  REFERENCE INTERVAL  LAB
  Sodium                               141 mmol/L   134 - 144 01
  Potassium                            4.5 mmol/L   3.5 - 5.2 01
  Chloride                             105 mmol/L    96 - 106 01
  Carbon Dioxide, Total                 20 mmol/L    20 - 29 01
  Calcium                              9.4 mg/dL   8.6 - 10.2 01
  Protein, Total                       6.3 g/dL   6.0 - 8.5 01
  Albumin                              4.2 g/dL   3.6 - 4.8 01
  Globulin, Total                      2.1 g/dL   1.5 - 4.5
  A/G Ratio                            2.0   1.2 - 2.2
  Bilirubin, Total                     1.2 mg/dL   0.0 - 1.2 01
  Alkaline Phosphatase                  71 IU/L    39 - 117 01
  AST (SGOT)                            19 IU/L     0 - 40 01
  ALT (SGPT)                            18 IU/L     0 - 44 01
 Urinalysis, Routine
  Urinalysis Gross Exam 01
  Specific Gravity                   1.021 1.005 - 1.030 01
  pH                                   6.0   5.0 - 7.5 01
  Urine-Color                       Yellow    Yellow 01
  Appearance                         Clear     Clear 01
  WBC Esterase                    Negative   Negative 01
  Protein                         Negative Negative/Trace 01
  Glucose                         Negative   Negative 01
  Ketones                         Negative   Negative 01
  Occult Blood                    Negative   Negative 01
  Bilirubin                       Negative   Negative 01
  Urobilinogen,Semi-Qn                 0.2 mg/dL   0.2 - 1.0 01
  Nitrite, Urine                  Negative   Negative 01
 Microscopic Examination 01
     Microscopic not indicated and not performed.
 Lipid Panel With LDL/HDL Ratio
  Cholesterol, Total                   220   High mg/dL   100 - 199 01
  Triglycerides                        152   High mg/dL     0 - 149 01
  HDL Cholesterol                       40 mg/dL      >39 01
  VLDL Cholesterol Cal                  30 mg/dL     5 - 40
  LDL Cholesterol Calc                 150   High mg/dL     0 - 99
  LDL/HDL Ratio                        3.8   High ratio   0.0 - 3.6
  Please Note: 01
                                                        LDL/HDL Ratio
                                                                Men  Women
                                                  1/2 Avg.Risk  1.0    1.5
                                                      Avg.Risk  3.6    3.2
                                                   2X Avg.Risk  6.2    5.0
 1.00
1 Patient Report   
Patient: WEIXELBAUM, LEE
 DOB: 06/20/1958
 Specimen ID: 214-216-4947-0
 Patient ID:
 Control ID: 30185013185
 Date collected: 08/02/2019  0933 Local
           TESTS              RESULT     FLAG      UNITS  REFERENCE INTERVAL  LAB
                                                   3X Avg.Risk  8.0    6.1
 Litholink CKD Program
 Interpretation       
               Note
     Supplemental report is available.
 PDF Image       
                       .
 TSH       
Prostate-Specific Ag, Serum
 Prostate Specific Ag, Serum       
                          4.550   High
   0.5
 uIU/mL
 ng/mL
 0.450 - 4.500
   0.0 - 4.0
     Roche ECLIA methodology.
     According to the American Urological Association, Serum PSA should
     decrease and remain at undetectable levels after radical
     prostatectomy. The AUA defines biochemical recurrence as an initial
     PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory
     PSA value 0.2 ng/mL or greater.
     Values obtained with different assay methods or kits cannot be used
     interchangeably. Results cannot be interpreted as absolute evidence
     of the presence or absence of malignant disease.
 01 TA
 LabCorp Tampa
 5610 W LaSalle Street, Tampa, FL 33607-1770
 Dir: Sean Farrier, MD
 02
 02
 01
 01
 02 LITIL Litholink Corporation
 2250 West Campbell Park Drive, Chicago, IL 60612-3502
 For inquiries, the physician may contact Branch: 800-877-5227 Lab: 800-877-5227
 Dir: John Asplin, MD
 Date Issued: 08/03/19 0511 ET
 FINAL REPORT
 This document contains private and confidential health information protected by state and federal law.
 If you have received this document in error, please call 800-877-5227
 Page 3 of 3
 © 1995-2019 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version:          
1.00
Accessions: 21421649470
 DISCLAIMER:These assessments and treatment suggestions are provided as a convenience in support of the physician-patient relationship and are not intended to
 replace the physician’s clinical judgment.  They are derived from national guidelines in addition to other evidence and expert opinion.  The clinician should consider
 this information within the context of clinical opinion and the individual patient.
 SEE GUIDANCE FOR CHRONIC KIDNEY DISEASE PROGRAM: Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines are at
 http://kdigo.org/home/guidelines/. National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI (TM)), with its limitations and disclaimers, are at
 www.kidney.org/professionals/KDOQI. This program is intended for patients who have been diagnosed with stages 3, 4, or pre-dialysis 5 CKD. It is not intended for
 children, pregnant patients, or transplant patients.
 Note:  Please refer to your LabCorp Report for all results as well as any test-specific and specimen-specific comments.
 Laboratory Director's Notes
 COLLECTION DATE RELATED NOTES ITEM
 Laboratory test values flagged with an asterisk (*) within this report refer to the following commentary from our physicians and quality assurance staff.
 08/02/2019 LDL:HDL Ratio LDL/HDL Ratio Men Women 1/2 Avg.Risk 1.0 1.5 Avg.Risk 3.6 3.2 2X Avg.Risk 6.2 5.0 3X Avg.Risk 8.0 6.1
 Mitchell S. Laks, PhD - Laboratory Director
 Current Laboratory Results
 Blood Draw Date: Date Received: 08/02/2019 Date Completed: 08/02/2019 08/02/2019 Fasting:YES
 Comp. Metabolic Panel (14)
 REF. INTERVAL RESULT ANALYTE LOW HIGH
 Glucose mg/dL 65-99 91
 BUN mg/dL 8-27 20
 Creatinine mg/dL 0.76-1.27 1.42H
 Sodium mmol/L 134-144 141
 Potassium mmol/L 3.5-5.2 4.5
 Chloride mmol/L 96-106 105
 Carbon Dioxide mmol/L 20-29 20
 Calcium mg/dL 8.6-10.2 9.4
 Protein, Total, Serum g/dL 6.0-8.5 6.3
 Albumin g/dL 3.6-4.8 4.2
 Globulin, Total g/dL 1.5-4.5 2.1
 A/G Ratio 1.2-2.2 2.0
 Bilirubin, Total mg/dL 0.0-1.2 1.2
 Alkaline Phosphatase, S IU/L 39-117 71
 AST IU/L 0-40 19
 ALT IU/L 0-44 18
 BUN: Creatinine Ratio 10-24 14
 Anion Gap mmol/L 10 - 18 16
 estimated GFR
 mL/min/1.73mE2
 > 59 53
 Albumin testing performed on the Roche Modular using the ALB PLUS assay.
 Lipid Panel With LDL/HDL Ratio
 REF. INTERVAL RESULT ANALYTE LOW HIGH
 Total Cholesterol mg/dL 100-199 220H
 Triglyceride mg/dL 0-149 152H
 HDL-C mg/dL >39 40
 VLDL mg/dL 5-40 30
 LDL(calc) mg/dL 0-99 150H
 non-HDL cholesterol  mg/dL 0 - 129 180H
 LDL:HDL Ratio ratio units 0.0-3.6 * 3.8H
 CBC With Differential/Platelet
 REF. INTERVAL RESULT ANALYTE LOW HIGH
 White Blood Count x10E3/uL 3.4-10.8 7.2
 Red Blood Count x10E6/uL 4.14-5.80 4.77
 Hemoglobin g/dL 13.0-17.7 14.9
 Hematocrit % 37.5-51.0 42.5
 MCV fL 79-97 89
 MCH pg 26.6-33.0 31.2
 MCHC g/dL 31.5-35.7 35.1
 RDW % 12.3-15.4 14.7
 Platelet Count x10E3/uL 150-450 225
 Neutrophils % Not Estab. 61
 Lymphocytes % Not Estab. 27
 Monocytes % Not Estab. 8
 Eosinophils % Not Estab. 3
 Basophils % Not Estab. 1
 Neutrophils (Abs) x10E3/uL 1.4-7.0 4.4
 Lymphocytes (Abs) x10E3/uL 0.7-3.1 2.0
 Monocytes (Abs) x10E3/uL 0.1-0.9 0.6
 Eosinophils (Abs) x10E3/uL 0.0-0.4 0.2
 Basophils (Abs) x10E3/uL 0.0-0.2 0.1
 Immature Granulocytes % Not Estab. 0
 Immature Grans (Abs)
 x10E3/uL
 0.0-0.1 0.0
 NRBC % 0 - 0
 L - Below Low Normal
 H - Above High Normal
 LL - Alert Low
 HH - Alert High
 < - Panic Low
 > - Panic High
 A - Abnormal (applies to non-numeric results)
 AA - Critical Abnormal (applies to non-numeric results)
 Legend for Abnormal Flags:
 CAMERON, JOHN E
 LabCorp Account #: 09683682
 08/02/2019 3a M 06/20/1958 WEIXELBAUM, LEE
 Litholink Patient Results Report PATIENT DATE OF BIRTH GENDER CKD STAGEDATE OF SERVICE PHYSICIAN
 8.1.4.3177 Version:
 Page: 1 of 4
 Printed: 08/02/2019 Laboratory Director
 CLIA# 14D0897314
 2250 West Campbell Park Drive
 Chicago, Illinois 60612 www.litholink.com
 866 361 7939 Facsimile
 Mitchell S. Laks, PhD Litholink, A LabCorp Company 800 338 4333 Telephone
PATIENT
 WEIXELBAUM, LEE
 DATE OF BIRTH
 06/20/1958
 Chronic Kidney Disease
 Analysis & Treatment Suggestions
 GENDER
 DIABETES
 SELF-REPORTED RACE
 CURRENT eGFR
 GENDER CKD STAGE DATE OF SERVICE
 M
 3a
 MOST RECENT CKD STAGE
 08/02/2019
 M
 ?
 Missing
 53
 3a
 PHYSICIAN
 Litholink Patient Results Report
 CAMERON, JOHN E
 LabCorp Account #: 09683682
 Prognosis of CKD by GFR And Albuminuria Categories
 A1
 GFR Categories: (ml/min/1.73m  )
 2
 G1
 >=90
 60-89
 45-59
 30-44
 15-29
 <15
 G2
 G3a
 G3b
 G4
 G5
 NORMAL OR HIGH
 MILDLY DECREASED
 MILDLY TO MODERATELY DECREASED
 MODERATELY TO SEVERELY DECREASED
 SEVERELY DECREASED
 KIDNEY FAILURE
 eGFR, Blood Pressure, and Proteinuria
 A2
 Estimated GFR  has not changed significantly, was 55 and now is 53
 mL/min/1.73mE2.  Current eGFR corresponds to CKD stage 3a.
 Multiply eGFR by 1.159 if patient is African American.  Potassium is
 within goal and has not changed significantly, was 4.5 and now is 4.5
 mmol/L.
 Persistent Albuminura Categories
 A3
 = NORMAL TO MILDLY INCREASED; ACR <30 ug/mg; PCR <=200 mg/g
 = MODERATELY INCREASED; ACR 30-300 ug/mg; PCR 201-500 mg/g
 = SEVERELY INCREASED; ACR >300 ug/mg; PCR >500 mg/g
 A1
 A2
 A3
 = LOW RISK
 = HIGH RISK
 = PATIENT'S RESULT
 = MODERATELY INCREASED RISK
 = VERY HIGH RISK
 Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012
 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney
 Disease.                                      2013; 3: 1-150.
 Kidney inter.; Suppl.
 Treatment Suggestions
 Guidelines recommend a target blood pressure of 140/90 mmHg or
 less in CKD patients to reduce cardiovascular risk and CKD
 progression.  Assessment of albuminuria (urine albumin:creatinine
 ratio or urine protein:creatinine ratio preferred) is recommended at
 least annually in CKD patients for staging and disease prognosis.
 Bone & Mineral
 Calcium is within goal and has not changed significantly, was 9.3 and
 now is 9.4 mg/dL.  Carbon Dioxide is below goal and has not changed
 significantly, was 19 and now is 20 mmol/L.  Guidelines recommend
 the measurement of 25-hydroxy vitamin D in patients with CKD.
 Treatment Suggestions
 Interpretations require simultaneous measurements of serum calcium
 and phosphorus.  If not on alkali, begin sodium bicarbonate, one 650
 mg pill 2-3 times daily, otherwise increase dose.
 Lipids
 LDL-C is high and has risen, was 87 and now is 150 mg/dL.
 Triglyceride is borderline high and has not changed significantly, was
 152 and now is 152 mg/dL.  Non-HDL Cholesterol  is high and has
 risen, was 117 and now is 180 mg/dL.  HDL-C is normal and has
 risen, was 34 and now is 40 mg/dL.
 Treatment Suggestions
 Therapeutic lifestyle changes are always valuable to maintain optimal
 blood lipid status (diet, exercise, weight management).  Begin statin. If
 statin already in use, consider increasing dose to achieve at least a
 50% LDL reduction from baseline.  Moderate or high intensity statin is
 preferred.  If statin cannot be tolerated or increased, alternatives
 include use of an intestinal agent (ezetimibe or bile acid sequestrant),
 niacin, and/or fish oil.
 Anemia
 Hemoglobin is normal and has risen, was 14.1 and now is 14.9 g/dL.
 Hemoglobin target assumes ESA is not in use.
 Treatment Suggestions
 No specific change of treatment is indicated at this time.
 Follow-Up Suggestions for CKD
 Recommended by KDOQI guidelines,
 at least yearly
 Spot Urine Panel
 3 months
 Fasting Renal Panel
 Fasting Lipid Panel
 12 months
 CBC
 Fasting PTH with Renal Panel
 25-Hydroxy Vitamin D
 Graphs
 DISCLAIMER: These assessments and treatment suggestions are provided as a convenience and are neither comprehensive nor intended to replace the
 physician’s clinical judgment. They do not include information such as family history, personal history, or physical findings as would be obtained by the clinician
 during patient evaluation because LabCorp does not have access to the complete patient medical record.
 Mitchell S. Laks, PhD
 Laboratory Director
 CLIA# 14D0897314
 Litholink, A LabCorp Company
 2250 West Campbell Park Drive
 Chicago, Illinois 60612
 800 338 4333 Telephone
 <PRESIDIO_ANONYMIZED_PHONE_NUMBER> Facsimile
 www.litholink.com
 Version:
 Printed:
 Page:
 8.1.4.3177
 08/02/2019
 2 of 4
CAMERON, JOHN E
 LabCorp Account #: 09683682
 08/02/2019 3a M 06/20/1958 WEIXELBAUM, LEE
 Litholink Patient Results Report PATIENT DATE OF BIRTH GENDER CKD STAGEDATE OF SERVICE PHYSICIAN
 months (since enrollment)
 eGFR
 months (since enrollment)
 = serum calcium result was corrected for low serum albumin
 Calcium
 months (since enrollment)
 Hemoglobin
 Test Results & Treatments
 The 8 most recent lab results as well as the treatments are reported.
 K BUN SCr Date eGFR Weight (kg) HB A1c
 Protein/Cr
 ACEI/ARB Diuretic (mg/g) (ug/mg)
 Alb/Cr 1 Date Meds Reported DBP SBP
 eGFR
 4.5 20 08/02/19 1.42 53 ? ? ? ? ? ?
 4.5 17 07/31/18 1.38 55 ? ? ? ? ? ?
    The CKD-EPI eGFR equation has only been validated for patients aged 18-70.  Self-reported race was not provided; eGFR was calculated as if the patient was not African American.
 Multiply eGFR by 1.159 if African American.
 1
 LPD Date PTH P 25-D K Ca PB CaPB C0 AVD Vit D Alkali 2
 Bone & Mineral
 ? 08/02/19 9.4 4.5 20 ? ? ? ? ?
 ? 07/31/18 9.3 4.5 19 ? ? ? ? ?
 Date LDL TG Chol HDL non-HDL Statin Fibrate Niacin Fasting
 Lipids
 08/02/19 150 152 180 220 40 ? ? ? Yes
 07/31/18 87 152 117 151 34 ? ? ? Yes
 DISCLAIMER:These assessments and treatment suggestions are provided as a convenience and are neither comprehensive nor intended to replace the
 physician’s clinical judgment. They do not include information such as family history, personal history, or physical findings as would be obtained by the clinician
 during patient evaluation because LabCorp does not have access to the complete patient medical record.
 8.1.4.3177 Version:
 Page: 3 of 4
 Printed: 08/02/2019 Laboratory Director
 CLIA# 14D0897314
 2250 West Campbell Park Drive
 Chicago, Illinois 60612 www.litholink.com
 866 361 7939 Facsimile
 Mitchell S. Laks, PhD Litholink, A LabCorp Company 800 338 4333 Telephone
PATIENT
 WEIXELBAUM, LEE
 Anemia
 Date
 Hb
 DATE OF BIRTH
 06/20/1958
 TSAT
 Ferritin
 GENDER CKD STAGE DATE OF SERVICE
 M
 3a
 08/02/2019
 PHYSICIAN
 Litholink Patient Results Report
 CAMERON, JOHN E
 LabCorp Account #: 09683682
 Iron
 ESA
 08/02/19 14.9
 ?
 ?
 07/31/18 14.1
 ?
 ?
 DISCLAIMER: These assessments and treatment suggestions are provided as a convenience and are neither comprehensive nor intended to replace the
 physician’s clinical judgment. They do not include information such as family history, personal history, or physical findings as would be obtained by the clinician
 during patient evaluation because LabCorp does not have access to the complete patient medical record.
 Mitchell S. Laks, PhD
 Laboratory Director
 CLIA# 14D0897314
 Litholink, A LabCorp Company
 2250 West Campbell Park Drive
 Chicago, Illinois 60612
 800 338 4333 Telephone
 <PRESIDIO_ANONYMIZED_PHONE_NUMBER> Facsimile
 www.litholink.com
 Version:
 Printed:
 Page:
 8.1.4.3177
 08/02/2019
 4 of 4
PATIENT
 WEIXELBAUM, LEE
 Your Test Results
 Test
 DATE OF BIRTH
 06/20/1958
 GENDER CKD STAGE DATE OF SERVICE
 M
 3a
 Your Results
 08/02/2019
 PHYSICIAN
 Litholink Patient Results Report
 CAMERON, JOHN E
 LabCorp Account #: 09683682
 Comments
 Blood Lipids
 LDL CHOLESTEROL is the bad
 cholesterol that can clog your arteries.
 LOWERING LDL IS IMPORTANT to protect your 150
 Ref. Range: 0 to 99 mg/dL
 heart and blood vessels. Your doctor may
 prescribe or increase medicine to lower your
 cholesterol. Remember to take all medicines as
 prescribed. Weight loss, exercise (at least 30
 minutes 5 times a week), eating less trans and
 saturated fats, and quitting smoking can also help
 to lower cholesterol.
 Kidney Health
 eGFR estimates how well your kidneys
 are filtering blood.  The higher the
 number, the better your kidneys are
 working.
 53
 Ref Range: >59
 mL/min/1.73mE2
 YOU ARE IN STAGE 3a CHRONIC KIDNEY
 DISEASE (CKD). There are 5 stages of CKD. See
 below for more information.
 POTASSIUM helps keep your heart and
 muscles working properly. High or low
 levels can be dangerous.
 4.5
 Ref. Range: 3.5 to 5.2 mmol/L
 YOUR POTASSIUM IS NORMAL. To keep it in
 the normal range, make sure you avoid foods high
 in potassium. For more information, visit
 www.kidney.org/atoz/content/potassium.cfm.
 HEMOGLOBIN is a test to look for
 anemia, or low blood count. Low
 hemoglobin levels may cause you to feel
 tired or have low energy.
 14.9
 Male Range: 13 to 17 g/dL
 YOUR HEMOGLOBIN IS NORMAL. Because
 low hemoglobin is common and can happen over
 time, it is important to follow up regularly with
 your doctor for continued monitoring.
 YOUR eGFR IS 53, YOU ARE IN STAGE 3a CKD. THINGS YOU NEED TO KNOW:
 · CKD means your kidneys show decreased function which may be caused by aging, diabetes, high blood
 pressure, or many other diseases. CKD can lead to heart disease.
 · Even if you feel fine, you may be at risk for problems such as high blood pressure, high cholesterol, anemia,
 and bone disease.  Your doctor should test you for these problems.
 · Avoid taking NSAIDs (e.g. ibuprofen, Advil®, Motrin®, Aleve®) as these may worsen your kidney function.
 · Your eGFR result may be slightly higher if you are African American.
 · To learn more, visit the National Kidney Foundation’s website: www.kidney.org/kidneydisease
 .
 DISCLAIMER: You should discuss this information with your physician. Litholink does not have a doctor-patient relationship with you, nor does it have access to a complete
 medical history or physical examination conducted by a physician that would be necessary for a complete diagnosis and comprehensive treatment plan. Neither you nor your
 physician should rely solely on this guidance. Bolded result descriptions in "Comments" consider either the reference range or target range for the test result. Reference range
 refers to the LabCorp reference interval. Target range refers to the guideline-suggested goal. REFERENCES:National Kidney Foundation Kidney Disease Outcomes Quality
 Initiative (KDOQI) at www.Kidney.org and Kidney Disease Improving Global Outcomes (KDIGO) at http://kdigo.org. Adapted from: http://nkdep.nih.gov/resources/nkdep-kidney
test-results-508.pdf.
 Mitchell S. Laks, PhD
 Laboratory Director
 CLIA# 14D0897314
 Litholink, A LabCorp Company
 2250 West Campbell Park Drive
 Chicago, Illinois 60612
 800 338 4333 Telephone
 <PRESIDIO_ANONYMIZED_PHONE_NUMBER> Facsimile
 www.litholink.com
 Version:
 Printed:
 Page:
 8.1.4.3177
 08/02/2019
 1 of 1
 1 Patient Report   
Specimen ID:  212-755-5872-0 Acct #: 09683682 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER> Rte: 30
 Control ID: 27418901
 Bloomingdale Medical Assoc.
 13403 BOYETTE RD
 RIVERVIEW FL 33569
 WEIXELBAUM, LEE S.
 2811 WINDING TRAIL DR
 VALRICO FL  33596
 (813) 445-1261
 Patient Details
 DOB: 06/20/1958
 Age(y/m/d): 060/01/11
 Gender:  M              SSN:  ***-**-3210
 Patient ID: 40097.0
 Specimen Details
 Date collected: 07/31/2018  0846 Local
 Date received: 07/31/2018
 Date entered: 07/31/2018
 Date reported: 08/01/2018  0609 ET
 Physician Details
 Ordering: J  CAMERON
 Referring:
 ID:     09683682
 NPI:  1720044027
 Date Issued: 08/01/18 0610 ET FINAL REPORT Page 1 of 3
 This document contains private and confidential health information protected by state and federal law.
 If you have received this document in error, please call 800-877-5227
 © 1995-2018 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version:          
General Comments & Additional Information
 Alternate Control Number: 27418901 Alternate Patient ID: 40097.0
 Total Volume: Not Provided Fasting: Yes
 Ordered Items
 CBC With Differential/Platelet; Comp. Metabolic Panel (14); Urinalysis, Routine; Lipid Panel; Litholink CKD Program; Thyroxine (T4)
 Free, Direct, S; TSH; Prostate-Specific Ag, Serum
           TESTS              RESULT     FLAG      UNITS  REFERENCE INTERVAL  LAB
 CBC With Differential/Platelet
  WBC                                  5.6 x10E3/uL   3.4 - 10.8 01
  RBC                                 4.74 x10E6/uL  4.14 - 5.80 01
  Hemoglobin                          14.1 g/dL  13.0 - 17.7 01
  Hematocrit                          42.0 %  37.5 - 51.0 01
  MCV                                   89 fL    79 - 97 01
  MCH                                 29.7 pg  26.6 - 33.0 01
  MCHC                                33.6 g/dL  31.5 - 35.7 01
  RDW                                 14.1 %  12.3 - 15.4 01
  Platelets                            235 x10E3/uL   150 - 379 01
  Neutrophils                           63 %  Not Estab. 01
  Lymphs                                23 %  Not Estab. 01
  Monocytes                             10 %  Not Estab. 01
  Eos                                    3 %  Not Estab. 01
  Basos                                  1 %  Not Estab. 01
  Neutrophils (Absolute)               3.5 x10E3/uL   1.4 - 7.0 01
  Lymphs (Absolute)                    1.3 x10E3/uL   0.7 - 3.1 01
  Monocytes(Absolute)                  0.6 x10E3/uL   0.1 - 0.9 01
  Eos (Absolute)                       0.2 x10E3/uL   0.0 - 0.4 01
  Baso (Absolute)                      0.0 x10E3/uL   0.0 - 0.2 01
  Immature Granulocytes                  0 %  Not Estab. 01
  Immature Grans (Abs)                 0.0 x10E3/uL   0.0 - 0.1 01
 Comp. Metabolic Panel (14)
  Glucose                               99 mg/dL    65 - 99 01
  BUN                                   17 mg/dL     8 - 27 01
  Creatinine                          1.38   High mg/dL  0.76 - 1.27 01
  eGFR If NonAfricn Am                  55    Low mL/min/1.73        >59
  eGFR If Africn Am                     64 mL/min/1.73        >59
 1.00
 1 Patient Report   
Patient: WEIXELBAUM, LEE S. Specimen ID: 212-755-5872-0
 DOB: 06/20/1958 Patient ID: 40097.0 Control ID: 27418901 Date collected: 07/31/2018  0846 Local
 Date Issued: 08/01/18 0610 ET FINAL REPORT Page 2 of 3
 This document contains private and confidential health information protected by state and federal law.
 If you have received this document in error, please call 800-877-5227
 © 1995-2018 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version:          
           TESTS              RESULT     FLAG      UNITS  REFERENCE INTERVAL  LAB
  BUN/Creatinine Ratio                  12    10 - 24
  Sodium                               142 mmol/L   134 - 144 01
  Potassium                            4.5 mmol/L   3.5 - 5.2 01
  Chloride                             106 mmol/L    96 - 106 01
  Carbon Dioxide, Total                 19    Low mmol/L    20 - 29 01
  Calcium                              9.3 mg/dL   8.6 - 10.2 01
  Protein, Total                       6.7 g/dL   6.0 - 8.5 01
  Albumin                              4.2 g/dL   3.6 - 4.8 01
  Globulin, Total                      2.5 g/dL   1.5 - 4.5
  A/G Ratio                            1.7   1.2 - 2.2
  Bilirubin, Total                     1.8   High mg/dL   0.0 - 1.2 01
  Alkaline Phosphatase                  73 IU/L    39 - 117 01
  AST (SGOT)                            18 IU/L     0 - 40 01
  ALT (SGPT)                            14 IU/L     0 - 44 01
 Urinalysis, Routine
  Urinalysis Gross Exam 01
  Specific Gravity                   1.015 1.005 - 1.030 01
  pH                                   5.5   5.0 - 7.5 01
  Urine-Color                       Yellow    Yellow 01
  Appearance                         Clear     Clear 01
  WBC Esterase                    Negative   Negative 01
  Protein                         Negative Negative/Trace 01
  Glucose                         Negative   Negative 01
  Ketones                         Negative   Negative 01
  Occult Blood                    Negative   Negative 01
  Bilirubin                       Negative   Negative 01
  Urobilinogen,Semi-Qn                 0.2 mg/dL   0.2 - 1.0 01
  Nitrite, Urine                  Negative   Negative 01
 Microscopic Examination 01
     Microscopic not indicated and not performed.
 Lipid Panel
  Cholesterol, Total                   151 mg/dL   100 - 199 01
  Triglycerides                        152   High mg/dL     0 - 149 01
  HDL Cholesterol                       34    Low mg/dL      >39 01
  VLDL Cholesterol Cal                  30 mg/dL     5 - 40
  LDL Cholesterol Calc                  87 mg/dL     0 - 99
 Litholink CKD Program
  Interpretation                      Note 02
     Supplemental report is available.
  PDF Image                              . 02
 1.00
1 Patient Report   
Patient: WEIXELBAUM, LEE S.
 DOB: 06/20/1958
 Patient ID: 40097.0
 Specimen ID: 212-755-5872-0
 Control ID: 27418901
 Date collected: 07/31/2018  0846 Local
           TESTS              RESULT     FLAG      UNITS  REFERENCE INTERVAL  LAB
 Thyroxine (T4) Free, Direct, S
 T4,Free(Direct)       
              1.82   High
 TSH       
Prostate-Specific Ag, Serum
 Prostate Specific Ag, Serum       
                          0.029    Low
   0.5
 ng/dL
 uIU/mL
 ng/mL
  0.82 - 1.77
 0.450 - 4.500
   0.0 - 4.0
     Roche ECLIA methodology.
     According to the American Urological Association, Serum PSA should
     decrease and remain at undetectable levels after radical
     prostatectomy. The AUA defines biochemical recurrence as an initial
     PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory
     PSA value 0.2 ng/mL or greater.
     Values obtained with different assay methods or kits cannot be used
     interchangeably. Results cannot be interpreted as absolute evidence
     of the presence or absence of malignant disease.
 01 TA
 LabCorp Tampa
 5610 W LaSalle Street, Tampa, FL 33607-1770
 Dir: Sean Farrier, MD
 01
 01
 01
 02 LITIL Litholink Corporation
 2250 West Campbell Park Drive, Chicago, IL 60612-3502
 For inquiries, the physician may contact Branch: 800-877-5227 Lab: 800-877-5227
 Dir: John Asplin, MD
 Date Issued: 08/01/18 0610 ET
 FINAL REPORT
 This document contains private and confidential health information protected by state and federal law.
 If you have received this document in error, please call 800-877-5227
 Page 3 of 3
 © 1995-2018 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version:          
1.00
Accessions: 21275558720
 DISCLAIMER:These assessments and treatment suggestions are provided as a convenience in support of the physician-patient relationship and are not intended to
 replace the physician’s clinical judgment.  They are derived from national guidelines in addition to other evidence and expert opinion.  The clinician should consider
 this information within the context of clinical opinion and the individual patient.
 SEE GUIDANCE FOR CHRONIC KIDNEY DISEASE PROGRAM: Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines are at
 http://kdigo.org/home/guidelines/. National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI (TM)), with its limitations and disclaimers, are at
 www.kidney.org/professionals/KDOQI. This program is intended for patients who have been diagnosed with stages 3, 4, or pre-dialysis 5 CKD. It is not intended for
 children, pregnant patients, or transplant patients.
 Note:  Please refer to your LabCorp Report for all results as well as any test-specific and specimen-specific comments.
 Current Laboratory Results
 Blood Draw Date: Date Received: 07/31/2018 Date Completed: 08/01/2018 07/31/2018 Fasting:YES
 Comp. Metabolic Panel (14)
 REF. INTERVAL RESULT ANALYTE LOW HIGH
 Glucose mg/dL 65-99 99
 BUN mg/dL 8-27 17
 Creatinine mg/dL 0.76-1.27 1.38H
 Sodium mmol/L 134-144 142
 Potassium mmol/L 3.5-5.2 4.5
 Chloride mmol/L 96-106 106
 Carbon Dioxide mmol/L 20-29 19L
 Calcium mg/dL 8.6-10.2 9.3
 Protein, Total, Serum g/dL 6.0-8.5 6.7
 Albumin g/dL 3.6-4.8 4.2
 Globulin, Total g/dL 1.5-4.5 2.5
 A/G Ratio 1.2-2.2 1.7
 Bilirubin, Total mg/dL 0.0-1.2 1.8H
 Alkaline Phosphatase, S IU/L 39-117 73
 AST IU/L 0-40 18
 ALT IU/L 0-44 14
 BUN: Creatinine Ratio 10-24 12
 Anion Gap mmol/L 10 - 18 17
 estimated GFR
 mL/min/1.73mE2
 > 59 55
 Albumin testing performed on the Roche Modular using the ALB PLUS assay.
 Lipid Panel
 REF. INTERVAL RESULT ANALYTE LOW HIGH
 Total Cholesterol mg/dL 100-199 151
 Triglyceride mg/dL 0-149 152H
 HDL-C mg/dL >39 34L
 VLDL mg/dL 5-40 30
 LDL(calc) mg/dL 0-99 87
 non-HDL cholesterol  mg/dL 0 - 129 117
 CBC With Differential/Platelet
 REF. INTERVAL RESULT ANALYTE LOW HIGH
 White Blood Count x10E3/uL 3.4-10.8 5.6
 Red Blood Count x10E6/uL 4.14-5.80 4.74
 Hemoglobin g/dL 13.0-17.7 14.1
 Hematocrit % 37.5-51.0 42.0
 MCV fL 79-97 89
 MCH pg 26.6-33.0 29.7
 MCHC g/dL 31.5-35.7 33.6
 RDW % 12.3-15.4 14.1
 Platelet Count x10E3/uL 150-379 235
 Neutrophils % Not Estab. 63
 Lymphocytes % Not Estab. 23
 Monocytes % Not Estab. 10
 Eosinophils % Not Estab. 3
 Basophils % Not Estab. 1
 Neutrophils (Abs) x10E3/uL 1.4-7.0 3.5
 Lymphocytes (Abs) x10E3/uL 0.7-3.1 1.3
 Monocytes (Abs) x10E3/uL 0.1-0.9 0.6
 Eosinophils (Abs) x10E3/uL 0.0-0.4 0.2
 Basophils (Abs) x10E3/uL 0.0-0.2 0.0
 Immature Granulocytes % Not Estab. 0
 Immature Grans (Abs)
 x10E3/uL
 0.0-0.1 0.0
 NRBC % 0 - 0
 L - Below Low Normal
 H - Above High Normal
 LL - Alert Low
 HH - Alert High
 < - Panic Low
 > - Panic High
 A - Abnormal (applies to non-numeric results)
 AA - Critical Abnormal (applies to non-numeric results)
 Legend for Abnormal Flags:
 CAMERON, JOHN E
 LabCorp Account #: 09683682
 07/31/2018 3a M 06/20/1958 WEIXELBAUM, LEE
 Litholink Patient Results Report PATIENT DATE OF BIRTH GENDER CKD STAGEDATE OF SERVICE PHYSICIAN
 7.7.5.8251 Version:
 Page: 1 of 4
 Printed: 08/01/2018 Laboratory Director
 CLIA# 14D0897314
 2250 West Campbell Park Drive
 Chicago, Illinois 60612 www.litholink.com
 866 361 7939 Facsimile
 Mitchell S. Laks, PhD Litholink, A LabCorp Company 800 338 4333 Telephone
CAMERON, JOHN E
 LabCorp Account #: 09683682
 07/31/2018 3a M 06/20/1958 WEIXELBAUM, LEE
 Litholink Patient Results Report PATIENT DATE OF BIRTH GENDER CKD STAGEDATE OF SERVICE PHYSICIAN
 GENDER SELF-REPORTED RACE MOST RECENT CKD STAGE
 M Missing 3a
 CURRENT eGFR
 55
 DIABETES
 ?
 Chronic Kidney Disease
 Analysis & Treatment Suggestions
 GFR Categories: (ml/min/1.73m  )
 G1
 Prognosis of CKD by GFR And Albuminuria Categories
 G2
 G3a
 G3b
 G4
 G5
 >=90
 60-89
 45-59
 30-44
 15-29
 <15
 NORMAL OR HIGH
 MILDLY DECREASED
 MILDLY TO MODERATELY DECREASED
 MODERATELY TO SEVERELY DECREASED
 SEVERELY DECREASED
 KIDNEY FAILURE
 A1 A2 A3
 Persistent Albuminura Categories
 A1
 A2
 A3
 = NORMAL TO MILDLY INCREASED; ACR <30 ug/mg; PCR <=200 mg/g
 = MODERATELY INCREASED; ACR 30-300 ug/mg; PCR 201-500 mg/g
 = SEVERELY INCREASED; ACR >300 ug/mg; PCR >500 mg/g
 = LOW RISK
 = HIGH RISK
 = MODERATELY INCREASED RISK
 = VERY HIGH RISK
 = PATIENT'S RESULT
 Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012
 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney
 Disease.                                      2013; 3: 1-150.
 2
 Kidney inter.; Suppl.
 We presume eGFR has been less than 60 mL/min/1.73mE2 on at
 least two occasions spaced at least 3 months apart.  Current eGFR is
 55 mL/min/1.73mE2 corresponding to CKD stage 3a.  Multiply eGFR
 by 1.159 if patient is African American.  Potassium is within goal, 4.5
 mmol/L.
 Treatment Suggestions
 Guidelines recommend a target blood pressure of 140/90 mmHg or
 less in CKD patients to reduce cardiovascular risk and CKD
 progression.  Assessment of albuminuria (urine albumin:creatinine
 ratio or urine protein:creatinine ratio preferred) is recommended at
 least annually in CKD patients for staging and disease prognosis.
 eGFR, Blood Pressure, and Proteinuria
 Calcium is within goal, 9.3 mg/dL.  Carbon Dioxide is below goal, 19
 mmol/L.  Guidelines recommend the measurement of 25-hydroxy
 vitamin D in patients with CKD.
 Treatment Suggestions
 Interpretations require simultaneous measurements of serum calcium
 and phosphorus.  If not on alkali, begin sodium bicarbonate, one 650
 mg pill 2-3 times daily, otherwise increase dose.
 Bone & Mineral
 LDL-C is normal, 87 mg/dL.  Triglyceride is borderline high, 152
 mg/dL.  Non-HDL Cholesterol  is normal, 117 mg/dL.  HDL-C is low, 34
 mg/dL.
 Treatment Suggestions
 Therapeutic lifestyle changes are always valuable to maintain optimal
 blood lipid status (diet, exercise, weight management).  If at least a
 50% LDL reduction from baseline has not been achieved, begin or
 increase statin.  Consider measurement of LDL particle number or Apo
 B to adjudicate need for further LDL lowering therapy.  If statin cannot
 be tolerated or increased, alternatives include use of an intestinal
 agent (ezetimibe or bile acid sequestrant), niacin, and/or fish oil.
 Lipids
 Hemoglobin is normal, 14.1 g/dL.  Hemoglobin target assumes ESA is
 not in use.
 Treatment Suggestions
 No specific change of treatment is indicated at this time.
 Anemia
 Follow-Up Suggestions for CKD
 Recommended by KDOQI guidelines,
 at least yearly
 Spot Urine Panel
 Fasting PTH with Renal Panel
 25-Hydroxy Vitamin D
 3 months
 Fasting Renal Panel
 12 months
 Fasting Lipid Panel
 CBC
 Graphs
 DISCLAIMER:These assessments and treatment suggestions are provided as a convenience and are neither comprehensive nor intended to replace the
 physician’s clinical judgment. They do not include information such as family history, personal history, or physical findings as would be obtained by the clinician
 during patient evaluation because LabCorp does not have access to the complete patient medical record.
 7.7.5.8251 Version:
 Page: 2 of 4
 Printed: 08/01/2018 Laboratory Director
 CLIA# 14D0897314
 2250 West Campbell Park Drive
 Chicago, Illinois 60612 www.litholink.com
 866 361 7939 Facsimile
 Mitchell S. Laks, PhD Litholink, A LabCorp Company 800 338 4333 Telephone
PATIENT
 WEIXELBAUM, LEE
 eGFR
 DATE OF BIRTH
 06/20/1958
 GENDER CKD STAGE DATE OF SERVICE
 M
 months (since enrollment)
 3a
 07/31/2018
 Calcium
 PHYSICIAN
 Litholink Patient Results Report
 CAMERON, JOHN E
 LabCorp Account #: 09683682
 months (since enrollment)
 = serum calcium result was corrected for low serum albumin
 Hemoglobin
 months (since enrollment)
 Test Results & Treatments
 The 8 most recent lab results as well as the treatments are reported.
 eGFR
 Date
 07/31/18
 Protein/Cr
 1
 K
 4.5
 BUN
 17
 SCr
 1.38
 eGFR
 55
 HB A1c
 (mg/g)
 Alb/Cr
 (ug/mg)
 Weight (kg)
 ?
 SBP
 ?
 DBP
 Date Meds Reported
 ACEI/ARB Diuretic
 ?
 1
 ?
 ?
 The CKD-EPI eGFR equation has only been validated for patients aged 18-70.  Self-reported race was not provided; eGFR was calculated as if the patient was not African American.
 Multiply eGFR by 1.159 if African American.
 Bone & Mineral
 Date
 PTH
 P
 Ca
 C0
 2
 K
 25-D
 LPD
 PB
 CaPB
 AVD
 ?
 07/31/18
 9.3
 19
 4.5
 ?
 Vit D
 Alkali
 ?
 ?
 ?
 ?
 ?
 Lipids
 Date
 07/31/18
 LDL
 87
 TG
 152
 non-HDL
 117
 Chol
 151
 HDL
 34
 Statin
 ?
 Fibrate
 Niacin
 Fasting
 ?
 ?
 Yes
 DISCLAIMER: These assessments and treatment suggestions are provided as a convenience and are neither comprehensive nor intended to replace the
 physician’s clinical judgment. They do not include information such as family history, personal history, or physical findings as would be obtained by the clinician
 during patient evaluation because LabCorp does not have access to the complete patient medical record.
 Mitchell S. Laks, PhD
 Laboratory Director
 CLIA# 14D0897314
 Litholink, A LabCorp Company
 2250 West Campbell Park Drive
 Chicago, Illinois 60612
 800 338 4333 Telephone
 <PRESIDIO_ANONYMIZED_PHONE_NUMBER> Facsimile
 www.litholink.com
 Version:
 Printed:
 Page:
 7.7.5.8251
 08/01/2018
 3 of 4
PATIENT
 WEIXELBAUM, LEE
 Anemia
 Date
 Hb
 DATE OF BIRTH
 06/20/1958
 TSAT
 Ferritin
 GENDER CKD STAGE DATE OF SERVICE
 M
 3a
 07/31/2018
 PHYSICIAN
 Litholink Patient Results Report
 CAMERON, JOHN E
 LabCorp Account #: 09683682
 Iron
 ESA
 07/31/18 14.1
 ?
 ?
 DISCLAIMER: These assessments and treatment suggestions are provided as a convenience and are neither comprehensive nor intended to replace the
 physician’s clinical judgment. They do not include information such as family history, personal history, or physical findings as would be obtained by the clinician
 during patient evaluation because LabCorp does not have access to the complete patient medical record.
 Mitchell S. Laks, PhD
 Laboratory Director
 CLIA# 14D0897314
 Litholink, A LabCorp Company
 2250 West Campbell Park Drive
 Chicago, Illinois 60612
 800 338 4333 Telephone
 <PRESIDIO_ANONYMIZED_PHONE_NUMBER> Facsimile
 www.litholink.com
 Version:
 Printed:
 Page:
 7.7.5.8251
 08/01/2018
 4 of 4
PATIENT
 WEIXELBAUM, LEE
 Your Test Results
 Test
 DATE OF BIRTH
 06/20/1958
 GENDER CKD STAGE DATE OF SERVICE
 M
 3a
 Your Results
 07/31/2018
 PHYSICIAN
 Litholink Patient Results Report
 CAMERON, JOHN E
 LabCorp Account #: 09683682
 Comments
 Blood Lipids
 LDL CHOLESTEROL is the bad
 cholesterol that can clog your arteries.
 87
 Ref. Range: 0 to 99 mg/dL
 HAVING LOW LDL HELPS PROTECT YOUR
 HEART AND BLOOD VESSELS. Remember to
 take any medications prescribed by your doctor.
 Your doctor may recommend even lower
 cholesterol levels to reduce your risk of heart
 disease. Weight loss, exercise (at least 30
 minutes 5 times a week), a diet low in trans and
 saturated fats, and quitting smoking can keep
 cholesterol low.
 Kidney Health
 eGFR estimates how well your kidneys
 are filtering blood.  The higher the
 number, the better your kidneys are
 working.
 55
 Ref Range: >59
 mL/min/1.73mE2
 YOUR RESULT COULD MEAN YOU HAVE
 STAGE 3a CHRONIC KIDNEY DISEASE
 (CKD). There are 5 stages of CKD. See below for
 more information.
 POTASSIUM helps keep your heart and
 muscles working properly. High or low
 levels can be dangerous.
 4.5
 Ref. Range: 3.5 to 5.2 mmol/L
 YOUR POTASSIUM IS NORMAL. To keep it in
 the normal range, make sure you avoid foods high
 in potassium. For more information, visit
 www.kidney.org/atoz/content/potassium.cfm.
 HEMOGLOBIN is a test to look for
 anemia, or low blood count. Low
 hemoglobin levels may cause you to feel
 tired or have low energy.
 14.1
 Male Range: 13 to 17 g/dL
 YOUR HEMOGLOBIN IS NORMAL. Because
 low hemoglobin is common and can happen over
 time, it is important to follow up regularly with
 your doctor for continued monitoring.
 YOUR eGFR IS 55, YOU ARE IN STAGE 3a CKD. THINGS YOU NEED TO KNOW:
 · CKD means your kidneys have been damaged by diabetes, high blood pressure, or many other diseases.
 CKD can lead to heart disease.
 · Even if you feel fine, you may be at risk for problems such as high blood pressure, high cholesterol, anemia,
 and bone disease.  Your doctor will test you for these problems.
 · Avoid taking NSAIDs (e.g. ibuprofen, Advil®, Motrin®, Aleve®) as these may worsen your kidney function.
 · Your eGFR result may be slightly higher if you are African American.
 · To learn more, visit the National Kidney Foundation’s website: www.kidney.org/kidneydisease
 .
 DISCLAIMER: You should discuss this information with your physician. Litholink does not have a doctor-patient relationship with you, nor does it have access to a complete
 medical history or physical examination conducted by a physician that would be necessary for a complete diagnosis and comprehensive treatment plan. Neither you nor your
 physician should rely solely on this guidance. Bolded result descriptions in "Comments" consider either the reference range or target range for the test result. Reference range
 refers to the LabCorp reference interval. Target range refers to the guideline-suggested goal. REFERENCES:National Kidney Foundation Kidney Disease Outcomes Quality
 Initiative (KDOQI) at www.Kidney.org and Kidney Disease Improving Global Outcomes (KDIGO) at http://kdigo.org. Adapted from: http://nkdep.nih.gov/resources/nkdep-kidney
test-results-508.pdf.
 Mitchell S. Laks, PhD
 Laboratory Director
 CLIA# 14D0897314
 Litholink, A LabCorp Company
 2250 West Campbell Park Drive
 Chicago, Illinois 60612
 800 338 4333 Telephone
 <PRESIDIO_ANONYMIZED_PHONE_NUMBER> Facsimile
 www.litholink.com
 Version:
 Printed:
 Page:
 7.7.5.8251
 08/01/2018
 1 of 1
 1 Patient Report   
Specimen ID:  279-216-2229-0 Acct #: 09241500 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER> Rte: 00
 Control ID: 30185029914
 Andrew Henry MD
 9260 BAY PLAZA BLVD, STE 502
 Brandon FL 33619
 WEIXELBAUM, LEE S.
 2811 WINDING TRAIL DR
 VALRICO FL  33596
 (813) 445-1261
 Patient Details
 DOB: 06/20/1958
 Age(y/m/d): 062/03/15
 Gender:  M
 Patient ID:
 Specimen Details
 Date collected: 10/05/2020  0801 Local
 Date received: 10/05/2020
 Date entered: 10/05/2020
 Date reported: 10/07/2020  0813 ET
 Physician Details
 Ordering: A  HENRY
 Referring:
 ID:
 NPI:  1194892141
 Date Issued: 01/19/21 0724 ET FINAL REPORT Page 1 of 2
 This document contains private and confidential health information protected by state and federal law.
 If you have received this document in error, please call 800-877-5227
 © 1995-2021 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version:          
General Comments & Additional Information
 Total Volume: Not Provided Fasting: Yes
 Ordered Items
 Comp. Metabolic Panel (14); Testosterone,Free and Total; Ambig Abbrev CMP14 Default; Venipuncture; Handwritten Order
           TESTS              RESULT     FLAG      UNITS  REFERENCE INTERVAL  LAB
 Comp. Metabolic Panel (14)
  Glucose                               90 mg/dL     65-99 01
  BUN                                   15 mg/dL      8-27 01
  Creatinine                          1.53   High mg/dL   0.76-1.27 01
  eGFR If NonAfricn Am                  48    Low mL/min/1.73        >59
  eGFR If Africn Am                     56    Low mL/min/1.73        >59
  BUN/Creatinine Ratio                  10     10-24
  Sodium                               140 mmol/L    134-144 01
  Potassium                            4.6 mmol/L    3.5-5.2 01
  Chloride                             103 mmol/L     96-106 01
  Carbon Dioxide, Total                 23 mmol/L     20-29 01
  Calcium                              8.7 mg/dL    8.6-10.2 01
  Protein, Total                       6.0 g/dL    6.0-8.5 01
  Albumin                              4.1 g/dL    3.8-4.8 01
  Globulin, Total                      1.9 g/dL    1.5-4.5
  A/G Ratio                            2.2    1.2-2.2
  Bilirubin, Total                     1.2 mg/dL    0.0-1.2 01
  Alkaline Phosphatase                  74 IU/L     39-117 01
  AST (SGOT)                            18 IU/L      0-40 01
  ALT (SGPT)                            14 IU/L      0-44 01
 Testosterone,Free and Total
  Testosterone, Serum                  255    Low ng/dL    264-916 01
     Adult male reference interval is based on a population of
     healthy nonobese males (BMI <30) between 19 and 39 years old.
     Travison, et.al. JCEM 2017,102;1161-1173. PMID: 28324103.
  Free Testosterone(Direct)           13.3 pg/mL    6.6-18.1 02
 Ambig Abbrev CMP14 Default 01
     A hand-written panel/profile was received from your office. In
     accordance with the LabCorp Ambiguous Test Code Policy dated July
     2003, we have completed your order by using the closest currently
 1.00
1 Patient Report   
Patient: WEIXELBAUM, LEE S.
 DOB: 06/20/1958
 Patient ID:
 Specimen ID: 279-216-2229-0
 Control ID: 30185029914
 Date collected: 10/05/2020  0801 Local
           TESTS              RESULT     FLAG      UNITS  REFERENCE INTERVAL  LAB
     or formerly recognized AMA panel.  We have assigned Comprehensive
     Metabolic Panel (14), Test Code #322000 to this request.  If this
     is not the testing you wished to receive on this specimen, please
     contact the LabCorp Client Inquiry/Technical Services Department
     to clarify the test order.  We appreciate your business.
 01 TA
 LabCorp Tampa
 5610 W LaSalle Street, Tampa, FL 33607-1770
 Dir: Sean Farrier, MD
 02 BN LabCorp Burlington
 1447 York Court, Burlington, NC 27215-3361
 For inquiries, the physician may contact Branch: 800-877-5227 Lab: 800-877-5227
 Dir: Sanjai Nagendra, MD
 Date Issued: 01/19/21 0724 ET
 FINAL REPORT
 This document contains private and confidential health information protected by state and federal law.
 If you have received this document in error, please call 800-877-5227
 Page 2 of 2
 © 1995-2021 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version:          
1.00
1 Patient Report   
Specimen ID:  170-216-2674-0
 Control ID: 30185011311
 WEIXELBAUM, LEE
 2811 WINDING TRAIL DR
 VALRICO FL  33596
 (813) 445-1261
 Patient Details
 DOB: 06/20/1958
 Age(y/m/d): 060/11/30
 Gender:  M              
SSN:
 Patient ID:
 Acct #: 09241500
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Andrew Henry MD
 9260 BAY PLAZA BLVD, STE 502
 Brandon FL 33619
 Specimen Details
 Physician Details
 Rte: 00
 Date collected: 06/19/2019  0853 Local
 Date received: 06/19/2019
 Date entered: 06/19/2019
 Date reported: 06/24/2019  1008 ET
 General Comments & Additional Information
 Total Volume: Not Provided
 Ordering: A  HENRY
 Referring:
 ID:
 NPI:  1194892141
 Fasting: Yes
 Ordered Items
 Free T4 by Dialysis/Mass Spec; TSH; Thyroid Stim Immunoglobulin; Triiodothyronine (T3); Venipuncture; Handwritten Order
           TESTS              RESULT     FLAG      UNITS  REFERENCE INTERVAL  LAB
 Free T4 by Dialysis/Mass Spec
 0.72
 Low
 Reference Range:
 Pubertal Children and Adults:
 0.8 - 1.7
 TSH       
Thyroid Stim Immunoglobulin       
Triiodothyronine (T3)       
01 ES
                          6.820   High
   0.11
           97
 Esoterix Inc
 4301 Lost Hills Road, Calabasas Hills, CA 91301-5358
 ng/dL
 uIU/mL
 IU/L
 ng/dL
 0.450 - 4.500
  0.00 - 0.55
    71 - 180
 Dir: Samuel Pepkowitz, MD
 02 TA
 LabCorp Tampa
 5610 W LaSalle Street, Tampa, FL 33607-1770
 01
 02
 03
 02
 Dir: Sean Farrier, MD
 03 BN LabCorp Burlington
 1447 York Court, Burlington, NC 27215-3361
 For inquiries, the physician may contact Branch: 800-877-5227 Lab: 800-444-9111
 Dir: Sanjai Nagendra, MD
 Date Issued: 07/09/19 0722 ET
 FINAL REPORT
 This document contains private and confidential health information protected by state and federal law.
 If you have received this document in error, please call 800-877-5227
 Page 1 of 1
 © 1995-2019 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version:          
1.00
1 Patient Report   
Specimen ID:  003-216-3202-0
 Control ID: 30185018894
 WEIXELBAUM, LEE
 2811 WINDING TRAIL DR
 VALRICO FL  33596
 (813) 445-1261
 Patient Details
 DOB: 06/20/1958
 Age(y/m/d): 061/06/14
 Gender:  M              
SSN:
 Patient ID:
 Acct #: 09241500
 Phone: <PRESIDIO_ANONYMIZED_PHONE_NUMBER>
 Andrew Henry MD
 9260 BAY PLAZA BLVD, STE 502
 Brandon FL 33619
 Specimen Details
 Physician Details
 Rte: 00
 Date collected: 01/03/2020  0841 Local
 Date received: 01/03/2020
 Date entered: 01/03/2020
 Date reported: 01/08/2020  0811 ET
 General Comments & Additional Information
 Total Volume: Not Provided
 Ordering: A  HENRY
 Referring:
 ID:
 NPI:  1194892141
 Fasting: Yes
 Ordered Items
 Free T4 by Dialysis/Mass Spec; Testosterone, Serum; TSH; Thyroid Peroxidase (TPO) Ab; Venipuncture
           TESTS              RESULT     FLAG      UNITS  REFERENCE INTERVAL  LAB
 Free T4 by Dialysis/Mass Spec
 0.90
     Reference Range:
     Pubertal Children and Adults:
     0.8 - 1.7
 Testosterone, Serum       
            179    Low
 ng/dL
 ng/dL
   264 - 916
 Adult male reference interval is based on a population of
 healthy nonobese males (BMI <30) between 19 and 39 years old.
 Travison, et.al. JCEM 2017,102;1161-1173. PMID: 28324103.
 TSH       
Thyroid Peroxidase (TPO) Ab       
01 ES
                          5.340   High
    165   High
 Esoterix Inc
 4301 Lost Hills Road, Calabasas Hills, CA 91301-5358
 02 TA
 uIU/mL
 IU/mL
 0.450 - 4.500
     0 - 34
 Dir: Samuel Pepkowitz, MD
 01
 02
 02
 02
 LabCorp Tampa
 5610 W LaSalle Street, Tampa, FL 33607-1770
 For inquiries, the physician may contact Branch: 800-877-5227 Lab: 800-444-9111
 Dir: Sean Farrier, MD
 Date Issued: 01/09/20 1151 ET
 FINAL REPORT
 This document contains private and confidential health information protected by state and federal law.
 If you have received this document in error, please call 800-877-5227
 Page 1 of 1
 © 1995-2020 Laboratory Corporation of America® Holdings
 All Rights Reserved - Enterprise Report Version:          
1.00 aboratory Results
 Color: Yellow
 Appearance: Clear
 Spec Grav: 1.016
 pH: 7
 Protein: Negative
 Glucose: Negative
 Ketone: Negative
 Bilirubin: Negative
 Blood: Negative
 Urobilinogen: Negative
 Leuk Est: Negative
 Nitrite: Negative
 RBC: 0-3
 WBC: 0-2
 Mucous: Occasional Abnormal
 Culture Reflexed: No
 COVID 19 RESULT RT-PCR: NEGATIVE
 Influenza A PCR: NEGATIVE
 Influenza B PCR: NEGAT